



## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification <sup>6</sup> : <b>C12N 15/12, 5/10, C12Q 1/68, C07K 14/705, G01N 33/68, A01N 37/28, 65/00</b>		<b>A1</b>	(11) International Publication Number: <b>WO 99/36520</b>
			(43) International Publication Date: 22 July 1999 (22.07.99)
(21) International Application Number: PCT/AU99/00033		(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).	
(22) International Filing Date: 15 January 1999 (15.01.99)		<b>Published</b> <i>With international search report.</i>	
(30) Priority Data: PP 1356 15 January 1998 (15.01.98) AU			
(71) Applicant (for all designated States except US): COMMON-WEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION [AU/AU]; Limestone Avenue, Campbell, ACT 2601 (AU).			
(72) Inventors; and (75) Inventors/Applicants (for US only): HILL, Ronald, Johnston [AU/AU]; 17 Altona Avenue, Forestville, NSW 2087 (AU). HANNAN, Garry, Noel [AU/AU]; 32 Earl Street, Hunters Hill, NSW 2110 (AU).			
(74) Agents: SLATTERY, John, M. et al.; Davies Collison Cave, 1 Little Collins Street, Melbourne, VIC 3000 (AU).			
(54) Title: NOVEL GENETIC SEQUENCES ENCODING STEROID AND JUVENILE HORMONE RECEPTOR POLYPEPTIDES AND INSECTICIDAL MODALITIES THEREFOR			
(57) Abstract			
<p>The present invention provides isolated nucleic acid molecules encoding polypeptides comprising functional steroid hormone and juvenile hormone receptors, in particular isolated nucleic acid molecules which encode polypeptides comprising the <i>Lucilia cuprina</i> and <i>Myzus persicae</i> ecdysone receptors and juvenile hormone receptors. The present invention further provides functional recombinant steroid and juvenile hormone receptors and recombinant polypeptide subunits thereof and derivatives and analogues thereof. The present invention further provides screening systems and methods of identifying insecticidally-active agents which are capable of agonising or antagonising insect receptor function, or alternatively or in addition, which modify the affinity of said receptors for their cellular stimuli (e.g. insect steroids or juvenile hormones) or analogues thereof, or alternatively or in addition, which act as insecticides by virtue of their ability to agonise or antagonise the activity of insect hormones.</p>			

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon			PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakhstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

## NOVEL GENETIC SEQUENCES ENCODING STEROID AND JUVENILE HORMONE RECEPTOR POLYPEPTIDES AND INSECTICIDAL MODALITIES THEREFOR

### FIELD OF THE INVENTION

5 The present invention relates generally to novel genetic sequences encoding receptor polypeptides and insecticidal modalities therefor, which insecticidal modalities are based upon non-polypeptide insect hormones and their receptors. More specifically, the present invention provides isolated nucleic acid molecules encoding polypeptides comprising functional steroid hormone and juvenile hormone receptors, in particular isolated nucleic acid molecules which  
10 encode polypeptides comprising the *Lucilia cuprina* and *Myzus persicae* ecdysone receptors and juvenile hormone receptors. In a particularly preferred embodiment, the present invention relates to isolated nucleic acid molecules which encode the *L. cuprina* and *M. persicae* EcR polypeptide subunits and EcR partner protein (USP polypeptide) subunits which form functional heterodimeric ecdysone receptor, and to the *L. cuprina* and *M. persicae* USP  
15 polypeptide of the juvenile hormone receptor. The present invention further relates to the production of functional recombinant insect receptors and recombinant polypeptide subunits thereof and derivatives and analogues thereof. The present invention further relates to the uses of the recombinant receptor and isolated nucleic acid molecules of the present invention in the regulation of gene expression. The present invention further relates to screening  
20 systems and methods of identifying insecticidally-active agents which are capable of agonising or antagonising insect receptor function, such as molecules and/or ligands which associate with steroid receptors or juvenile hormone receptors so as to modify the affinity of said receptors for their cognate *cis*-acting response elements (eg. insect steroid response elements, juvenile hormone response elements) in the genes which they regulate, or  
25 alternatively or in addition, which modify the affinity of said receptors for their cellular stimuli (eg. insect steroids or juvenile hormones) or analogues thereof, or alternatively or in addition, which act as insecticides by virtue of their ability to agonise or antagonise the activity of insect hormones, such as by mimicry of a ligand which binds to said receptor or a ligand-binding region thereof. The invention further extends to such compounds and/or ligands.

30

### GENERAL

This specification contains nucleotide and amino acid sequence information prepared using the programme PatentIn Version 2.0, presented herein after the bibliography. Each nucleotide

- 2 -

or amino acid sequence is identified in the sequence listing by the numeric indicator <210> followed by the sequence identifier (e.g. <210>1, <210>2, etc). The length, type of sequence (DNA, protein (PRT), etc) and source organism for each nucleotide or amino acid sequence are indicated by information provided in the numeric indicator fields <211>, <212> and <213>, respectively. Nucleotide and amino acid sequences referred to in the specification are defined by the information provided in numeric indicator field <400> followed by the sequence identifier (eg. <400>1, <400>2, etc).

The designation of nucleotide residues referred to herein are those recommended by the IUPAC-IUB Biochemical Nomenclature Commission, wherein A represents Adenine, C represents Cytosine, G represents Guanine, T represents thymine, Y represents a pyrimidine residue, R represents a purine residue, M represents Adenine or Cytosine, K represents Guanine or Thymine, S represents Guanine or Cytosine, W represents Adenine or Thymine, H represents a nucleotide other than Guanine, B represents a nucleotide other than Adenine, V represents a nucleotide other than Thymine, D represents a nucleotide other than Cytosine and N represents any nucleotide residue.

Bibliographic details of the publications referred to in this specification are collected at the end of the description.

As used herein the term "derived from" shall be taken to indicate that a specified integer may be obtained from a particular source albeit not necessarily directly from that source.

Throughout this specification, unless the context requires otherwise, the word "comprise", or variations such as "comprises" or "comprising", will be understood to imply the inclusion of a stated step or element or integer or group of steps or elements or integers but not the exclusion of any other step or element or integer or group of elements or integers.

Those skilled in the art will appreciate that the invention described herein is susceptible to variations and modifications other than those specifically described. It is to be understood that the invention includes all such variations and modifications. The invention also includes all of the steps, features, compositions and compounds referred to or indicated in this specification,

- 3 -

individually or collectively, and any and all combinations or any two or more of said steps or features.

The present invention is not to be limited in scope by the specific embodiments described herein, which are intended for the purposes of exemplification only. Functionally-equivalent products, compositions and methods are clearly within the scope of the invention, as described herein.

### BACKGROUND TO THE INVENTION

10 International Patent Application No WO91/13167 (applicant, The Board of Trustees of Leyland Stanford University, and hereinafter referred to as WO91/13167) describes the identification, characterization, expression and uses of insect steroid receptors and DNA sequences encoding same and, in particular, the identification, characterization, expression and uses of the steroid receptor of the common fruit fly, *Drosophila melanogaster*.

15

It has been found by the present inventors that the limited homology between the *D. melanogaster* steroid receptor-encoding gene sequences and the steroid receptor -encoding sequences derived from other insects, in particular those derived from diptera such as the Australian sheep blowfly *L. cuprina*, hemiptera such as aphids, scale insects and leaf hoppers, 20 coleoptera, neuroptera, lepidoptera, and ants, as well as from helminths and protozoa, prevents the routine isolation of DNA sequences encoding steroid receptors and/or juvenile hormone receptors from these latter-mentioned organisms.

Moreover, the present inventors have discovered that the *D. melanogaster* steroid receptor 25 described in WO91/13167 is temperature-sensitive, showing reduced activity at temperatures above 30°C, such as at temperatures about 37°C, particularly at low concentrations of the receptor. Accordingly, the *D. melanogaster* steroid receptor described in WO91/13167 is of limited utility at physiological temperatures applicable to animal or bacterial cells. Moreover, wherein it is desirable to produce a biologically-active steroid receptor using *in vivo* or *in situ* 30 expression systems, which expression systems routinely utilise cells or tissues in the temperature range of about 28°C to about 42°C, the *D. melanogaster* steroid receptor is also

of limited utility.

In work leading up to the present invention, the present inventors developed a novel screening protocol, involving the utilisation of highly-degenerate oligonucleotide probes and primers  
5 derived from the amino acid sequences of the DNA-binding domains of the *D. melanogaster* and *Chironomus tentans* ecdysone receptor polypeptides, to identify nucleotide sequences encoding novel steroid receptor polypeptides and novel insect juvenile hormone receptor polypeptides. The present inventors have further identified specific regions within these novel polypeptides which are suitable for use in preparing a surprising range of novel steroid  
10 receptor polypeptide derivatives and insect juvenile hormone receptor polypeptide derivatives. The novel steroid receptor polypeptides and novel insect juvenile hormone receptor polypeptides of the present invention, and derivative polypeptides thereof, and assembled steroid receptors and insect juvenile hormone receptors derived from said polypeptides and derivatives, and nucleic acid molecules encoding same as exemplified herein, provide the  
15 means for developing a wide range of insecticidally-active agents, as well as methods for the regulated production of bioactive molecules. In particular, the present invention provides the means for developing specific ligands which bind to and either agonise or antagonise the steroid receptors and/or juvenile hormone receptors and/or polypeptide subunits thereof as described herein, thereby functioning as highly-specific insecticides, offering significant  
20 commercial and environmental benefits.

The present inventors have been surprisingly successful in characterizing the ecdysone receptor and juvenile hormone receptor derived from insects of the orders Diptera and Hemiptera, and polypeptide components thereof and functional derivatives of said polypeptides  
25 and receptors, particularly in light of the extreme difficulties in dealing with these organisms. The nature of these molecules was unknown prior to the present invention.

The various aspects of this invention overcome the problems associated with *Drosophila* ecdysone receptors which lack thermal stability. Moreover, those aspects of the invention  
30 pertaining to methods of screening for insecticidally active agents do not involve competition assays which are generally complex, and often inaccurate or difficult to calibrate.

**SUMMARY OF THE INVENTION**

One aspect of the present invention provides an isolated nucleic acid molecule comprising a nucleotide sequence which encodes or is complementary to a sequence which encodes a steroid receptor polypeptide or a juvenile hormone receptor polypeptide or a bioactive derivative or analogue thereof, wherein said polypeptide:

- (i) is selected from the list comprising EcR polypeptide of an steroid receptor, the partner protein (USP polypeptide) of an steroid receptor and the USP polypeptide of a juvenile hormone receptor; and
- (ii) comprises an amino acid sequence that is at least 40% identical to any one of the amino acid sequences set forth in <400>2, <400>4, <400>6, <400>10, <400>12 or <400>14.

In an alternative embodiment, the isolated nucleic acid molecule of the present invention comprises a nucleotide sequence which encodes or is complementary to a sequence which encodes a steroid receptor polypeptide or a juvenile hormone receptor polypeptide or a bioactive derivative or analogue thereof, wherein said nucleotide sequence is selected from the list comprising:

- (i) a nucleotide sequence having at least 40% identity to any one of the nucleotide sequences set forth in <400>1, <400>3, <400>5, <400>9, <400>11 or <400>13 or a complementary nucleotide sequence thereto;
- (ii) a nucleotide sequence that is capable of hybridising under at least low stringency conditions to any one of the nucleotide sequences set forth in <400>1, <400>3, <400>5, <400>7, <400>8, <400>9, <400>11 or <400>13 or to a complementary nucleotide sequence thereto; and
- (iii) a nucleotide sequence that is amplifiable by PCR using a nucleic acid primer sequence set forth in any one of <400>15, <400>16, <400>17, <400>18, <400>19 or <400>20.

In a further alternative embodiment, the present invention provides an isolated nucleic acid molecule which encodes a steroid receptor polypeptide and comprises the nucleotide sequence set forth in <400>1 or a complementary nucleotide sequence thereto.

In a further alternative embodiment, the present invention provides an isolated nucleic acid molecule which encodes a steroid receptor polypeptide or a juvenile hormone receptor polypeptide and comprises the nucleotide sequence set forth in <400>3 or <400>13 or a complementary nucleotide sequence thereto.

5

In a further alternative embodiment, the present invention provides an isolated nucleic acid molecule which encodes a steroid receptor polypeptide and comprises the nucleotide sequence set forth in <400>5 or <400>7 or <400>8 or <400>9 or a complementary nucleotide sequence thereto.

10

In a further alternative embodiment, the present invention provides an isolated nucleic acid molecule which encodes a steroid receptor polypeptide or a juvenile hormone receptor polypeptide and comprises the nucleotide sequence set forth in <400>11 or a complementary nucleotide sequence thereto.

15

A second aspect of the present invention provides a method of identifying an isolated nucleic acid molecule which encodes a steroid receptor polypeptide or a juvenile hormone receptor polypeptide comprising the steps of:

- (i) hybridising genomic DNA, mRNA or cDNA with a hybridisation-effective amount of one or more probes selected from the list comprising:
  - (a) probes comprising at least 10 contiguous nucleotides in length derived from any one of <400>1, <400>3, <400>5, <400>7, <400>8, <400>9, <400>11, <400>13, <400>15, <400>16, <400>17, <400>18, <400>19 or <400>20 or a complementary nucleotide sequence thereto; and
  - (b) hybridisation probes comprising the nucleotide sequences set forth in any one of <400>1, <400>3, <400>5, <400>7, <400>8, <400>9, <400>11, or <400>13 or a complementary nucleotide sequence thereto or a homologue, analogue or derivative thereof which is at least 40% identical to said sequence or complement; and
- (ii) detecting the hybridisation.

30



- 7 -

In an alternative embodiment, the inventive method comprises the steps of:

- (i) annealing one or more PCR primers comprising at least 10 contiguous nucleotides in length derived from any one of <400>1, <400>3, <400>5, <400>7, <400>8, <400>9, <400>11, <400>13, <400>15, <400>16, <400>17, <400>18, <400>19 or <400>20 or a complementary nucleotide sequence thereto, to genomic DNA, mRNA or cDNA; and
- (ii) amplifying a nucleotide sequence which encodes a steroid receptor polypeptide or a juvenile hormone receptor polypeptide in a polymerase chain reaction.

10 In a further alternative embodiment, the inventive method comprises the steps of:

- (i) amplifying a nucleotide sequence which encodes a steroid receptor polypeptide or a juvenile hormone receptor polypeptide in a polymerase chain reaction using one or more PCR primers comprising at least 10 contiguous nucleotides in length derived from any one of <400>1, <400>3, <400>5, <400>7, <400>8, <400>9, <400>11, <400>13, <400>15, <400>16, <400>17, <400>18, <400>19 or <400>20 or a complementary nucleotide sequence thereto;
- (i) hybridising the amplified nucleotide sequence to genomic DNA, mRNA or cDNA with a hybridisation-effective amount of one or more probes selected from the list comprising:
  - (a) probes comprising at least 10 contiguous nucleotides in length derived from any one of <400>1, <400>3, <400>5, <400>7, <400>8, <400>9, <400>11, <400>13, <400>15, <400>16, <400>17, <400>18, <400>19 or <400>20 or a complementary nucleotide sequence thereto; and
  - (b) hybridisation probes comprising the nucleotide sequences set forth in any one of <400>1, <400>3, <400>5, <400>7, <400>8, <400>9, <400>11, or <400>13 or a complementary nucleotide sequence thereto or a homologue, analogue or derivative thereof which is at least 40% identical to said sequence or complement; and
  - (iii) detecting the hybridisation.

A third aspect of the present invention provides a genetic construct comprising the subject

isolated nucleic acid molecule which encodes a steroid receptor polypeptide or a juvenile hormone receptor polypeptide, operably linked to a promoter sequence. Preferably, the subject nucleic acid molecule is in an expressible format, such that it is possible to produce a recombinant polypeptide therefrom.

5

Accordingly, a fourth aspect of the invention provides a recombinant or isolated polypeptide comprising a steroid receptor polypeptide or juvenile hormone receptor polypeptide or a bioactive derivative or analogue thereof, wherein said polypeptide:

- (i) is selected from the list comprising EcR polypeptide of a steroid receptor, the partner protein (USP polypeptide) of a steroid receptor and the USP polypeptide of a juvenile hormone receptor; and
- (ii) comprises an amino acid sequence that is at least 40% identical to any one of the amino acid sequences set forth in <400>2, <400>4, <400>6, <400>10, <400>12 or <400>14;

15 wherein said polypeptide is substantially free of naturally-associated insect cell components.

A fifth aspect of the invention provides a cell comprising the subject isolated nucleic acid molecule which encodes a steroid receptor polypeptide or a juvenile hormone receptor polypeptide.

20

In a preferred embodiment, the cell of the present invention expresses the polypeptide encoded by the nucleic acid molecule.

In a preferred embodiment, the cell expresses a steroid receptor polypeptide or a fragment thereof which receptor is capable of binding to an insect steroid or analogue thereof or a candidate insecticidally active agent to form an activated complex, and comprises a nucleic acid sequence encoding a bioactive molecule or a reporter molecule operably linked to one or more insect steroid response elements which on binding of the said activated complex promotes transcription of the nucleic acid sequence, wherein said cell on exposure to insect  
30 steroid or an analogue thereof, regulates expression of said bioactive molecule or allows detection of said reporter molecule.

In a further aspect of this invention, there is provided an animal (such as a mammal), microorganism, plant or aquatic organism, containing one or more cells as mentioned above.

5 A further aspect of the present invention provides a method of identifying a modulator of insect steroid receptor-mediated gene expression or insect juvenile hormone receptor-mediated gene expression comprising:

- 10 (i) assaying the expression of a reporter gene in the presence of a recombinant or isolated insect steroid receptor polypeptide or a juvenile hormone receptor polypeptide of the invention and a potential modulator; and
- (ii) assaying the expression of a reporter gene in the presence of a recombinant or isolated insect steroid receptor polypeptide or a juvenile hormone receptor polypeptide of the invention and without said potential modulator; and
- 15 (ii) comparing expression of the reporter gene in the presence of the potential modulator to the expression of a reporter gene in the absence of the potential modulator,

wherein said reporter gene is placed operably under the control of a steroid response element (SRE) to which said insect steroid receptor binds or a promoter sequence comprising said SRE.

20

A still further aspect of the invention provides a method of identifying a potential insecticidal compound comprising:

- 25 (i) assaying the binding directly or indirectly of a recombinant or isolated insect steroid receptor polypeptide or a juvenile hormone receptor polypeptide of the invention to a steroid response element (SRE) to which said insect steroid receptor binds, in the presence of a candidate compound; and
- (ii) assaying the binding directly or indirectly of a recombinant or isolated insect steroid receptor polypeptide or a juvenile hormone receptor polypeptide of the invention to a steroid response element (SRE) to which said insect steroid receptor binds, in the absence of said candidate compound; and
- 30 (ii) comparing the binding assayed at (i) and (ii), wherein a difference in the level

- 10 -

of binding indicates that the candidate compound possesses potential insecticidal activity.

A still further aspect of the invention provides a method of identifying a candidate insecticidally-active agent comprising the steps of:

- 5 a) expressing an EcR polypeptide of a steroid receptor or a fragment thereof which includes the ligand-binding region, optionally in association with an EcR partner protein (USP polypeptide) of a steroid receptor or ligand binding domain thereof, optionally in association with an insect steroid or analogue thereof so as to form a complex;
- 10 b) purifying or precipitating the complex;
- c) determining the three-dimensional structure of the ligand binding domain of the complex; and
- 15 d) identifying compounds which bind to or associate with the three-dimensional structure of the ligand binding domain, wherein said compounds represent candidate insecticidally-active agents.

A still further aspect of the invention provides a method of identifying a candidate insecticidally-active agent comprising the steps of:

- 20 a) expressing a USP polypeptide of a juvenile hormone receptor or a fragment thereof which includes the ligand-binding region, optionally in association with an EcR polypeptide of a steroid receptor or ligand binding domain thereof, and optionally in association with an insect steroid or analogue thereof, so as to form a complex;
- 25 b) purifying or precipitating the complex;
- c) determining the three-dimensional structure of the ligand binding domain of the complex; and
- 30 d) identifying compounds which bind to or associate with the three-dimensional structure of the ligand binding domain, wherein said compounds represent candidate insecticidally-active agents.

In another aspect this invention relates to a method or assay for screening insecticidally active

- 11 -

compounds which comprises reacting a candidate insecticidal compound with a steroid receptor polypeptide or fragment thereof encompassing the ligand binding domain, or complex thereof with a partner protein or a fragment thereof which encompasses the ligand binding domain, and detecting binding or absence of binding of said compound so as to determine  
5 insecticidal activity.

A still further aspect of the invention provides a synthetic compound which interacts with the three dimensional structure of a polypeptide or protein selected from the list comprising:

- (i) an EcR polypeptide of a steroid receptor or a fragment thereof;
- 10 (ii) an EcR partner protein (USP polypeptide) of a steroid receptor or a fragment thereof;
- (iii) a USP polypeptide of a juvenile hormone receptor; and
- (iv) a functional receptor or protein complex formed by association of (i) and (ii),

wherein said compound is capable of binding to said polypeptide or protein to agonise or  
15 antagonise the binding activity or bioactivity thereof.

Preferably, the synthetic compounds are derived from the three dimensional structure of insect steroid receptor(s) or juvenile hormone receptor(s) which compounds bind to said receptor(s) and have the effect of either inactivating the receptor(s) or potentiating the activity of the  
20 receptor(s). More preferably, the compounds mimic the three-dimensional structure of a ligand which binds to the receptor(s) and more preferably, mimic the three-dimensional structure of a ligand which binds to the ligand-binding region of said receptor(s).

In a still further aspect of this invention, there is provided a screening system for insecticidally  
25 active agents comprising a nucleotide sequence encoding a steroid receptor or a fragment thereof, and a nucleotide sequence encoding a partner protein or a fragment thereof which associates with the receptor so as to confer enhanced affinity for insect steroid response elements, enhanced affinity for insect steroids or analogues thereof, or insecticidally active agents and/or thermostability or enhanced thermostability of said receptor, which receptor and  
30 partner protein is capable of binding to a candidate insecticidally active agent to form an activated complex, and a nucleic acid sequence encoding a bioactive molecule or a reporter

- 12 -

molecule operably linked to one or more insect steroid response elements which on binding of the said activated complex regulates transcription of the nucleic acid sequence, wherein on exposure to said agent expression of the bioactive molecule or reporter molecule correlates with insecticidal activity.

5

In another aspect of this invention, there is provided a method for the regulated production of a bioactive molecule or a reporter molecule in a cell, said method comprising the steps of introducing into said cell:

- 10 a) a nucleotide sequence encoding a steroid receptor or a fragment thereof which is capable of binding an insect steroid or analogue thereof, to form an activated complex; and
  - b) a nucleotide sequence encoding said bioactive molecule or reporter molecule operably linked to one or more insect steroid response elements which on binding of the said activated complex regulates transcription of the nucleic acid sequence
  - 15 encoding said bioactive molecule or reporter molecule,
- wherein exposing the cell to an insect steroid or analogue thereof regulates expression of the bioactive molecule or reporter molecule.

#### SUMMARY OF SEQUENCE LISTING

- 20 **<400>1:** The nucleotide sequence of the open reading frame of a cDNA molecule which encodes the EcR polypeptide subunit of the *L. cuprina* ecdysone receptor and amino acid sequence therefor.
- <400>2:** The amino acid sequence of the EcR polypeptide subunit of the *L. cuprina* ecdysone receptor.
- 25 **<400>3:** The nucleotide sequence of the open reading frame of a cDNA molecule which encodes the EcR partner protein (USP polypeptide) subunit of the *L. cuprina* ecdysone receptor and/or which encodes the USP polypeptide subunit of the *L. cuprina* juvenile hormone receptor, and amino acid sequence therefor.
- <400>4:** The amino acid sequence of the EcR partner protein (USP polypeptide) subunit
- 30 of the *L. cuprina* ecdysone receptor and/or the amino acid sequence of the USP polypeptide subunit of the *L. cuprina* juvenile hormone receptor.

- <400>5:** The nucleotide sequence of a cDNA molecule which encodes part of the EcR polypeptide subunit of the *M. persicae* ecdysone receptor and amino acid sequence therefor.
- <400>6:** The amino acid sequence of a part of the EcR polypeptide subunit of the *M.*  
5 *persicae* ecdysone receptor.
- <400>7:** The nucleotide sequence of the EcR probe 1 which is specific for genetic sequences encoding the EcR polypeptide subunit of aphid ecdysone receptors, in particular the EcR polypeptide subunit of the *M. persicae* ecdysone receptor.
- <400>8:** The nucleotide sequence of the EcR probe 2 sequence which is specific for  
10 genetic sequences encoding the EcR polypeptide subunit of aphid ecdysone receptors, in particular the EcR polypeptide subunit of the *M. persicae* ecdysone receptor.
- <400>9:** The nucleotide sequence of the open reading frame of a cDNA molecule which encodes the EcR polypeptide subunit of the *M. persicae* ecdysone receptor and  
15 amino acid sequence therefor.
- <400>10:** The amino acid sequence of a part of the EcR polypeptide subunit of the *M. persicae* ecdysone receptor.
- <400>11:** The nucleotide sequence of a 140 base-pair cDNA molecule which encodes  
20 part of the EcR partner protein (USP polypeptide) subunit of the *M. persicae* ecdysone receptor and/or which encodes part of the USP polypeptide subunit of the *M. persicae* juvenile hormone receptor, and amino acid sequence therefor.
- <400>12:** The amino acid sequence of a fragment of the EcR partner protein (USP polypeptide) subunit of the *M. persicae* ecdysone receptor and/or a fragment  
25 of the amino acid sequence of the USP polypeptide subunit of the *M. persicae* juvenile hormone receptor.
- <400>13:** The nucleotide sequence of a 150 base-pair probe which is specific for genetic sequences encoding the EcR partner protein (USP polypeptide) subunit of  
insect ecdysone receptors and/or the USP polypeptide subunit of insect  
30 juvenile hormone receptors, and amino acid sequence therefor.
- <400>14:** The amino acid sequence encoded by the nucleotide sequence of <400>13,

comprising amino acid residues 108-149 of the EcR partner protein (USP polypeptide) subunit of the *L. cuprina* ecdysone receptor and/or amino acid residues 108-149 of the amino acid sequence of the USP polypeptide subunit of the *L. cuprina* juvenile hormone receptor set forth herein as <400>4.

- 5 <400>15: The nucleotide sequence of the degenerate primer Rdna3.  
 <400>16: The nucleotide sequence of the degenerate primer Rdna4.  
 <400>17: The nucleotide sequence of the primer Mdna1.  
 <400>18: The nucleotide sequence of the primer Mdna2.  
 <400>19: The nucleotide sequence of the primer AP1.  
 10 <400>20: The nucleotide sequence of the degenerate primer AP2.

#### BRIEF DESCRIPTION OF THE DRAWINGS

- Figure 1** is a graphical representation showing function of the EcR polypeptide subunit of the *L. cuprina* ecdysone receptor *in vivo*. CHO cells were cotransfected with:
- (1) one of the following expression plasmids: pSGDmEcR, pSGLcEcR, or the parental expression plasmid pSG5 as a control, at 1 µg/ml;
  - (2) plasmid p(EcRE)<sub>7</sub>-CAT (1 µg/ml); and
  - (3) an independent reporter plasmid, pPGKLacZ, at 1 µg/ml.
- 20 CAT expression was induced with Muriesterone A at either 10 µM or 50 µM while control cells received only the carrier ethanol. ELISA kits were used to quantify the synthesis of CAT and β-galactosidase in extracts of cells forty eight hours after transfection. The level of CAT was normalized to the level of β-galactosidase in the same extract. Fold-induction represents the normalized values for CAT gene expression in cells transfected with pSGDmEcR, pSGLcEcR
- 25 or pSG5 in the presence of hormone, relative to the normalized values for CAT gene expression in cells transfected with the same plasmid, but in the absence of hormone. The average values of three independent experiments are shown and the error bars indicate standard error of the mean.
- 30 **Figure 2** is a copy of a graphical representation showing the activity of plasmid pSGLD and pSGDL, containing chimeric EcR polypeptide subunits of insect ecdysone receptors,



- 15 -

produced as described in the Examples. Cotransfection assays were performed as described in the Examples using plasmids pSGLD and pSGDL and the CAT reporter plasmid p(EcRE)<sub>7</sub>-CAT (1µg/ml) and an independent reporter, pPGKLacZ at 1 µg/ml each. CAT/b-Gal (%) refers to CAT reporter activity expressed as a percentage relative to β-galactosidase activity produced by the internal control reporter, pPGKLacZ.

**Figure 3** is a copy of a graphical representation showing the binding activity in extracts of Sf9 and Sf21 cells containing a baculovirus expressing LcEcRDEF and LcUSPDEF, as described in the Examples. Control cells contained baculovirus expressing β-galactosidase and CAT only.

#### DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

One aspect of the present invention provides an isolated nucleic acid molecule comprising a nucleotide sequence which encodes or is complementary to a sequence which encodes a steroid receptor polypeptide or a juvenile hormone receptor polypeptide or a bioactive derivative or analogue thereof, wherein said polypeptide:

- (i) is selected from the list comprising EcR polypeptide of a steroid receptor, the partner protein (USP polypeptide) of a steroid receptor and the USP polypeptide of a juvenile hormone receptor; and
- (ii) comprises an amino acid sequence that is at least 40% identical to any one of the amino acid sequences set forth in <400>2, <400>4, <400>6, <400>10, <400>12 or <400>14.

Accordingly, the isolated nucleic acid molecule of the invention may comprise a fragment of a nucleotide sequence encoding a full-length receptor polypeptide.

It is to be understood that a "fragment" of a nucleotide sequence encoding an EcR polypeptide subunit of a steroid receptor or an EcR partner protein (USP polypeptide) of a steroid receptor or a USP polypeptide of a juvenile hormone receptor, refers to a nucleotide sequence encoding a part or fragment of such a receptor which is capable of binding or associating with an insect steroid or an analogue thereof, or a candidate insecticidally active compound.

- 16 -

Fragments of a nucleotide sequence would generally comprise in excess of twenty contiguous nucleotides derived from the base sequence and may encode one or more domains of a functional insect steroid receptor or juvenile hormone receptor.

- 5 Preferably, the isolated nucleic acid molecule of the invention encodes an ecdysteroid receptor polypeptide. Those skilled in the art are aware that ecdysteroid receptors derived from insects are heterodimeric receptors comprising an EcR polypeptide subunit and an EcR partner protein (USP polypeptide) (see also Jones and Sharp, 1997). In this regard, the present inventors have discovered that the USP polypeptide of the insect juvenile hormone receptor
- 10 is structurally-identical to the EcR partner protein of the ecdysteroid receptor of the present invention, however juvenile hormone receptors comprise monomers or multimers of the USP polypeptide acting without the EcR polypeptide subunit that is present in the ecdysteroid receptors. Accordingly, the present invention extends equally to nucleotide sequences encoding polypeptides of both the ecdysteroid receptors and polypeptides of the juvenile
- 15 hormone receptors of insects.

More preferably, the isolated nucleic acid molecule of the invention encodes an ecdysteroid receptor that is modulated by one or more of the steroids ecdysone, ponasterone A, or muristerone, or an analogue of an ecdysteroid.

20

The isolated nucleic acid molecule of the invention may be derived from any organism that contains steroid receptors that are responsive to ecdysteroids or ecdysteroid-like compounds or juvenile hormones, or analogues of such receptor-ligands. Accordingly, the present invention is not to be limited in any of its embodiments to the particular source of the subject

- 25 nucleic acid, or polypeptide encoded therefor.

Preferably, the isolated nucleic acid molecule of the invention is derived from insects, helminths (nematodes, cestodes, trematodes), protozoa, and ants, amongst others.

- 30 More preferably, the isolated nucleic acid molecule of the invention is derived from an insect selected from the list comprising diptera, hemiptera, coleoptera, neuroptera, lepidoptera and

ants, amongst others. Still more preferably, the isolated nucleic acid molecule of the present invention is derived from aphids, scale insects, leaf hoppers, white fly, and blowflies such as sheep blowflies.

- 5 The present invention does not extend to amino acid sequences comprising the complete EcR polypeptide subunit of the *D. melanogaster* ecdysone receptor as described in WO91/13167, or to nucleotide sequences encoding same. However, this exclusion is made on the understanding that the present invention does encompass chimeric genes and fusion proteins which include the *D. melanogaster* nucleotide and amino acid sequences, respectively.

10

In a particularly preferred embodiment, the isolated nucleic acid molecule of the present invention is derived from the aphid *M. persicae* or alternatively, from the Australian sheep blowfly, *L. cuprina*.

- 15 The ecdysteroid receptor is preferably modulated by one or more of the steroids ecdysone, ponasterone A, or muristerone, or an analogue of an ecdysteroid.

- As used herein, the term "analogue of an ecdysteroid" shall be taken to indicate any compound that binds to one or more polypeptide subunits of an ecdysteroid receptor or the heterodimeric
- 20 holoreceptor comprising same or alternatively or in addition, which binds to the USP polypeptide of a juvenile hormone receptor or alternatively or in addition, which binds to a bioactive derivative or analogue of said polypeptides or holoreceptor. The term "analogue of an ecdysteroid" shall further be taken to indicate any compound that modulates the bioactivity of one or more polypeptide subunits of an ecdysteroid receptor or the heterodimeric
- 25 holoreceptor comprising same or alternatively or in addition, that modulates the bioactivity of the USP polypeptide of a juvenile hormone receptor or alternatively or in addition, that modulates the bioactivity of a bioactive derivative or analogue of said polypeptides or holoreceptor.
- 30 The present invention is not to be limited in scope to the specific *L. cuprina* and *M. persicae* nucleotide and amino acid sequences set forth in the accompanying Sequence Listing and

persons skilled in the art will readily be able to identify additional related sequences from other sources using art-recognised procedures, for example using nucleic acid hybridisation and/or polymerase chain reaction essentially as described by Ausubel *et al.* (1992) and/or McPherson *et al.* (1991) and/or Sambrook *et al.* (1989).

5

Accordingly, the present invention clearly encompasses isolated nucleic acid molecules which encode or are complementary to isolated nucleic acid molecules which encode the subject EcR polypeptide of a steroid receptor or fragments thereof, and/or the subject EcR partner proteins (USP polypeptide) of a steroid receptor and/or the subject USP polypeptide of a juvenile hormone receptor, in addition to derivatives, fragments and analogues thereof which comprise amino acid sequences having at least 40% identity to the amino acid sequences set forth in any one of <400>2, <400>4, <400>6, <400>10, <400>12 or <400>14.

Preferably, the percentage similarity to any one of <400>2, <400>4, <400>6, <400>10, <400>12 or <400>14 is at least about 60%, more preferably at least about 80%, even more preferably at least about 90%.

In determining whether or not two amino acid sequences fall within these percentage limits, those skilled in the art will be aware that it is necessary to conduct a side-by-side comparison or multiple alignment of sequences. In such comparisons or alignments, differences will arise in the positioning of non-identical residues, depending upon the algorithm used to perform the alignment. In the present context, reference to a percentage identity or similarity between two or more amino acid sequences shall be taken to refer to the number of identical and similar residues respectively, between said sequences as determined using any standard algorithm known to those skilled in the art. For example, amino acid sequence identities or similarities may be calculated using the GAP programme and/or aligned using the PILEUP programme of the Computer Genetics Group, Inc., University Research Park, Madison, Wisconsin, United States of America (Devereaux *et al.*, 1984). The GAP programme utilizes the algorithm of Needleman and Wunsch (1970) to maximise the number of identical/similar residues and to minimise the number and/or length of sequence gaps in the alignment. Alternatively or in addition, wherein more than two amino acid sequences are being compared, the ClustalW

30

- 19 -

programme of Thompson *et al* (1994) is used.

In an alternative embodiment, the isolated nucleic acid molecule of the invention encodes or is complementary to an isolated nucleic acid molecule which encodes a steroid receptor  
5 polypeptide or a fragment thereof, or a partner protein (USP) or a fragment thereof, which at least comprises an amino acid sequence which is substantially identical to any one of <400>2, <400>4, <400>6, <400>10, <400>12 or <400>14.

As used herein, the term "substantially identical" or similar term shall be taken to include any  
10 sequence which is at least about 95% identical to a stated nucleotide sequence or amino acid sequence, including any homologue, analogue or derivative of said stated nucleotide sequence or amino acid sequence.

Those skilled in the art will be aware that variants of the nucleotide sequences sequence set  
15 forth in any one of <400>1 or <400>3 or <400>5 or <400>7 or <400>8 or <400>9 or <400>11 or <400>13, which variants encode EcR polypeptides of insect steroid receptors or fragments thereof or EcR partner proteins (USP polypeptides) or fragments thereof, or USP polypeptides of insect juvenile hormone receptors, may be isolated by hybridization under low stringency conditions as exemplified herein.

20

Such variants include any genomic sequences, cDNA sequences mRNA or other isolated nucleic acid molecules derived from the nucleic acid molecules exemplified herein by the Sequence Listing. Additional variants are not excluded.

25 In a particularly preferred embodiment of the invention, the variant nucleotide sequences encode a fragment of the EcR polypeptide of the insect steroid receptor or a fragment of the EcR partner protein (USP polypeptide) of the insect steroid receptor or a fragment of the USP polypeptide of the insect juvenile hormone receptor.

30 Preferred fragments of the subject polypeptides include one or more regions or domains which are involved in the interaction or association between the monomeric polypeptide subunits of

- 20 -

a multimeric receptor and/or which are involved in the interaction or association between (i) a cognate steroid or receptor ligand or *cis*-acting DNA sequence; and (ii) said monomeric polypeptide subunits or the receptor *per se*. In a particularly preferred embodiment, the fragments comprise the DNA-binding domain, linker domain (domain D) or a part thereof, or

5 ligand-binding domain (eg. hormone-binding domain) of a steroid receptor polypeptide or juvenile hormone receptor polypeptide or receptor holoenzyme. As exemplified herein, wherein biological activity of the *L. cuprina* ecdysone receptor is required, it is preferably to include at least a ligand-binding region comprising the ligand-binding domain and at least a part of the linker domain of the EcR polypeptide subunit, optionally in association with a ligand-binding

10 region comprising at least the ligand-binding domain and at least a part of the linker domain of the EcR partner protein (USP polypeptide) subunit of said receptor. Additional fragments are not excluded.

Homologues, analogues and derivatives of the nucleotide sequences exemplified herein may

15 be isolated by hybridising same under at least low stringency conditions and preferably under at least medium stringency conditions, to the nucleic acid molecule set forth in any one of <400>1 or <400>3 or <400>5 or <400>7 or <400>8 or <400>9 or <400>11 or <400>13 or to a complementary strand thereof. More preferably, the isolated nucleic acid molecule according to this aspect of the invention is capable of hybridising under at least high stringency conditions

20 to the nucleic acid molecule set forth in any one of <400>1 or <400>3 or <400>5 or <400>7 or <400>8 or <400>9 or <400>11 or <400>13 or to a complementary strand thereof.

For the purposes of defining the level of stringency, a low stringency is defined herein as being a hybridisation and/or a wash carried out in 6xSSC buffer, 0.1% (w/v) SDS at 28°C or

25 alternatively, as exemplified herein. Generally, the stringency is increased by reducing the concentration of SSC buffer, and/or increasing the concentration of SDS and/or increasing the temperature of the hybridisation and/or wash. A medium stringency comprises a hybridisation and/or a wash carried out in 0.2xSSC-2xSSC buffer, 0.1% (w/v) SDS at 42°C to 65°C, while a high stringency comprises a hybridisation and/or a wash carried out in 0.1xSSC-0.2xSSC

30 buffer, 0.1% (w/v) SDS at a temperature of at least 55°C. Conditions for hybridisations and washes are well understood by one normally skilled in the art. For the purposes of further

clarification only, reference to the parameters affecting hybridisation between nucleic acid molecules is found in Ausubel *et al.* (1992), which is herein incorporated by reference.

- In an even more preferred embodiment of the invention, a hybridising nucleic acid molecule
- 5 further comprises a sequence of nucleotides which is at least 40% identical to at least 10 contiguous nucleotides, preferably at least 50 contiguous nucleotides and more preferably at least 100 contiguous nucleotides, derived from any one of <400>1 or <400>3 or <400>5 or <400>7 or <400>8 or <400>9 or <400>11 or <400>13 or a complementary strand thereof.
- 10 In determining whether or not two nucleotide sequences fall within these percentage limits, those skilled in the art will be aware that it is necessary to conduct a side-by-side comparison or multiple alignment of sequences. In such comparisons or alignments, differences may arise in the positioning of non-identical residues, depending upon the algorithm used to perform the alignment. In the present context, reference to a percentage identity between two or more
- 15 nucleotide sequences shall be taken to refer to the number of identical residues between said sequences as determined using any standard algorithm known to those skilled in the art. For example, nucleotide sequences may be aligned and their identity calculated using the BESTFIT programme or other appropriate programme of the Computer Genetics Group, Inc., University Research Park, Madison, Wisconsin, United States of America (Devereaux *et al.*, 20 1984).

- In an alternative embodiment, nucleotide sequences encoding EcR polypeptide subunits of insect steroid receptors or fragments thereof and/or EcR partner proteins (USP polypeptides) of insect steroid receptor or fragments thereof, or USP polypeptides of insect juvenile hormone
- 25 receptor polypeptides, are amplified in the polymerase chain reaction. According to this embodiment, one or two or more nucleic acid "primer molecules" derived from a nucleotide sequence exemplified herein as <400>1 or <400>3 or <400>5 or <400>7 or <400>8 or <400>9 or <400>11 or <400>13 or a complementary strand thereof, are annealed or hybridized to a nucleic acid "template molecule" which at least comprises a nucleotide sequence encoding a
- 30 related genetic sequence or a functional part thereof, and nucleic acid molecule copies of the template molecule are amplified enzymatically using a thermostable DNA polymerase enzyme,

- 22 -

such as *TaqI* polymerase or *Pfu* polymerase, amongst others.

More particularly, one of the primer molecules comprises contiguous nucleotides derived from any one of <400>1 or <400>3 or <400>5 or <400>7 or <400>8 or <400>9 or <400>11 or  
5 <400>13 and another of said primers comprises contiguous nucleotides complementary to <400>1 or <400>3 or <400>5 or <400>7 or <400>8 or <400>9 or <400>11 or <400>13, subject to the proviso that the first and second primers are not complementary to each other.

In a preferred embodiment, each nucleic acid primer molecule is at least 10 nucleotides in  
10 length, more preferably at least 20 nucleotides in length, even more preferably at least 30 nucleotides in length, still more preferably at least 40 nucleotides in length and even still more preferably at least 50 nucleotides in length.

Furthermore, the nucleic acid primer molecules consists of a combination of any of the  
15 nucleotides adenine, cytidine, guanine, thymidine, or inosine, or functional analogues or derivatives thereof which are at least capable of being incorporated into a polynucleotide molecule without having an inhibitory effect on the hybridisation of said primer to the template molecule in the environment in which it is used.

20 Furthermore, one or both of the nucleic acid primer molecules may be contained in an aqueous mixture of other nucleic acid primer molecules, for example a mixture of degenerate primer sequences which vary from each other by one or more nucleotide substitutions or deletions. Alternatively, one or both of the nucleic acid primer molecules may be in a substantially pure form.

25

In a particularly preferred embodiment exemplified herein, two primer nucleotide sequences are used to amplify related sequences, said primers comprising the nucleotide sequences as set forth in any one of <400>15 to <400>20 inclusive. Even more preferably, the primers are used in the combination of (i) <400>15 and <400>16; or (ii) <400>17 and <400>18; or (iii)  
30 <400>19 and <400>20.



- 23 -

The nucleic acid template molecule may be in a recombinant form, in a virus particle, insect cell, bacteriophage particle, yeast cell, animal cell, or a plant cell. Preferably, the nucleic acid template molecule is derived from an insect species.

5 Those skilled in the art will be aware that there are many known variations of the basic polymerase chain reaction procedure. Such variations are discussed, for example, in McPherson *et al* (1991). The present invention extends to the use of all such variations in the isolation of variant insect steroid receptor-encoding genes or fragments thereof, and/or variant partner protein-encoding genes or fragments thereof to those exemplified herein.

10

The isolated nucleic acid molecule of the present invention, including those sequences exemplified herein and any variants thereof, may be cloned into a plasmid or bacteriophage molecule, for example to facilitate the preparation of primer molecules or hybridisation probes or for the production of recombinant gene products. Methods for the production of such  
15 recombinant plasmids, cosmids, bacteriophage molecules or other recombinant molecules are well-known to those of ordinary skill in the art and can be accomplished without undue experimentation. Accordingly, the invention further extends to any recombinant plasmid, bacteriophage, cosmid or other recombinant molecule comprising the nucleotide sequence set forth in any one of <400>1 or <400>3 or <400>5 or <400>7 or <400>8 or <400>9 or <400>11  
20 or <400>13 or <400>15 to <400>20, or a complementary sequence, homologue, analogue or derivative thereof.

The nucleic acid molecule of the present invention is also useful for developing genetic constructs which comprise and preferably, express, the EcR polypeptide subunit of the insect  
25 steroid receptor and/or the EcR partner protein (USP polypeptide) of the steroid receptor and/or the USP polypeptide of the juvenile hormone receptor, thereby providing for the production of the recombinant polypeptides in isolated cells or transformed tissues.

Accordingly, a further aspect of the present invention provides a genetic construct comprising  
30 the subject isolated nucleic acid molecule encoding the insect steroid receptor polypeptide or a juvenile hormone receptor polypeptide, operably linked to a promoter sequence. Preferably,

- 24 -

the subject nucleic acid molecule is in an expressible format, such that it is possible to produce a recombinant polypeptide therefrom.

- Reference herein to a "promoter" is to be taken in its broadest context and includes the transcriptional regulatory sequences of a classical genomic gene, including the TATA box which is required for accurate transcription initiation in a eukaryotic cell, with or without a CCAAT box sequence or alternatively, the Pribnow box required for accurate expression in prokaryotic cells.
- 10 Promoters may be cell, tissue, organ or system specific, or may be non-specific. Using specific promoters, the expression of a bioactive agent or other polypeptide encoded by a structural gene to which the promoter is operably connected may be targeted to a desired cellular site. For example, in transgenic animals such as sheep, it can be envisaged that cells of the transgenic animal may contain a gene encoding a steroid receptor, preferably a steroid
- 15 receptor linked to an epidermal specific promoter and a separate gene encoding, for example, epidermal growth factor (EGF) which is functionally linked to one or more insect hormone response elements and may or may not also be linked to epidermal specific promoter elements. On administration of the appropriate insect steroid hormone to the transgenic animal, the activated complex between the insect steroid receptor and insect steroid may bind
- 20 to the one or more insect steroid hormone response element thereby inducing EGF production solely in epidermal cells which may give rise to defleecing. It is to be understood that this aspect of the invention is independent of the degree of thermostability of the insect steroid receptor. The same principle applies to expression of any bioactive molecule or reporter molecule in a specific cell type which is regulated by a transactivating complex between a
- 25 steroid receptor complex and an appropriate insect steroid.

- In the present context, the term "promoter" is also used to describe a synthetic or fusion molecule, or derivative which confers, activates or enhances expression in a cell in response to an external stimulus. Accordingly, the promoter may include further regulatory elements (i.e.
- 30 upstream activating sequences, enhancers and silencers) which alter gene expression in response to developmental and/or external stimuli, or in a tissue-specific manner. Preferred

- 25 -

promoters may contain copies of one or more specific regulatory elements, in particular steroid responsive elements (SREs) or hormone-responsive elements (HREs), to further enhance expression and/or to alter the spatial expression and/or temporal expression pattern.

- 5 Reference herein to the term "steroid response element" shall be taken to refer to one or more *cis*-acting nucleotide sequences present in a naturally-occurring or synthetic or recombinant gene the expression of which is regulated by an insect steroid, such as an ecdysteroid, for example ecdysone or ponasterone A, wherein said regulation of expression results from an direct or indirect interaction between a steroid receptor and said *cis*-acting
- 10 nucleotide sequence response element. Exemplary insect steroid hormone response elements include the ecdysone response element hsp27 (EcRE) and any other nucleotide sequence which is capable of binding ecdysteroid receptors or polypeptide subunits thereof or fragments or analogies thereof (such as associated with E75, E74 or other *Drosophila* early genes), as described for example by Riddihough and Pelham (1987).

15

For example, an SRE or a plurality of such elements may be operably linked to a promoter such as the polyhedron promoter, p10 promoter, MMTV promoter or SV40 promoter, to make transcription of a structural gene to which said promoter is operably connected responsive to the presence of a steroid bound to the insect receptor (which may act as a transcription factor).

- 20 One or more insect SREs may be located within a promoter, and may replace sequences within a selected promoter which confer responsiveness to hormones or other agents which regulate promoter activity. Where response elements are different they may lead to preferential binding of different insect steroids or analogues thereof such that a promoter may be differentially regulated.

25

Particularly preferred SREs according to this embodiment include, but are not limited to, the hsp27 ecdysone response element described by Riddihough and Pelham (1987) or the 13 base-pair palindromic core contained therein.

- 30 A promoter is usually, but not necessarily, positioned upstream or 5', of a structural gene, the expression of which it regulates. Furthermore, the regulatory elements comprising a promoter

- 26 -

are usually positioned within 2 kb of the start site of transcription of the gene.

Placing a gene or isolated nucleic acid molecule operably under the control of a promoter sequence means positioning said gene or isolated nucleic acid molecule such that its  
5 expression is controlled by the promoter sequence. Promoters are generally positioned 5' (upstream) to the genes that they control. In the construction of heterologous promoter/structural gene combinations it is generally preferred to position the promoter at a distance from the gene transcription start site that is approximately the same as the distance between that promoter and the gene it controls in its natural setting, i.e., the gene from which  
10 the promoter is derived. As is known in the art, some variation in this distance can be accommodated without loss of promoter function. Similarly, the preferred positioning of a regulatory sequence element with respect to a heterologous gene to be placed under its control is defined by the positioning of the element in its natural setting, i.e., the genes from which it is derived. Again, as is known in the art, some variation in this distance can also  
15 occur.

Those skilled in the art will recognise that the choice of promoter will depend upon the nature of the cell being transformed and when expression is required. Furthermore, it is well-known in the art that the promoter sequence used in the expression vector will also vary depending  
20 upon the level of expression required and whether expression is intended to be constitutive or regulated.

For expression in eukaryotic cells, the genetic construct generally comprises, in addition to the nucleic acid molecule of the invention, a promoter and optionally other regulatory sequences  
25 designed to facilitate expression of said nucleic acid molecule. The promoter may be derived from a genomic clone which normally encodes the expressed protein or alternatively, it may be a heterologous promoter derived from another genetic source. Promoter sequences suitable for expression of genes in eukaryotic cells are well-known in the art.

30 Suitable promoters for use in eukaryotic expression vectors include those capable of regulating expression in mammalian cells, insect cells such as Sf9 or Sf21. (*Spodoptera frugiperda*) cells,

- 27 -

yeast cells and plant cells. Preferred promoters for expression in eukaryotic cells include the p10 promoter, MMTV promoter, polyhedron promoter, the SV40 early promoter and the cytomegalovirus (CMV- IE) promoter, promoters derived from immunoglobulin-producing cells (see, United States Patent No 4,663,281), polyoma virus promoters, and the LTR from various retroviruses (such as murine leukemia virus, murine or Rous sarcoma virus and HIV), amongst others ( See, *Enhancers and Eukaryotic Gene Expression*, Cold Spring Harbor Press, New York, 1983, which is incorporated herein by reference). Examples of other expression control sequences are enhancers or promoters derived from viruses, such as SV40, Adenovirus, Bovine Papilloma Virus, and the like.

10

Wherein the expression vector is intended for the production of recombinant protein, the promoter is further selected such that it is capable of regulating expression in a cell which is capable of performing any post-translational modification to the polypeptide which may be required for the subject recombinant polypeptide to be functional, such as N-linked glycosylation. Cells suitable for such purposes may be readily determined by those skilled in the art. By way of exemplification, Chinese hamster ovary (CHO) cells may be employed to carry out the N-terminal glycosylation and signal sequence cleavage of a recombinant polypeptide produced therein. Alternatively, a baculovirus expression vector such as the pFastBac vector supplied by GibcoBRL may be used to express recombinant polypeptides in Sf9 (*Spodoptera frugiperda*) cells, following standard protocols.

20

Numerous expression vectors suitable for the present purpose have been described and are readily available. The expression vector may be based upon the pcDNA3 vector distributed by Medos Company Pty Ltd, Victoria, Australia, which comprises the CMV promoter and BGH terminator sequences for regulating expression of the recombinant polypeptide of the invention in a eukaryotic cell, when isolated nucleic acid sequences encoding same are inserted, in the sense orientation relative to the CMV promoter, into the multiple cloning site of said vector. Alternatively, the SG5 expression vector of Greene *et al.* (1988), supplied by Stratagene, or the pQE series of vectors supplied by Qiagen are particularly useful for such purposes, as exemplified herein.

30

- 28 -

Examples of eukaryotic cells contemplated herein to be suitable for expression include mammalian, yeast, insect, plant cells or cell lines such as COS, VERO, HeLa, mouse C127, Chinese hamster ovary (CHO), WI-38, baby hamster kidney (BHK), MDCK, sf21 (insect) or Sf9 (insect) cell lines. Such cell lines are readily available to those skilled in the art.

5

The prerequisite for expression in prokaryotic cells such as *Escherichia coli* is the use of a strong promoter with an effective ribosome binding site. Typical promoters suitable for expression in bacterial cells such as *E. coli* include, but are not limited to, the *lacZ* promoter, temperature-sensitive  $\lambda_{\text{L}}$  or  $\lambda_{\text{S}}$  promoters, T7 promoter or the IPTG-inducible *tac* promoter. A number of other vector systems for expressing the nucleic acid molecule of the invention in *E. coli* are well-known in the art and are described for example in Ausubel *et al* (1992).

10

Numerous vectors having suitable promoter sequences for expression in bacteria have been described, such as for example, pKC30 ( $\lambda_{\text{L}}$ ; Shimatake and Rosenberg, 1981), pKK173-3 (*tac*; Amann and Brosius, 1985), pET-3 (T7: Studier and Moffat, 1986) or the pQE series of expression vectors (Qiagen, CA), amongst others.

15

Suitable prokaryotic cells include corynebacterium, salmonella, *Escherichia coli*, *Bacillus* sp. and *Pseudomonas* sp., amongst others. Bacterial strains which are suitable for the present purpose are well-known in the relevant art (Ausubel *et al*, 1992).

20

The genetic constructs described herein may further comprise genetic sequences corresponding to a bacterial origin of replication and/or a selectable marker gene such as an antibiotic-resistance gene, suitable for the maintenance and replication of said genetic construct in a prokaryotic or eukaryotic cell, tissue or organism. Such sequences are well-known in the art.

25

Selectable marker genes include genes which when expressed are capable of conferring resistance on a cell to a compound which would, absent expression of said selectable marker gene, prevent or slow cell proliferation or result in cell death. Preferred selectable marker

30

genes contemplated herein include, but are not limited to antibiotic-resistance genes such as those conferring resistance to ampicillin, Claforan, gentamycin, G-418, hygromycin, rifampicin, kanamycin, neomycin, spectinomycin, tetracycline or a derivative or related compound thereof or any other compound which may be toxic to a cell.

5

The origin of replication or a selectable marker gene will be spatially-separated from those genetic sequences which encode the recombinant receptor polypeptide or fusion polypeptide comprising same.

- 10 Preferably, the genetic constructs of the invention, including any expression vectors, are capable of introduction into, and expression in, an *in vitro* cell culture, or for introduction into, with or without integration into the genome of a cultured cell, cell line and/or transgenic animal.

- A further aspect of the invention provides a cell comprising the subject isolated nucleic acid molecule which encodes a steroid receptor polypeptide or a juvenile hormone receptor polypeptide.

- As used herein, the word "cell" shall be taken to refer to a single cell, or a cell lysate, or a tissue, organ or whole organism comprising same, including a tissue, organ or whole organism comprising a clonal group of cells or a heterogenous mixture of cell types, which may be a prokaryotic or eukaryotic cell as described *supra*.

- In a preferred embodiment, the cell of the present invention expresses the isolated or recombinant polypeptide encoded by the nucleic acid molecule.

25

- In a preferred embodiment, the cell expresses a steroid receptor polypeptide or a fragment thereof which receptor is capable of binding to an insect steroid or analogue thereof or a candidate insecticidally active agent to form an activated complex, and comprises a nucleic acid sequence encoding a bioactive molecule or a reporter molecule operably linked to one or more insect steroid response elements which on binding of the said activated complex promotes transcription of the nucleic acid sequence, wherein said cell on exposure to insect

- 30 -

steroid or an analogue thereof, regulates expression of said bioactive molecule or allows detection of said reporter molecule.

To produce the cells of the invention, host cells are transfected or co-transfected or  
5 transformed with nucleotide sequences containing the DNA segments of interest (for example, the insect steroid receptor gene, the recombinant steroid response elements, or both) by well-known methods, which vary depending on the type of cellular host. For example, calcium chloride transfection is commonly utilized for prokaryotic cells, whereas lipofection or calcium phosphate treatment are often used for other cellular hosts. See, generally, Sambrook *et al*,  
10 (1989); Ausubel *et al*, (1992); and Potrykus (1990). Other transformation techniques include electroporation, DEAE-dextran, microprojectile bombardment, lipofection, microinjection, and others.

As used herein, the term "transformed cell" is meant to also include the progeny of a  
15 transformed cell.

In a further aspect of this invention, there is provided an animal (such as a mammal or insect), microorganism, plant or aquatic organism, containing one or more cells as mentioned above. Reference to plants, microorganisms and aquatic organisms includes any such organisms.  
20

In this embodiment of the invention, it is to be appreciated that administration of an insect steroid or an analogue thereof to an organism will induce expression of the desired bioactive molecule, such as a polypeptide, with attendant advantages. For example, an induced protein may have a therapeutic effect ameliorating a disease state or preventing susceptibility to  
25 disease or may modify in some way the phenotype of an organism to produce a desired effect. In humans, for example, cell transplants (such as liver cells) may under the action of insect steroids, produce desirable hormones such as insulin, growth hormone, growth factors and the like.

30 A further aspect of the invention provides a recombinant or isolated polypeptide comprising a steroid receptor polypeptide or juvenile hormone receptor polypeptide derived from an insect



- 31 -

or a bioactive derivative or analogue thereof, wherein said polypeptide:

- (i) is selected from the list comprising EcR polypeptide of a steroid receptor, the partner protein (USP polypeptide) of a steroid receptor and the USP polypeptide of a juvenile hormone receptor; and
- 5 (ii) comprises an amino acid sequence that is at least 40% identical to any one of the amino acid sequences set forth in <400>2, <400>4, <400>6, <400>10, <400>12 or <400>14;

wherein said polypeptide is substantially free of naturally-associated insect cell components.

- 10 Reference herein to "substantially free of naturally associated insect cell components" refers to at least 80% purity, preferably more than 90% purity, and more preferably more than 95% purity. Normally, purity is measured on a polyacrylamide gel with homogeneity determined by staining of protein bonds. Alternatively, high resolution may be necessary using HPLC or similar means. For most purposes, a simple chromatography column or polyacrylamide gel
- 15 may be used to determine purity. A protein which is chemically synthesized or synthesized in a cell system different from an insect cell from which it naturally originates would be free of naturally-associated insect cell components.

- The present invention clearly provides for the isolation of EcR polypeptide subunits and EcR
- 20 partner protein (USP polypeptide) subunits of ecdysteroid receptors and USP polypeptides of juvenile hormone receptors, from various organisms of the class *Insecta*, as described *supra*, in addition to protozoa and helminth sources.

- Insect steroid receptors are characterized by functional ligand-binding domains, and DNA-
- 25 binding domains, both of which interact to effect a change in the regulatory state of a gene operably linked to the DNA-binding site of the holoreceptor or a polypeptide or polypeptide fragment thereof. Thus, insect steroid receptors seem to be ligand-responsive transcription factors. Additionally, insect steroid receptors generally contain a DNA-binding domain (Domain C), and a ligand-binding domain (Domain E), separated and flanked by additional
- 30 domains as identified by Krust *et al* (1986). The C domain preferably comprises a zinc-finger DNA-binding domain which is usually hydrophilic, having high cysteine, lysine and arginine

- 32 -

content. The E domain preferably comprises hydrophobic amino acid residues and is further characterized by regions E1, E2 and E3. The ligand-binding domain of the members of the insect steroid receptor superfamily is typically carboxyl-proximal, relative to a DNA-binding domain (Evans, 1988). The entire ligand-binding domain is typically between about 200 and 5 250 amino acids but is potentially shorter. This domain has the subregions of high homology, designated the E1, E2 and E3 regions - which may be collectively referred to as the "E region". Amino acid residues proximal to the C domain comprise a region initially defined as separate A and B domains. Region D separates the more conserved domains C and E. Region D typically has a hydrophilic region whose predicted secondary structure is rich in turns and coils.

10 The F region is carboxy proximal to the E region (see, Krust *et al, supra*).

The receptor polypeptides of the present invention exhibit at least a ligand-binding domain, as characterized by sequence homology to regions E1, E2 and E3. The ligand-binding domains of the present invention are typically characterized by having significant homology in sequence 15 and structure to these three regions. Fragments of insect steroid receptors and partner proteins capable of binding insect steroids, and candidate insecticidally active compounds comprise an E-region or a sufficient portion of the E-region to allow binding.

Preferably, the recombinant or isolated EcR polypeptide subunit of the insect steroid receptor 20 or EcR partner protein (USP polypeptide) subunit of the steroid receptor or USP polypeptide of the juvenile hormone receptor as described herein is thermostable.

By "thermostable" is meant that a stated integer does not exhibit reduced activity at bacterial, plant or animal physiological temperatures above about 28°C or above about 30°C. The 25 thermostability of insect steroid hormone receptors also refers to the capacity of such receptors to bind to ligand-binding domains or regions and/or to transactivate genes linked to insect steroid hormone response elements at bacterial, plant or animal physiological temperatures above about 28°C or above about 30°C.

30 The present invention clearly extends to variants of said polypeptides, as described *supra*. The polypeptide may be substantially free of naturally associated insect cell components, or may

be in combination with a partner protein which associates with the insect steroid receptor so as to confer enhanced affinity for insect steroid response elements, enhanced affinity for insect steroids or analogues thereof. For Example, the amino acid sequences exemplified herein may be varied by the deletion, substitution or insertion of one or more amino acids.

5

In one embodiment, amino acids of a polypeptide exemplified herein may be replaced by other amino acids having similar properties, for example hydrophobicity, hydrophilicity, hydrophobic moment, charge or antigenicity, and so on.

- 10 Substitutions encompass amino acid alterations in which an amino acid of the base polypeptide is replaced with a different naturally-occurring or a non-conventional amino acid residue. Such substitutions may be classified as "conservative", in which case an amino acid residue contained in the base polypeptide is replaced with another naturally-occurring amino acid of similar character, for example Gly↔Ala, Val↔Ile↔Leu, Asp↔Glu, Lys↔Arg, Asn↔Gln  
15 or Phe↔Trp↔Tyr.

- Substitutions encompassed by the present invention may also be "non-conservative", in which an amino acid residue which is present in the base polypeptide is substituted with an amino acid having different properties, such as a naturally-occurring amino acid from a different group  
20 (eg. substituted a charged or hydrophobic amino acid with alanine), or alternatively, in which a naturally-occurring amino acid is substituted with a non-conventional amino acid.

- Those skilled in the art will be aware that several means are available for producing variants of the exemplified EcR polypeptide subunit of the insect steroid receptor or EcR partner protein  
25 (USP polypeptide) subunit of the steroid receptor or USP polypeptide of the juvenile hormone receptor, when provided with the nucleotide sequence of the nucleic acid molecule which encodes said polypeptide, for example site-directed mutagenesis of DNA and polymerase chain reaction utilising mutagenised oligonucleotide primers, amongst others.

- 30 Such polypeptide variants which are capable of binding insect steroids clearly form part of the present invention. Assays to determine such binding may be carried out according to

procedures well known in the art.

One such variant polypeptide encompassed by the present invention comprises an "in-frame" fusion polypeptide between different regions of different insect receptor polypeptides. As exemplified herein, the present inventors have discovered that, by producing synthetic genes in which various domains of a base insect steroid receptor-encoding nucleotide sequence derived from a first source are interchanged or substituted with similar sequences derived from a second source (referred to as "domain swapping"), it is possible to modify the bioactivity of the insect steroid receptor encoded therefor. For example, the biological activity of the EcR polypeptide of the *L. cuprina* or *M. persicae* ecdysone receptor exemplified herein may be modulated by replacing portions of its C-terminal or N-terminal sequences with the equivalent domains from the EcR polypeptide of the *D. melanogaster* ecdysone receptor or alternatively, by swapping regions of the EcR polypeptides of the *L. cuprina* and *M. persicae* ecdysone receptors *per se*.

15

As a further refinement, such changes in biological function can similarly be effected by making specific changes (e.g. addition, substitution or deletion) to only those amino-acids within each domain that are critical for determining the relevant catalytic function (eg. ligand-binding activity, DNA binding site affinity, etc), such as by site-directed mutagenesis.

20

According to this embodiment, there is provided a synthetic EcR polypeptide subunit of a steroid receptor, and/or a synthetic EcR partner protein (USP polypeptide) subunit of a steroid receptor, and/or a synthetic USP polypeptide of a juvenile hormone receptor, or an analogue or derive of said synthetic polypeptides, wherein said synthetic polypeptides comprise an amino acid sequence which has the following properties:

25

- (i) it differs in amino acid sequence or exhibits different biological properties to a naturally-occurring EcR polypeptide subunit of a steroid receptor, and/or a naturally-occurring EcR partner protein (USP polypeptide) subunit of a steroid receptor, and/or a naturally-occurring USP polypeptide of a juvenile hormone receptor;

30

- (ii) it comprises a first sequence of amino acids which are at least about 40% identical to a part of any one of <400>2, <400>4, <400>6, <400>10, <400>12 or <400>14

linked covalently to a second sequence of amino acids derived from an EcR polypeptide subunit of a steroid receptor, EcR partner protein (USP polypeptide) subunit of a steroid receptor, or USP polypeptide of a juvenile hormone receptor, wherein said first and second sequences are derived from different genomic sources.

5

Preferably, the first sequence of amino acids is derived from the EcR polypeptide subunit of a steroid receptor, more preferably from the EcR polypeptide of the *L. cuprina* or *M. persicae* ecdysone receptor, and even more preferably from the the EcR polypeptide of the *L. cuprina* ecdysone receptor.

10

In one embodiment, the synthetic EcR polypeptide subunit of a steroid receptor, and/or a synthetic EcR partner protein (USP polypeptide) subunit of a steroid receptor, and/or a synthetic USP polypeptide of a juvenile hormone receptor comprises a fusion polypeptide in which the ligand-binding regions of any one of <400>2, <400>4, <400>6, <400>10, <400>12 or <400>14 are replaced, in-frame, by the ligand-binding region of a different receptor polypeptide.

15

In a particularly preferred embodiment, 5'-end of the open reading frame of a first nucleotide sequence, encoding the N-terminal portion of the EcR polypeptide of a first ecdysteroid receptor to the end of the DNA-binding domain of said polypeptide, is fused in-frame, to the 3'-end of the open reading frame of a second nucleotide sequence, encoding the C-terminal portion of the EcR polypeptide of a second ecdysteroid receptor, from the D domain and hormone-binding domain to the carboxyl terminus.

20

Accordingly, the present invention extends to any variants of the insect receptor polypeptides referred to herein and genetic sequences encoding same, wherein said variants are derived from a receptor polypeptide as described herein and exhibit demonstrable ligand-binding activity, and either comprises an amino acid sequence which differs from a naturally-occurring receptor polypeptide, or exhibit biological activity.

25  
30

As with other aspects of the invention, the variants described herein may be produced as

recombinant polypeptides or in transgenic organisms, once the subject synthetic genes are introduced into a suitable host cell and expressed therein.

In an alternative embodiment, the recombinant receptor polypeptide of the invention is produced as an "in-frame" fusion polypeptide with a second polypeptide, for example a detectable reporter polypeptide such as  $\beta$ -galactosidase,  $\beta$ -glucuronidase, luciferase or other enzyme, or a FLAG peptide, hapten peptide such as a poly-lysine or poly-histidine or other polypeptide molecule.

- 10 By "in-frame" means that a nucleotide sequence which encodes a first polypeptide is placed (i.e. cloned or ligated) in the same open reading frame adjacent to a nucleotide sequence which encodes a second polypeptide with no intervening stop codons there between, such that when the ligated nucleic acid molecule is expressed, a single fusion polypeptide is produced which comprises a sequence of amino acids corresponding to the summation of the individual
- 15 amino acid sequences of the first and second polypeptides.

In order to produce a fusion polypeptide, the nucleic acid molecule which encodes the polypeptide of the invention, or an analogue or derivative thereof, is cloned adjacent to a second nucleic acid molecule encoding the second polypeptide, optionally separated by a

20 spacer nucleic acid molecule which encodes one or more amino acids (eg: poly-lysine or poly histidine, amongst others), such that the first coding region and the second coding region are in the same open reading frame, with no intervening stop codons between the two coding regions. When translated, the polypeptide thus produced comprises a fusion between the polypeptide products of the first and second coding regions. Wherein a spacer nucleic acid

25 molecule is utilised in the genetic construct, it may be desirable for said spacer to at least encode an amino acid sequence which is cleavable to assist in separation of the fused polypeptide products of the first and second coding regions, for example a thrombin cleavage site.

- 30 A genetic construct which encodes a fusion polypeptide further comprises at least one start codon and one stop codon, capable of being recognised by the cell's translational machinery

in which expression is intended.

Preferably, a genetic construct which encodes a fusion polypeptide may be further modified to include a genetic sequence which encodes a targeting signal placed in-frame with the  
5 coding region of the nucleotide sequence encoding the fusion polypeptide, to target the expressed recombinant polypeptide to the extracellular matrix or other cell compartment. More preferably, the genetic sequence encoding targeting signal is placed in-frame at the 5'-terminus or the 3'-terminus, but most preferably at the 5'-terminus, of the coding region of the nucleotide sequence which encodes the fusion polypeptide.

10

Methods for the production of a fusion polypeptide are well-known to those skilled in the art.

The recombinant EcR polypeptide subunit of the insect steroid receptor or EcR partner protein (USP polypeptide) subunit of the steroid receptor or USP polypeptide of the juvenile hormone  
15 receptor may be purified by standard techniques, such as column chromatography (using various matrices which interact with the protein products, such as ion exchange matrices, hydrophobic matrices and the like), affinity chromatography utilizing antibodies specific for the protein or other ligands such as dyes or insect steroids which bind to the protein.

20 Wherein the recombinant polypeptide is expressed as a fusion polypeptide, it is also possible to purify the fusion polypeptide based upon its properties (eg size, solubility, charge etc). Alternatively, the fusion polypeptide may be purified based upon the properties of the non-receptor moiety of said fusion polypeptide, for example substrate affinity. Once purified, the fusion polypeptide may be cleaved to release the intact polypeptide of the invention.

25

Alternatively, proteins may be synthesized by standard protein synthetic techniques as are well known in the art.

In a preferred embodiment, the recombinant or isolated polypeptides of the invention are  
30 provided as a precipitate or crystallized by standard techniques, preferably for X-ray crystal structure determination.

The three-dimensional structure of the polypeptide of the invention or a holoreceptor comprising same or a fragment of said polypeptide or holoreceptor is particularly useful for identifying candidate insecticidal agents which mimic ligands that bind to said three-dimensional structure and/or modulate the ability of insect steroids to bind thereto and activate  
5 the receptor (see, for example, Von Itzstein *et al.*, 1993; and Bugg *et al.*, 1993).

According to this embodiment, the EcR polypeptides of the invention or ligand binding domains thereof, or their complexes with EcR partner proteins or ligand binding domains thereof, which confer enhanced affinity for insect steroid response elements or partner proteins (USP  
10 polypeptides) or ligands, are particularly useful to model the three-dimensional structure of the receptor ligand-binding region. In this manner, insecticidal compounds may be produced which bind to, or otherwise interact with, the ligand-binding region of the receptor and/or preferably interfere with ligand binding. In the same way, compounds may be developed which have a potentiated interaction with the insect steroid receptor over and above that of the  
15 physiological insect steroid which binds to the receptor.

Accordingly, a still further aspect of the invention provides a method of identifying a candidate insecticidally-active agent comprising the steps of:

- a) expressing a USP polypeptide of a juvenile hormone receptor or a fragment  
20 thereof which includes the ligand-binding region, optionally in association with an EcR polypeptide of a steroid receptor or ligand binding domain thereof, and optionally in association with an insect steroid or analogue thereof, so as to form a complex;
- b) purifying or precipitating the complex;
- c) determining the three-dimensional structure of the ligand binding domain of the  
25 complex; and
- d) identifying compounds which bind to or associate with the three-dimensional structure of the ligand binding domain, wherein said compounds represent candidate insecticidally-active agents.

30 Standard procedures are used to determine the three dimensional structure of the receptor polypeptides of the invention, for example using X-ray crystallography and/or nuclear magnetic



resonance analysis (*see, for example, Bugg et al., 1993; Von Itstein et al., 1993*).

Insecticidally-active agents contemplated herein include synthetic chemicals that mimic one or more ligands of the holoreceptor or its polypeptide subunit, or the ligand-binding region of said holoreceptor or subunit, thereby modulating binding of steroids to said holoreceptor or subunit. Preferred insecticidally-active agents include bisacylhydrazines, iridoid glycosides or other non-steroidal modulators of ecdysteroid receptors or insect juvenile hormone receptors. Additionally, because the EcR partner protein (USP polypeptide) subunits of insect steroid receptors, and the USP polypeptides of insect juvenile hormone receptors, bind insect juvenile hormones, a sesquiterpenoid group of ligands that regulate developmental transitions in insects (*see Jones and Sharp, 1997*), compounds which interfere with the binding of juvenile hormone are also candidate insecticides.

A further aspect of the present invention provides a method of identifying a modulator of insect steroid receptor-mediated gene expression or insect juvenile hormone receptor-mediated gene expression comprising:

- (i) assaying the expression of a reporter gene in the presence of a recombinant or isolated insect steroid receptor polypeptide or a juvenile hormone receptor polypeptide of the invention and a potential modulator; and
- (ii) assaying the expression of a reporter gene in the presence of a recombinant or isolated insect steroid receptor polypeptide or a juvenile hormone receptor polypeptide of the invention and without said potential modulator; and
- (ii) comparing expression of the reporter gene in the presence of the potential modulator to the expression of a reporter gene in the absence of the potential modulator,

wherein said reporter gene is placed operably under the control of a steroid response element (SRE) to which said insect steroid receptor binds or a promoter sequence comprising said SRE.

In the present context, a "modulator" is a compound or molecule that agonises or antagonises the binding properties and/or biological activity of a receptor polypeptide or holoreceptor.

Preferred modulators according to this embodiment include those synthetic compounds that are suitable for use as insecticidally-active agents described *supra*.

The reporter gene may be any gene, the expression of which may be monitored or assayed  
5 readily. Preferably, the reporter gene is a structural gene that encodes a peptide, polypeptide or enzyme that is assayed readily by enzymic or immunological means, for example the  $\beta$ -galactosidase,  $\beta$ -glucuronidase, luciferase or chloramphenicol acetyltransferase (CAT) genes. Alternatively, the reporter gene may be a gene which encodes an immunologically-detectable protein, for example a FLAG peptide, poly-lysine peptide or poly-histidine peptide.

10

Standard methods are used to assay the expression of the reporter gene.

This embodiment of the invention may be applied directly to the identification of potential insecticidally-active compounds or alternatively, modified for such purposes by assaying for  
15 the binding (direct or indirect) of the recombinant or isolated insect steroid receptor polypeptide or a juvenile hormone receptor polypeptide of the invention to a steroid response element (SRE), rather than by assaying for reporter gene expression. According to this alternative embodiment, the binding assayed in the presence or absence of a potential insecticidally-active compound is compared, wherein a difference in the level of binding  
20 indicates that the candidate compound possesses potential insecticidal activity.

In addition, substances may be screened for insecticidal activity by assessing their ability to bind, *in vivo* or *in vitro*, to the intact ecdysone receptor or alternatively, the ligand-binding regions of the EcR polypeptide subunit of the ecdysone receptor (eg. <400>2 and/or <400>6  
25 and/or <400>10) and/or the EcR partner protein ( USP polypeptide) of the ecdysone receptor (eg. <400>4 and/or <400>12 and/or <400>14). Competition assays involving the native insect steroid may be employed to assess insecticidal activity.

The performance of this embodiment may, for example, involve binding the insect steroid  
30 receptor polypeptide to a support such as a plurality of polymeric pins, whereafter the polypeptide resident on the plurality of pins is brought into contact with candidate insecticidal

- 41 -

molecules for screening. The molecules being screened may be isotopically labelled so as to permit ready detection of binding. Alternatively, reporter molecules may be utilized which bind to the insect steroid receptor candidate molecule complex. Alternatively, compounds for screening may be bound to a solid support, such as a plurality of pins which are then reacted  
5 with the thermostable insect steroid receptor or complex with a partner protein. Binding may, for example, be determined again by isotopic-labelling of the receptor, or by antibody detection or use of another reporting agent.

In an alternative embodiment, insecticidally-active agent are identified using rational drug  
10 design, by expressing a USP polypeptide of a juvenile hormone receptor or a fragment thereof which includes the ligand-binding region, optionally in association with an EcR polypeptide of a steroid receptor or ligand binding domain thereof, and optionally in association with an insect steroid or analogue thereof, so as to form a complex, determining the three-dimensional structure of the ligand binding domain of the complex, and identifying compounds which bind  
15 to or associate with the three-dimensional structure of the ligand binding domain, wherein said compounds represent candidate insecticidally-active agents.

The methods described herein for identifying modulators of gene expression and insecticidal compounds, may be performed using prokaryotic or eukaryotic cells, cell lysates or aqueous  
20 solutions.

A further aspect of this invention accordingly relates to synthetic compounds derived from the three dimensional structure of EcR polypeptides and/or EcR partner protein (USP polypeptide) subunits of insect steroid receptors, or fragments thereof, or insect steroid receptors or  
25 fragments thereof, or USP polypeptides of insect juvenile hormone receptors or fragments thereof, which compounds are capable of binding to said receptors which have the effects of either inactivating the receptors (and thus acting as antagonists) or potentiating the activity of the receptor.

30 By "derived from" it is meant that the compounds are based on the three dimensional structure of the aforementioned proteins, that is, synthesized to bind, associate or interfere with insect

steroid binding or juvenile hormone binding.

The compounds may bind strongly or irreversibly to the ligand binding site or another region of the receptor or USP and act as agonists or antagonists of insect steroids, or juvenile hormone binding, or otherwise interfere with the binding of ligand, such that ecdysteroids or juvenile hormones. Such compounds would have potent insecticidal activity given the key role of insect steroids, or juvenile hormone, in insect physiology and biochemistry. Such compounds would also possess a unique specificity.

10

This invention is also described with reference to the following non-limiting examples.

#### EXAMPLE 1

**Construction of a plasmid (pSV40-EcR) expressing the EcR polypeptide subunit of the *D. melanogaster* ecdysone receptor**

15

A 3110 base-pair Fsp1-HindIII fragment was excised from a cDNA encoding the EcR polypeptide subunit of the *D. melanogaster* ecdysone receptor (Koelle *et al.*, 1991), the excised sequence comprising the complete 2634 base pair coding region and 214 base pairs of 5'-leader sequence and 258 base pairs of 3'-untranslated sequence. The fragment was ligated into the BamHI site of the expression plasmid pSG5 (Greene *et al.*, 1988) to produce the expression plasmid pSV40-EcR, wherein expression of the EcR polypeptide subunit of the *Drosophila melanogaster* ecdysone receptor is placed operably under the control of the SV40 promoter sequence.

25

#### EXAMPLE 2

**Construction of the reporter plasmid p(EcRE)<sub>7</sub>-CAT**

The reporter plasmid p(EcRE)<sub>7</sub>-CAT was constructed by insertion of seven copies of the hsp27 ecdysone response element, containing a central 13 base pair palindromic ecdysone response element (EcRE), derived from the hsp27 gene (Riddihough and Pelham, 1987) into the HindIII

30

site of the plasmid pMMTV-CAT (Hollenberg and Evans, 1988), 93 base pairs upstream of the transcription start site of the MMTV promoter, thereby operably connecting expression of the chloramphenicol acetyltransferase structural gene to regulation by an insect receptor which binds to the hsp27 ecdysone response element.

5

### EXAMPLE 3

#### Cell Culture and Transient Transfection

Chinese hamster ovary (CHO) cells were maintained in 50% (v/v) Dubbecco's modified Eagle's medium (DMEM) and 50% (v/v) Hamm F12 nutrient mixture (GIBCO) supplemented with 10% (v/v) foetal bovine serum. Transfection was carried out by the DNA-calcium phosphate co-precipitation method (Ausubel *et al.*, 1992). One day before transfection with the plasmids described in Examples 1 and/or 2, or other expression plasmids, CHO cells were plated out at  $5 - 8 \times 10^5$  cells per 6 cm diameter culture dish in the above DMEM/F12 medium. Three hours before the addition of the DNA-calcium phosphate co-precipitate, the cells were washed with phosphate buffered saline (PBS; Sambrook *et al.*, 1989) and cultured in fresh DMEM plus 10% (v/v) foetal bovine serum. The cells were incubated in the presence of the co-precipitate for eighteen hours before excess DNA was removed by washing with PBS. The cells were then cultured for another day in DMEM/F12 supplemented with 10% (v/v) foetal bovine serum with or without added ponasterone A (PNA), before harvesting. Cells were washed with PBS, harvested by mechanical scraping in 0.25 M Tris-HCl (pH 7.8), and disrupted by three freeze-thaw cycles.

All transfections included, in addition to expression and reporter plasmids, a  $\beta$ -galactosidase-expressing plasmid designated pPgK-LacZ (McBurney *et al.*, 1991), which served as an internal control for the efficiency of transfection, and pUC18 DNA in an amount sufficient to produce 10  $\mu$ g total DNA per culture dish.

The chloramphenicol acetyltransferase (CAT) and  $\beta$ -galactosidase activities encoded by the reporter genes present in the reporter plasmids were assayed as described in Sambrook *et al.*, (1989). Cells that were co-transfected with p(EcRE)<sub>7</sub>-CAT and pSV40-EcR clearly showed

induction of CAT activity in the presence of PNA, showing 50 units of activity. Controls showed negligible activity.

We have observed that the ecdysone receptor can lead to stimulation of expression from an ecdysone responsive promoter in some cell types, for example in CHO cells, but not in CV-1 cells. Whilst not being bound by any theory or mode of action, this may reflect a cell-type specific distribution of at least one other transcription factor essential for ecdysone responsiveness. To determine cell types suitable for expressing reporter genes under the control of the steroid receptor of the present invention, the cell-type specificity of ecdysone-responsive gene expression is assayed in cell-free transcription lysates derived from several target cell lines. Additionally, by fractionating and/or isolating the nuclear proteins of cell lines that express the reporter genes and supplementing lysates derived from non-expressing cell lines with such nuclear protein fractions or isolated proteins, any essential auxiliary factors are defined and the genes encoding them cloned. Co-transfection of the receptor-encoding genes with genes encoding such auxiliary factors removes limitations imposed by cell-type restricted ecdysone responsiveness.

#### EXAMPLE 4

##### Testing the Effect of temperature on transient expression

To determine whether the *D. melanogaster* ecdysone receptor polypeptide is stable at physiological temperatures above about 30°C, CHO cells were transfected as described in Example 3, with the plasmid pSV40-EcR and the reporter plasmid p(EcRE)<sub>3</sub>-CAT in the presence of PNA, at 30°C and 37°C.

Briefly, CHO cells were plated out at 37°C sixteen to twenty hours before transfection. After washing away the DNA, the cells were cultured for two hours in fresh medium with or without hormone and the dishes divided into duplicate sets. One set was cultured for another day at 37°C before harvesting for CAT and  $\beta$ -galactosidase assays. The other set was cultured for three days at 30°C before assaying enzyme activities. Results indicated a reduction in the

- 45 -

fold-induction of gene expression regulated by the *D. melanogaster* ecdysone receptor polypeptide at 37°C, compared to the fold-induction at 30°C, as shown in Table 1.

5

**EXAMPLE 5**

**Attempted screening of an *L. cuprina* genomic DNA library to isolate genes encoding the EcR polypeptide subunit of the *L. cuprina* ecdysone receptor**

A 627 bp Eco - Kpn I fragment encompassing the DNA-binding domain of the EcR polypeptide subunit of the *D. melanogaster* ecdysone receptor was isolated, radioactively labelled and used to screen a *L. cuprina* genomic library constructed in bacteriophage lambda (prepared by CSIRO, division of Entomology, Canberra, Australia). In the first round of screening, twenty-four regions of the plates showed potential positive hybridization to the *D. melanogaster* probe. However, second-round screening of these 24 first round positive plaques failed to yield any plaque giving a reproducible positive signal when hybridized to the *D. melanogaster* probe.

20

**TABLE 1**

pSV40-EcR (µg/dish)	PNA (µM)	Fold-induction of expression	
		37°C	30°C
2.5	20	14X	35X
	100	59X	54X
0.5	20	8X	26X
	100	47X	33X
0.1	20	1.6X	25X
	100	9.0X	39X

25

**EXAMPLE 6****Cloning and characterization of a cDNA molecule encoding  
the EcR polypeptide of the *L. cuprina* ecdysone receptor****5 Rationale for amplification primer design**

The nucleotide sequences of the primers Rdna3 (400>15) and Rdna4 (<400>16) were derived from the amino acid sequence conserved between the DNA-binding domains of the EcR polypeptide subunits of the *D. melanogaster* and *C. tentans* ecdysone receptors. However, amino acid sequences homologous to two other members of the steroid receptor superfamily of *D. melanogaster*, *Drosophila* hormone receptor 3 (DHR3; Koelle, *et al.*, 1991) and *Drosophila* early gene (E75; Segraves and Hogness, 1990) were excluded from the primer designs, to reduce the possibility of amplifying the *L. cuprina* homologues of genes encoding DHR3 and/or E75 by PCR.

**15 Amplification primers and PCR conditions**

A 105 base pair DNA fragment, encoding the DNA-binding domain of the EcR polypeptide subunit of the *L. cuprina* ecdysone receptor, was amplified from the *L. cuprina* genome by PCR, by using the following degenerate primers:

**20 Rdna3 (32mer with EcoRI site):**

5'-CGGAATTCGCGCTCTGGTTA(C/T)CA(C/T)TA(C/T)AA(C/T)GC 3' (i.e. <400>15); and  
Rdna4 (32mer with BamHI site):

5'-CGCGGATCC(G/A)CACTCCTGACACTTTTCG(C/T)CTCA 3' (i.e. <400>16).

**25 Amplification reactions employed *TaqI* DNA polymerase (Promega) and the following  
amplification conditions:**

**cycle 1:** 97°C/5 minutes, 50°C hold; add polymerase 50°C/5 minutes;

**cycles 2-3:** 72°C/3 minutes, 94°C/1 minute, 50°C/1 minute;

**cycles 4-43:** 72°C/3 minutes, 94°C/1 minute, 55°C/1 minute;

**30 cycle 44:** 72°C/10 minutes.



- 47 -

To facilitate cloning of the amplified fragments for use as hybridisation probes, the 5' end of primer Rdna3 contained an *EcoRI* site and the 5' end of primer Rdna4 contained a *BamHI* site. The amplified *L. cuprina* gene fragments were cloned into pBluescript SK+, following digestion using the enzymes *EcoRI* and *BamHI*, purification of the digested DNA by agarose gel electrophoresis and electro elution of the product band.

#### Hybridisation probe preparation

For probe preparation, the insert was cut out of the pBluescript SK+ vector using *EcoRI* and *BamHI*, and <sup>32</sup>P-labelled using the GIGAPrime DNA Labelling Kit (Bresatec Limited, Adelaide, Australia) essentially according to the manufacturer's instructions, except that random primers were replaced with the specific primers Rdna3 and Rdna4 (see above). Unincorporated label was removed by size exclusion chromatography over Biogel-P60 (Biorad Ltd, Sydney, Australia). The probe was used at 10<sup>8</sup> cpm/ml in hybridizations.

#### 15 Construction and screening of *L. cuprina* cDNA libraries

Two independent *L. cuprina* cDNA libraries derived from late third instar *L. cuprina* larvae were prepared by random priming and oligo-dT priming respectively, and cloned into the *EcoRI* site of the *Lambda/ZapII* vector (Stratagene). The primary libraries generated were subsequently amplified according to the manufacturer's instructions, using standard protocols.

20

Both cDNA libraries generated are superior to existing *L. cuprina* libraries in terms of their phage titre (i.e. pfu/ml) and insert sizes (0.5 - 4 kbp in both cases). In particular, the primary oligo-dT primed library comprised 4.7 x 10<sup>8</sup> pfu, whilst the amplified oligo-dT primed library comprised 7.5 x 10<sup>10</sup> pfu/ml; the primary random-primed library comprised 1.3 x 10<sup>6</sup> pfu, whilst the amplified random-primed library comprised 3.4 x 10<sup>10</sup> pfu/ml.

The prepared cDNA libraries were screened by lifting 500,000 plaques from each library in duplicate onto Hybond N membranes (Amersham) and hybridizing same under low stringency conditions to the <sup>32</sup>P-labelled amplification product produced using the primers Rdna3 and Rdna4 (see above). In particular, hybridisations were performed for twenty four hours at 37°C in a hybridisation solution comprising 42% (w/v) formamide; 5 x SSPE solution; 5 x Denhardt's

- 48 -

solution; and 0.1% (w/v) sodium dodecyl sulphate, as described essentially by Ausubel *et al.*, (1992) and/or Sambrook *et al.* (1989). The membranes were then washed at 37°C in 2XSSC solution containing 0.1% (w/v) sodium dodecyl sulphate. Following washing, positive plaques were detected by autoradiography, using XOMAT-AR film (Kodak) for two to three days, at  
5 -70°C.

Two positive-hybridising plaques were obtained from screening of the random-primed library (containing cDNA inserts comprising 561 base pairs and 1600 base pairs in length, respectively), and one positive-hybridising plaque was obtained from the screening of the  
10 oligo-dT primed library (containing a cDNA insert comprising approximately 3400 base pairs in length). pBluescript phagemids containing cDNA inserts were excised *in vivo* from these positive plaques using the Exassist Helper Phage system (Stratagene).

The nucleotide sequences of the isolated cDNA clones were obtained using the USB  
15 Sequenase Version 2.5 Kit. Sequence data obtained indicated that the 561 bp and 1600 bp cDNAs encode amino acid sequences comprising the important DNA-binding domain and the hormone-binding domain of the EcR polypeptide subunit of the *L. cuprina* ecdysone receptor, whilst the 3400 bp cDNA comprises an entire 2274 bp open reading frame encoding the EcR polypeptide subunit of the *L. cuprina* ecdysone receptor. Accordingly, the 3400 bp cDNA is  
20 a full-length cDNA clone. The nucleotide sequence of the open reading frame and 3'-untranslated region is set forth herein as <400> 1. The derived amino acid sequence of the EcR polypeptide subunit of the *L. cuprina* ecdysone receptor encoded by this open reading frame is set out in <400> 2.

25

#### EXAMPLE 7

##### First attempt at cloning and characterization of a cDNA molecule encoding the EcR polypeptide of the *M. persicae* ecdysone receptor

30 Direct screening of a *M. persicae* cDNA library was not effective in isolating a full-length cDNA encoding the EcR polypeptide of the *M. persicae* ecdysone receptor.

DNA encoding the DNA-binding domain of the EcR polypeptide of the *M. persicae* ecdysone receptor was isolated successfully, by amplification as described in Example 6 for the amplification of the homologous *L. cuprina* fragment. The amplified DNA was cloned into pBluescript SK+ and the nucleotide sequence of the cloned insert was obtained using the USB Sequenase version 2.0 Kit, as described in Example 6.

Based upon the nucleotide sequence of the amplified DNA fragment, two authentic primers were synthesized as follows:

- 10 Mdna1 (23mer): 5'- GCCTCGGGGTATCACTATAACGC -3' (i.e. <400>17); and  
Mdna2 (23mer): 5'- GCACTCCTGACACTTTCGTCTCA -3' (i.e. <400>18).

#### Hybridisation probe preparation

For *M. persicae* probe preparation, the amplified 105 bp DNA insert was excised from the pBluescript SK+ vector using EcoRI and BamHI, and <sup>32</sup>P-labelled using the GIGAprime DNA Labelling Kit (BresaGen Limited, Adelaide, Australia) essentially according to the manufacturer's instructions, except that random primers were replaced with the specific primers Mdna1 and Mdna2 (see above). Unincorporated label was removed by size exclusion chromatography over Biogel-P60 (Biorad Ltd, Sydney, Australia). The probe was used at 10<sup>6</sup> cpm/ml in hybridizations.

#### Construction and screening of *M. persicae* cDNA libraries:

Two independent *M. persicae* cDNA libraries derived from late third instar *M. persicae* larvae were prepared by random priming and oligo-dT priming respectively, and cloned into the EcoRI site of the *Lambda/ZapII* vector (Stratagene). The primary libraries generated were subsequently amplified according to the manufacturer's instructions, using standard protocols.

Both cDNA libraries generated are superior to existing *M. persicae* libraries in terms of their phage titre (i.e. pfu/ml) and insert sizes (0.5 - 4 kbp in both cases). In particular, the primary oligo-dT-primed library comprised 1 x 10<sup>7</sup> pfu, whilst the amplified oligo-dT primed library comprised 1 x 10<sup>10</sup> pfu/ml; the primary random-primed library comprised 1 x 10<sup>8</sup> pfu, whilst the

- 50 -

amplified random-primed library comprised  $2 \times 10^{11}$  pfu/ml.

Additionally, a further cDNA library was produced in the Lambda ZAP Express insertion vector (Stratagene). To produce this library, cDNA derived from late third instar *M. persicae* larvae was prepared by oligo-dT priming and cloned directionally into *EcoRI*-*XhoI* digested vector DNA. The primary library comprised  $1 \times 10^6$  pfu, whilst the amplified oligo-dT primed library comprised  $1 \times 10^9$  pfu/ml, with insert sizes in the range 0.5 - >4 kbp.

The random-primed *M. persicae* cDNA phage library was screened as described in Example 6, using the *M. persicae* hybridisation probe prepared as described above.

A single positive-hybridising plaque was isolated and sequenced according to standard procedures. The nucleotide sequence of this clone is set forth herein as <400>5. This cDNA clone comprises a 585bp protein-encoding sequence which encodes the DNA-binding domain of a EcR polypeptide of a putative *M. persicae* ecdysone receptor. The amino acid sequence encoded by this partial cDNA clone is set forth herein as <400> 6.

## EXAMPLE 8

### 20 Second attempt at cloning and characterization of a cDNA molecule encoding the EcR polypeptide of the *M. persicae* ecdysone receptor

#### Hybridisation probe preparation

Further hybridisation probes specific for the EcR polypeptide of the *M. persicae* ecdysone receptor were generated using PCR from the Lambda ZAPII oligo dT-primed library using primers AP1 and AP2. The forward primer AP1 was designed to anneal to nucleotide sequences of the partial cDNA (<400>5) encoding part of the first zinc finger motif present in the DNA-binding domain. The reverse primer, AP2, was adapted from degenerate primers designed to anneal to nucleotide sequences complementary to those encoding an EcR ligand binding domain (Kamimura *et al.*, 1996). The nucleotide sequences of primers AP1 and AP2 are as follows:

- 51 -

Primer AP1: 5'- TCGTCCGTTACCATTACAACGC -3' (<400>19); and

Primer AP2: 5'- TAGACCTTTGGC(A/G)AA(C/T)TC(A/G/C/T)ACAAT -3'(<400>20)

The PCR reaction mixture contained 4 µl of each primer (50 pm/µl), 5 µl of deoxynucleotide triphosphate mix (2mM), 1 µl of aphid oligo dT primed Lambda ZAPII cDNA library, 1 µl of recombinant *Pfu* DNA Polymerase (5 units/µl, Stratagene®), 5 µl of 10x *Pfu* buffer (Stratagene®) and 30 µl of MilliQ water. The *Pfu* polymerase was used in this reaction because it possesses proof-reading activity, which reduces the possibility of misincorporation of nucleotides. The PCR conditions included 42 cycles, each cycle comprising annealing at 55°C, extension at 72°C and melting at 94°C.

The major amplification product obtained in this reaction was gel-purified, kinased and ligated into the *Sma*I site of pUC18.

To screen *M. persicae* cDNA libraries, the cloned amplification product was digested to generate two non-overlapping probes, designated "EcR probe 1" (i.e. <400>7) and "EcR probe 2" (i.e. <400>8). In this regard, digestion of the cloned product with *Sph*I produced a DNA fragment comprising a nucleotide sequence specific for a region encoding the DNA-binding domain (EcR probe 1; <400> 7), whilst digestion with *Sph*I/*Eco*RI produced a DNA fragment comprising a nucleotide sequence having homology to a region encoding a putative linker domain, designated domain D, and the 5'-end of a putative hormone-binding domain, present in the EcR polypeptide of the insect ecdysone receptors (EcR probe 2, <400> 8).

EcR probe 1 and EcR probe 2 were labelled with [ $\alpha$ -<sup>32</sup>P]dATP in a reaction catalysed by Klenow fragment. All reagents were components of a GIGaprime DNA labelling kit (BresaGen Limited, Adelaide, Australia), except that the random primers were replaced with specific oligonucleotides synthesised to be complementary to the ends of EcR probe 1 and EcR probe 2.

### 30 Screening of *M. persicae* cDNA libraries

480,000 plaques from the oligo dT primed Lambda Zap Express cDNA library (Example 7)

were screened as described above, using EcR probe 1. This approach yielded about 300 positive clones. Positive-hybridising clones were pooled and rescreened separately using EcR probe 1 and EcR probe 2, on duplicate lifts. Only four plaques were identified which hybridised to both probes. One of these was found by sequencing to contain a full-length cDNA encoding the EcR polypeptide of the *M. persicae* ecdysone receptor. The nucleotide sequence of the open reading frame of this cDNA is set forth herein as <400> 9. The derived amino acid sequence of the EcR polypeptide subunit of the *M. persicae* ecdysone receptor encoded by this open reading frame is set out in <400> 10.

## EXAMPLE 9

### *In vivo* function of recombinant EcR polypeptides of the *L. cuprina* ecdysone receptor

#### Construction of plasmid pF3

15 Plasmid pF3 was constructed in four steps as follows:

First, plasmid p5S1, comprising the full-length cDNA encoding the EcR polypeptide of the *L. cuprina* ecdysone receptor, was digested with *Eat*I and a 3' *Eat*I cDNA fragment thus generated, encoding the C-terminal end of the EcR polypeptide of the *L. cuprina* ecdysone receptor, was end-filled and sub-cloned into the HindIII site of pUC19, to construct plasmid  
20 pEAR. In plasmid pEAR, the 3' end of the cDNA was oriented towards the KpnI site of the pUC19 vector.

Second, plasmid p5S1 was also digested separately with:

- (1) *Apo*I and *Pst*II, to isolate the 5' end of the cDNA as a 179 bp fragment (fragment A);
- 25 (2) *Pst*II and *Spe*I, to isolate a 1650 bp cDNA fragment (fragment B); and
- (3) *Spe*I and *Bgl*II, to isolate a 203 bp fragment (fragment C).

Third, plasmid pEAR was digested with *Bgl*II and *Kpn*I, to isolate the 3' end of the cloned cDNA fragment therein as a 313 bp fragment (fragment D).

30

Fourth, DNA fragments A, B, C and D were each isolated by agarose electrophoresis and

- 53 -

ligated together into pBluescriptSK+, which had been digested with *EcoRI* and *KpnI*, to produce plasmid pF3.

Plasmid pF3 thus contains the complete open reading frame of the cDNA encoding the EcR polypeptide of the *L. cuprina* ecdysone receptor, as a 2368 bp fragment located between two *Bam*HI sites.

#### Construction of plasmid pSGLcEcR and plasmid pLcK8

Plasmid pSGLcEcR was constructed by cloning the 2368 bp *Bam*HI fragment from pF3, into the *Bam*HI site of the mammalian expression vector pSG5 (Stratagene). Plasmid pLcK8 is a clone of pSGLcEcR.

#### Construction of plasmid pSGDmEcR

Plasmid pSGDmEcR is identical to plasmid pSV40-EcR (Example 1) comprising the EcR polypeptide of the *D. melanogaster* ecdysone receptor placed operably under control of the SV40 promoter.

#### Transfection of CHO cells

CHO cells were co-transfected with a mixture comprising the following DNAs, lysed and assayed for CAT and  $\beta$ -galactosidase enzyme activity, as described in the preceding Examples:

- (1) one of the expression plasmids designated pSGDmEcR, or pSGLcEcR, or the parental expression plasmid pSG5 as a negative control, at a concentration of 1  $\mu$ g/ml; and
- (2) the CAT reporter plasmid p(EcRE)<sub>3</sub>CAT at a concentration of 1  $\mu$ g/ml; and
- (3) an independent LacZ reporter plasmid, pPGKLacZ, at a concentration of 1  $\mu$ g/ml, included as a control to monitor transfection efficiency .

CAT reporter gene expression was induced with 10  $\mu$ M or 50  $\mu$ M Muriesterone A. In control samples, cells received only the carrier ethanol in place of Muriesterone A.

ELISA was used to quantify the synthesis of CAT and  $\beta$ -galactosidase enzymes, in extracts

of cells forty eight hours after transfection. Account was taken of the variation between experiments, by normalizing the level of CAT enzyme to the level of  $\beta$ -galactosidase enzyme present in the same extract. Fold induction represents the normalized values for CAT gene expression in cells transfected with pSGDmEcR, pSGLcEcR or pSG5 in the presence of hormone divided by the normalized values for CAT gene expression in cells transfected with the same plasmid but in the absence of hormone. The average values of three independent experiments are shown in Figure 1 and the error bars indicate standard error of the mean.

Data shown in figure 1 indicate that the EcR polypeptide of the *L. cuprina* ecdysone receptor from Example 3 is biologically active *in vivo*. CAT induction is observed at both 50  $\mu$ M and 10  $\mu$ M steroid (Muristerone A), with about 30 and 15 fold induction respectively. In view of the *in vivo* activity of the EcR polypeptide of the *L. cuprina* ecdysone receptor obtained according to this protocol, potential insecticidal substances acting by interaction with an insect steroid receptor, such as an ecdysone receptor, are screened by addition of the substances to the *in vivo* assay described herein. Substances are added in an amount from 0.05  $\mu$ M to 100  $\mu$ M. Candidate insecticidal compounds are identified by their ability to modulate the reporter gene expression which results from trans-activation by the EcR polypeptide of the *L. cuprina* ecdysone receptor.

20

## EXAMPLE 10

### Chimeric EcR polypeptides of insect ecdysone receptors

Chimeric ecdysone receptors comprising regions derived from EcR polypeptides of ecdysone receptors of different species are produced and assayed for enhanced activity. In a particularly preferred embodiment, a chimeric ecdysone receptor is produced using the EcR polypeptides of the *D. melanogaster*, *M. persicae* and *L. cuprina* ecdysone receptors.

In one exemplification of this embodiment, plasmids pSGLD and pSGDL are produced comprising coding regions derived from the EcR polypeptides of the *D. melanogaster* and *L. cuprina* ecdysone receptors. In plasmid pSGLD, the 5'-end of the open reading frame of the *D. melanogaster* sequence, encoding the N-terminal portion of the EcR polypeptide of the *D. melanogaster* ecdysone receptor to the end of the DNA-binding domain of said polypeptide,



is fused to the 3'-end of the open reading frame of the *L. cuprina* sequence, encoding the C-terminal portion of the EcR polypeptide of the *L. cuprina* ecdysone receptor, from the D domain and hormone-binding domain to the carboxyl terminus. In plasmid pSGDL, the 5'-end of the open reading frame of the *L. cuprina* sequence, encoding the N-terminal portion of the EcR polypeptide of the *L. cuprina* ecdysone receptor to the end of the DNA-binding domain of said polypeptide, is fused to the 3'-end of the open reading frame of the *D. melanogaster* sequence, encoding the C-terminal portion of the EcR polypeptide of the *D. melanogaster* ecdysone receptor, from the D domain and hormone-binding domain to the carboxyl terminus. These plasmids thus encode chimeric EcR polypeptides which form ecdysone receptor variants.

As shown in Figure 2, chimeric EcR polypeptides of *L. cuprina* and *D. melanogaster* ecdysone receptors, comprising fusion polypeptides between the DNA-binding domains and hormone-binding domains of the base *L. cuprina* and *D. melanogaster* polypeptides, exhibit bioactivity when measured in the CAT assay described above. Significant bioactivity of the chimeric EcR polypeptides encoded by plasmids pSGLD and pSGDL, comparable to the bioactivity of the *D. melanogaster* base EcR polypeptide, is observed at both 10  $\mu$ M and 50  $\mu$ M concentrations of Muristerone A.

20

## EXAMPLE 11

### Isolation and characterisation of a full-length cDNA encoding the EcR partner protein (USP polypeptide) of the *L. cuprina* ecdysone receptor

The EcR partner protein (USP polypeptide) subunit of the *L. cuprina* ecdysone receptor also functions alone as a USP polypeptide of the *L. cuprina* juvenile hormone receptor. A cDNA encoding both receptor polypeptide activities was isolated using PCR and hybridisation as follows.

#### Hybridisation probe preparation

A 150 base-pair probe, specific for genetic sequences encoding the EcR partner protein (USP polypeptide) subunit of insect ecdysone receptors and/or the USP polypeptide subunit of insect juvenile hormone receptors (<400>13), was isolated by PCR from *L. cuprina* genomic

- 56 -

DNA using the degenerate primers described by Tzertzinis *et al.* (1994). The PCR reaction conditions were as described in Example 6, except that *Pfu* polymerase was used in place of *TaqI* polymerase.

- 5 The amplified DNA fragment was sub-cloned into *EcoRI* and *ClaI* double-digested pBluescript SK+ vector (Stratagene), after double-digestion of the fragment using the enzymes *EcoRI* and *ClaI*, purification of the amplified fragment by agarose gel electrophoresis, and electro elution of the product band. The nucleotide sequence of the probe was obtained using the USB Sequenase version 2.0 Kit (<400> 13).

10

- For probe preparation, the amplified *L. cuprina* DNA fragment was excised from the vector using *EcoRI* and *Sall*, gel purified and <sup>32</sup>P-labelled using the GIGaprime DNA Labelling Kit (BresaGen Limited, Adelaide, Australia) essentially according to the manufacturer's instructions except that random primers were replaced with the two degenerate primers
- 15 described by Tzertzinis *et al.* (1994) (see above). Unincorporated label was removed by size exclusion chromatography over Biogel-P60 (Biorad Ltd, Sydney, Australia). The probe was used at 10<sup>6</sup> cpm/ml in hybridizations.

#### Screening of *L. cuprina* cDNA libraries

- 20 The *L. cuprina* cDNA library described above (Example 6) was screened with the amplified probe as described in Example 6. The nucleotide sequence of the full-length open reading frame of this cDNA molecule and amino acid sequence therefor, are set forth herein as <400> 3 and <400> 4, respectively.

25

### EXAMPLE 12

#### **Isolation and characterisation of a partial cDNA encoding the EcR partner protein (USP polypeptide) of the *M. persicae* ecdysone receptor**

- 30 The EcR partner protein (USP polypeptide) subunit of the *M. persicae* ecdysone receptor also functions alone as a USP polypeptide of the *M. persicae* juvenile hormone receptor. To isolate

- 57 -

a partial cDNA encoding both receptor polypeptide activities, a 140 bp probe was amplified from *M. persicae* genomic DNA, by PCR, using the two degenerate primers described by Tzertzinis *et al.* (1994) (see preceding Example). The PCR reaction conditions were as described in Example 6, except that *Pfu* polymerase was used in place of *TaqI* polymerase.

5

The amplified DNA fragment was sub-cloned into *EcoRI* and *ClaI* double-digested *pBluescript* SK+ vector (Stratagene), after double-digestion of the fragment using the enzymes *EcoRI* and *ClaI*, purification of the amplified fragment by agarose gel electrophoresis, and electro elution of the product band.

10

The nucleotide sequence of the insert in the *pBluescript* SK+ vector was obtained using automated fluorescent dye terminator sequencing (SUPAMAC, Sydney Australia) and is set forth herein as <400> 11. The derived amino acid sequence of this partial gene fragment is set forth as <400>12.

15

#### Hybridisation probe preparation and library screening

For probe preparation the amplified *M. persicae* DNA insert was cut out of the *pBluescript*+ vector with *EcoRI* and *SaI*, gel purified and <sup>32</sup>P-labelled using the GIGAprime DNA Labelling Kit (Bresatec Limited, Adelaide, Australia) essentially according to the manufacturer's instructions except that random primers were replaced with the degenerate primers described by Tzertzinis *et al.* (1994) (see preceding Example). Unincorporated label was removed by size exclusion chromatography over Biogel-P60 (Biorad Ltd, Sydney, Australia). The probe was used at 10<sup>6</sup> cpm/ml in hybridizations to screen the *M. persicae* cDNA library as described in Examples 7 and 8.

25

The positive-hybridising clones are plaque-purified and sequenced using standard procedures as described herein.

30

**EXAMPLE 13**

**A construct for the baculovirus-directed co-expression of functional ligand-binding regions of the EcR polypeptide and partner protein (USP polypeptide) of the *D. melanogaster* ecdysone receptor**

5

A vector was prepared to facilitate the baculovirus-directed co-expression of ligand-binding regions derived from the EcR polypeptide and partner protein (USP polypeptide) of the *D. melanogaster* ecdysone receptor, the protein products of which associate on co-expression to form a functional hormone-binding complex. The associated proteins are then used in high

10 through-put assays or three-dimensional structural analysis. We have found that the ligand-binding domain, together with most of the linker domain of the EcR polypeptide subunit and of the EcR partner protein (USP polypeptide), are sufficient to associate to form a functional hormone-binding complex.

15 1. Isolation of the ligand-binding region and linker region of the EcR polypeptide of the *D. melanogaster* ecdysone receptor.

A Sac I- HindIII fragment encoding most of the linker (domain D) and all of the ligand-binding domain (domains E and F) of the EcR polypeptide of the *Drosophila melanogaster* ecdysone receptor was excised from a plasmid comprising DNA encoding the complete EcR polypeptide

20 (Koelle *et al.* 1991). The excised fragment was cloned into SacI - HindIII-digested expression vector pQE31(Qiagen), to produce the plasmid vector pQE31DmECR.

2. Construction of a baculovirus expressing the linker regions of EcR and USP polypeptides

A baculovirus was constructed for the co-expression in insect cells of:

- 25 (i) a cDNA region comprising a nucleotide sequence which encodes at least the ligand-binding domain and much of the linker domain of the EcR polypeptide of the *D. melanogaster* ecdysone receptor isolated as described at paragraph (1) above; and
- (ii) a cDNA region comprising a nucleotide sequence which encodes at least the ligand-binding domain and much of the linker domain of the partner protein (USP
- 30 polypeptide) of the *D. melanogaster* ecdysone receptor.

- 59 -

To produce this baculovirus, a *EcoR* I - *Hind*III fragment was excised from pQE31DmEcR, said fragment encoding an oligo-His tag, and most of the linker domain, together with all of the ligand-binding domain of EcR polypeptide. This *EcoR* I - *Hind*III fragment was ligated into *EcoR* I - *Hind*III cleaved pFastBacDUAL, to produce the plasmid pDmEcR.DUAL. To insert gene sequences specific for the partner protein (USP polypeptide), the *Hind*III - *Nsi*I fragment encoding most of the linker and all of the ligand-binding domain of the partner protein (USP polypeptide) was excised from a full-length cDNA clone in plasmid pZ7-1 (supplied by Vince Henrich) and ligated into *Nco*I - *Nsi*I cleaved pDmEcR.DUAL. A nucleotide sequence encoding a "FLAG" peptide was subsequently incorporated upstream of, and in the same reading frame as, the nucleotide sequence encoding the linker and ligand-binding regions of the partner protein (USP polypeptide), by ligation into the unique *Sma*I site, thereby producing the plasmid pDmEcR.USP.DUAL. Plasmids containing the FLAG-encoding nucleotide sequence in the correct orientation were selected by nucleotide sequence determination.

The segment of pDmEcR.USP.DUAL which encodes the tagged linker and ligand-binding regions of the EcR polypeptide and partner protein (USP polypeptide) sequences, placed operably under the control of polyhedrin and p10 promoters, respectively, was recombined into a baculovirus genome, by employing the Tn7 transposition system (Luckow *et al.*, (1993). The polypeptide products were then co-expressed in insect Sf21 and Sf9 cells, where they associated into a functional complex.

Expression of the tagged linker and ligand-binding regions of the EcR polypeptide and partner protein (USP polypeptide) sequences was examined by immunoblot analysis of extracts derived from insect Sf21 cells infected with the recombinant baculovirus, employing antibodies directed against the oligo-His and FLAG tags. This analysis detected bands on immunoblot analysis of approximately the predicted sizes for the expressed tagged linker and ligand-binding regions of the EcR polypeptide and partner protein (USP polypeptide).

The protein detected by anti-oligo-His-antibodies was enriched by affinity purification on nickel-NTA resin (Qiagen), and the FLAG-labelled protein was affinity-purified using FLAG M2 Affinity Gel (Kodak). It was further demonstrated that the oligo-His-tagged EcR polypeptide and the

- 60 -

FLAG-tagged EcR partner protein (USP polypeptide) bound as a hetero-oligomeric complex to FLAG M2 Affinity Gel (Kodak).

Furthermore, binding assays, performed using a modification of the method of Yund *et al* (1978), demonstrated a highly-significant increase in the binding of the a labelled ecdysone analogue, [<sup>3</sup>H]ponasterone A, in cells infected by the recombinant baculovirus, compared to the binding observed for the naturally-occurring ecdysone holoreceptor in *L. cuprina* embryos. In contrast, cells infected by a control virus displayed neither antibody-positive bands on western analysis, nor specific binding of [<sup>3</sup>H] ponasterone A, above background levels. These data indicate correct folding and association of the variant polypeptides comprising the linker and ligand-binding regions of the *D. melanogaster* EcR polypeptide and *D. melanogaster* partner protein (USP polypeptide). The correctly-folded and associated complex formed by the truncated EcR polypeptide and truncated EcR partner protein (USP polypeptide), is used for X-ray and NMR structural analysis and for high-throughput screens.

15

#### EXAMPLE 14

**Construct for the baculovirus-directed co-expression of functional ligand-binding regions of the EcR polypeptide and partner protein (USP polypeptide) of the *L. cuprina* ecdysone receptor**

20

A vector for the baculovirus-directed co-expression of ligand-binding domains derived from the EcR polypeptide and partner protein (USP polypeptide) of the *L. cuprina* ecdysone receptor was prepared essentially as described in the preceding Example.

#### 25 1. Isolation of the ligand-binding region and linker region of the EcR polypeptide of the *L. cuprina* ecdysone receptor.

A *SphI* – *KpnI* fragment encoding most of the linker (domain D) and all of the ligand-binding domain (domains E and F) of the EcR polypeptide of the *L. cuprina* ecdysone receptor was excised from a cDNA clone encoding the complete EcR polypeptide and cloned into the *SphI*

30 – *KpnI* cleaved expression vector pQE32 (Qiagen), to produce the plasmid pQE32LcEcR.

- 61 -

2. Isolation of the ligand-binding region and linker region of the partner protein (USP polypeptide) of the *L. cuprina* ecdysone receptor.

A DNA fragment encoding most of the linker domain and all of the ligand-binding domain of the partner protein (USP polypeptide) of the *L. cuprina* ecdysone receptor was sub-cloned to  
5 produce the plasmid pBLU1.

3. Construction of a baculovirus expressing the linker regions of *L. cuprina* EcR and USP polypeptides

A baculovirus was constructed for the co-expression in insect cells of:

- 10 (i) a cDNA region comprising a nucleotide sequence which encodes at least the ligand-binding domain and much of the linker domain of the EcR polypeptide of the *L. cuprina* ecdysone receptor isolated as described at paragraph (1) above; and
- (ii) a cDNA region comprising a nucleotide sequence which encodes at least the ligand-binding domain and much of the linker domain of the partner protein (USP  
15 polypeptide) of the *L. cuprina* ecdysone receptor isolated as described at paragraph (2) above.

To produce this baculovirus, a *EcoR* I – *Pst*I fragment derived from plasmid pQE32LcEcR, encoding an oligo-His tag and most of the linker domain together with all of the ligand-binding  
20 domain of the *L. cuprina* EcR polypeptide was ligated into *EcoR*I– *Pst*I cleaved pFastBac.DUAL, to produce the plasmid pLcEcR.DUAL. An *Av*all–*EcoRV* fragment, encoding most of the linker and all of the ligand-binding domain of *L. cuprina* partner protein (USP polypeptide) was excised from plasmid pBLU1 and ligated, together with a "FLAG" encoding sequence into the *Pvu*II site of pLcEcR.DUAL, to produce plasmid pLcEcR.USP.DUAL .

25

The segment of pLcEcR.USP.DUAL which encodes the tagged linker and ligand-binding regions of the EcR polypeptide and partner protein (USP polypeptide) sequences, placed operably under the control of polyhedrin and p10 promoters, respectively, was recombined into a baculovirus genome, by employing the Tn7 transposition system (Luckow *et al.*, (1993). The  
30 polypeptide products were then co-expressed in insect Sf21 and Sf9 cells, where they associated into a functional complex.

- 62 -

Expression was examined by immunoblot analysis. Antibodies directed against oligo-His and FLAG tags detected bands on immunoblot analysis of approximately the predicted sizes for the expressed EcR and USP polypeptide regions respectively, in extracts from insect Sf21 cells infected with the recombinant baculovirus. The protein detected by anti-oligo-His was greatly enriched utilising a nickel-NTA resin (Qiagen) and the FLAG-labelled protein purified on FLAG M2 Affinity Gel (Kodak). It was also demonstrated by immunoblot analysis that oligo-His-tagged *L. cuprina* truncated EcR polypeptides and FLAG-tagged *L. cuprina* truncated EcR partner protein (USP polypeptide) bind as a hetero-oligomeric complex to FLAG M2 Affinity Gel (Kodak).

10

Furthermore, binding assays, carried out by a modification of the method of Yund *et al* (1978), demonstrated a highly-significant increase in the binding of the tritiated ecdysone analogue, ponasterone A, in cells infected by recombinant virus indicating correct folding and association of the two protein subunits (Figure 3), greater than that of the ecdysone holoreceptor in *L. cuprina* embryos. Cells infected by a control virus displayed neither antibody-positive bands on western analysis nor specific binding of tritiated hormone above background.

Expression of the tagged linker and ligand-binding regions of the *L. cuprina* EcR polypeptide and partner protein (USP polypeptide) sequences was examined by immunoblot analysis of extracts derived from insect Sf21 cells infected with the recombinant baculovirus, employing antibodies directed against the oligo-His and FLAG tags. This analysis detected bands on immunoblot analysis of approximately the predicted sizes for the expressed tagged linker and ligand-binding regions of the *L. cuprina* EcR polypeptide and partner protein (USP polypeptide).

25

The protein detected by anti-oligo-His-antibodies was enriched by affinity purification on nickel-NTA resin (Qiagen), and the FLAG-labelled protein was affinity-purified using FLAG M2 Affinity Gel (Kodak).

30 Furthermore, binding assays, performed using a modification of the method of Yund *et al* (1978), demonstrated a significant increase in the binding of the labelled ecdysone analogue,



[<sup>3</sup>H] ponasterone A, in cells infected by the recombinant baculovirus, compared to the binding observed for the naturally-occurring ecdysone holoreceptor in *L. cuprina* embryos (Figure 3). In contrast, cells infected by a control virus displayed neither antibody-positive bands on western analysis, nor specific binding of [<sup>3</sup>H] ponasterone A, above background levels.

5

These data indicate correct folding and association of the variant polypeptides comprising the linker and ligand-binding regions of the *L. cuprina* EcR polypeptide and *L. cuprina* partner protein (USP polypeptide). The correctly-folded and associated complex formed by the truncated EcR polypeptide and truncated EcR partner protein (USP polypeptide), is used for X-

10 ray and NMR structural analysis and for high-throughput screens.

#### EXAMPLE 15

##### **A construct for the expression of the ligand-binding region of the USP polypeptide of the *L. cuprina* juvenile hormone receptor**

15

The donor plasmid pLcEcR.USP.DUAL (Example 14) was digested with *Bss*HI and *Pst*II to remove the *L. cuprina* EcR polypeptide-encoding segment therein, thereby leaving the tagged linker and ligand-binding regions of the *L. cuprina* USP polypeptide-encoding nucleotide  
20 sequence. The digested plasmid was blunt-ended using T4 DNA polymerase and Klenow polymerase, isolated by gel purification, and finally re-ligated to produce the plasmid pLc.USP.SINGLE.

To produce recombinant baculovirus capable of expressing the tagged linker and ligand-  
25 binding regions of the USP polypeptide, the segment of pLc.USP.SINGLE encoding this polypeptide and the p10 promoter sequence to which said segment is operably connected, is recombined into a baculovirus genome employing the Tn7 transposition system (Luckow *et al.*, 1993). The polypeptide product is then expressed to form a functional juvenile hormone-binding polypeptide and preferably, a modulator of a juvenile hormone receptor. The correctly-  
30 folded truncated USP polypeptide is used for X-ray and NMR structural analysis and for high-throughput screens.

**EXAMPLE 16*****In-vitro* Screening for the Detection of Insecticidal Compounds**

- The EcR partner protein (USP polypeptide) of the insect ecdysone receptor and USP  
5 polypeptide of the insect juvenile hormone receptor of the present invention, optionally  
associated with the EcR polypeptides of insect ecdysone receptors of the present invention  
as described in the preceding Examples, are coupled to pins according to the procedure of  
Geysen *et al.* (1987), and reacted with candidate insecticidal compounds, generally at a  
concentration in the range from about 0.05  $\mu$ M to about 100  $\mu$ M of the candidate compound.
- 10 The binding of compounds is detected using standard procedures, and compounds having  
insecticidal activity are identified. Preferably, such compounds exhibit insecticidal activity  
against a range of insects, including diptera, hemiptera, coleoptera, ants, and moths, amongst  
others. More preferably, the compounds will exhibit insecticidal activity against *L. cuprina*, *M.*  
*persicae*, *D. melanogaster*, scale insect, white fly, and leaf hopper, amongst others. In a  
15 particularly preferred embodiment, insecticidal compounds are specific to *L. cuprina* and/or *M.*  
*persicae* and close relatives thereof.

## REFERENCES

1. Amann and Brosius (1985). *Gene* 40: 183.
2. Ausubel, *et al* (1992). *Current Protocols in Molecular Biology*, Greene/Wiley, New York
3. Bugg, *et al* (1993) *Scientific American*, December Issue: pp 60-66.
- 5 4. Devereux, J., *et al.* (1984). *Nucl. Acids Res.* 12:387-395.
5. Evans (1988) *Science*, 240: 889-895.
6. Geysen *et al* (1987) *J. Immunol Methods*, 102, 259-274.
7. Greene *et al.* (1988) *Nucleic Acids Res.* 15:369.
8. Hollenberd and Evans (1988) *Cell* 55: 899-906.
- 10 9. Hollenberg *et al* (1991) *Cell*, 67, 59-77.
10. Jones, G and Sharp, P, (1997) *Proc. Nat. Acad. Sci. USA* 94:13499-13503.
11. Kamimura *et al* (1996) *Comp. Biochem. Physiol.* 113, 341-347.
12. Koelle *et al* (1991) *Cell*, 67:59-77
13. Krust *et al* (1986) *EMBO. J.*, 5: 891-897.
- 15 14. Luckow *et al*, (1993) *J. Virol*, 67: 4566.
15. McBurney *et al* (1991), *Nucleic Acids Res.*, 19, 5755-5761.
16. McPherson, M.J., Quirke, P. and Taylor, G.R. (1991) *PCR A Practical Approach*. IRL Press, Oxford University Press, Oxford, United Kingdom.
17. Needleman and Wunsch (1970) *J. Mol. Biol.* 48:443-453.
- 20 18. Potrykus (1990) *Bio/Technology* 8: 535-542.
19. Riddihough, G., and Pelham, H. R. B., (1987), *EMBO J.*, 6, 3729-3734
20. Sambrook *et al* (1989), *Molecular Cloning: A Laboratory Manual*, Cold Springs Harbor Laboratory Press
21. Segraves and Hogness (1990) *Genes Devel.* 4: 204-219.
- 25 22. Shimatake and Rosenberg (1981) *Nature* 292: 128
23. Studier and Moffat (1986) *J. Mol. Biol.* 189: 113
24. Thompson, *et al.*, (1994) *Nucl. Acids Res.* 22:4673-4680.
25. Tzertzinis *et al* (1994) *J. Mol. Biol.* 258, 479-486.
26. Von Itzstein *et al* (1993) *Nature Vol.* 363: 418-423.
- 30 27. Yund, *et al.* (1978) *Proc. Nat. Acad. Sci. USA*, 24: 6039-6043.

**WE CLAIM:**

1. An isolated nucleic acid molecule comprising a nucleotide sequence which encodes or is complementary to a sequence which encodes a steroid receptor polypeptide or a juvenile hormone receptor polypeptide or a bioactive derivative or analogue thereof, wherein said polypeptide:
  - (i) is selected from the list comprising EcR polypeptide of a steroid receptor, the partner protein (USP polypeptide) of a steroid receptor and the USP polypeptide of a juvenile hormone receptor; and
  - (ii) comprises an amino acid sequence that is at least 40% identical to any one of the amino acid sequences set forth in <400>2, <400>4, <400>6, <400>10, <400>12 or <400>14.
2. The isolated nucleic acid molecule according to claim 1, wherein the steroid receptor is an ecdysteroid receptor.
3. The isolated nucleic acid molecule according to claim 2, wherein the ecdysteroid receptor is an insect ecdysone receptor.
4. The isolated nucleic acid molecule according to claim 3, wherein the insect ecdysone receptor comprises the EcR polypeptide of an insect ecdysone receptor or the partner protein (USP polypeptide) of an insect ecdysone receptor.
5. The isolated nucleic acid molecule according to claims 3 or 4, wherein the insect is selected from the list comprising dipteran, hemipteran, coleopteran, lepidopteran, and neuropteran insects and ants.
6. The isolated nucleic acid molecule according to claim 5, wherein the hemipteran insect is *Myzus persicae* or a close relative thereof.
7. The isolated nucleic acid molecule according to claim 6, wherein the insect steroid receptor polypeptide comprises an EcR polypeptide of the *M. persicae* ecdysone receptor

having the amino acid sequence set forth in <400>6 or <400>10 or a bioactive analogue or derivative thereof.

8. The isolated nucleic acid molecule according to claim 6, wherein the insect steroid receptor polypeptide comprises an EcR partner protein (USP polypeptide) of the *M. persicae* ecdysone receptor or a USP polypeptide of the *M. persicae* juvenile hormone receptor having or including the amino acid sequence set forth in <400>12 or a bioactive analogue or derivative thereof.

9. The isolated nucleic acid molecule according to claim 5, wherein the dipteran insect is *L. cuprina* or a close relative thereof.

10. The isolated nucleic acid molecule according to claim 9, wherein the insect steroid receptor polypeptide comprises an EcR polypeptide of the *L. cuprina* ecdysone receptor having the amino acid sequence set forth in <400>2 or a bioactive analogue or derivative thereof.

11. The isolated nucleic acid molecule according to claim 9, wherein the insect steroid receptor polypeptide comprises an EcR partner protein (USP polypeptide) of the *L. cuprina* ecdysone receptor or a USP polypeptide of the *L. cuprina* juvenile hormone receptor having the amino acid sequence set forth in <400>4 or <400>14 or a bioactive analogue or derivative thereof.

12. The isolated nucleic acid molecule according to any one of claims 1 to 11, wherein the bioactive derivative or analogue comprises a fragment of an EcR polypeptide of an insect ecdysone receptor or a fragment of an EcR partner protein (USP polypeptide) of an insect ecdysone receptor, wherein said fragment includes at least one ligand-binding region of said EcR polypeptide or said EcR partner protein (USP polypeptide).

13. The isolated nucleic acid molecule according to claim 12, wherein the ligand-binding region comprises a linker domain of the EcR polypeptide or a linker domain of the EcR partner protein (USP polypeptide).

14. The isolated nucleic acid molecule according to claim 12, wherein the ligand-binding region comprises a hormone-binding domain of the EcR polypeptide or a hormone-binding domain of the EcR partner protein (USP polypeptide).
15. The isolated nucleic acid molecule according to claim 12, wherein the ligand-binding region comprises a linker domain and hormone-binding domain of the EcR polypeptide or a linker domain and hormone-binding domain of the EcR partner protein (USP polypeptide).
16. The isolated nucleic acid molecule according to any one of claims 1 to 15, comprising a protein-encoding nucleotide sequence which is at least 40% identical to any one of the nucleotide sequences set forth in <400>1, <400>3, <400>5, <400>9, <400>11 or <400>13 or a complementary nucleotide sequence thereto.
17. An isolated nucleic acid molecule comprising a nucleotide sequence which encodes or is complementary to a sequence which encodes a steroid receptor polypeptide or a juvenile hormone receptor polypeptide or a bioactive derivative or analogue thereof, wherein said nucleotide sequence is selected from the list comprising:
- (i) a nucleotide sequence having at least 40% identity to any one of the nucleotide sequences set forth in <400>1, <400>3, <400>5, <400>9, <400>11 or <400>13 or a complementary nucleotide sequence thereto;
  - (ii) a nucleotide sequence that is capable of hybridising under at least low stringency conditions to any one of the nucleotide sequences set forth in <400>1, <400>3, <400>5, <400>7, <400>8, <400>9, <400>11 or <400>13 or to a complementary nucleotide sequence thereto; and
  - (iii) a nucleotide sequence that is amplifiable by PCR using a nucleic acid primer sequence set forth in any one of <400>15, <400>16, <400>17, <400>18, <400>19 or <400>20.
18. An isolated nucleic acid molecule which encodes an insect steroid receptor polypeptide and comprises the nucleotide sequence set forth in <400>1 or a complementary nucleotide sequence thereto.

19. An isolated nucleic acid molecule which encodes an insect steroid receptor polypeptide or a juvenile hormone receptor polypeptide and comprises the nucleotide sequence set forth in <400>3 or <400>13 or a complementary nucleotide sequence thereto.
20. An isolated nucleic acid molecule which encodes an insect steroid receptor polypeptide and comprises the nucleotide sequence set forth in <400>5 or <400>7 or <400>8 or <400>9 or a complementary nucleotide sequence thereto.
21. An isolated nucleic acid molecule which encodes an insect steroid receptor polypeptide or a juvenile hormone receptor polypeptide and comprises the nucleotide sequence set forth in <400>11 or a complementary nucleotide sequence thereto.
22. A method of identifying the isolated nucleic acid molecule according to any one of claims 1 to 21, comprising the steps of:
- (i) hybridising genomic DNA, mRNA or cDNA derived from an insect cell, tissue or organ with a hybridisation-effective amount of one or more probes selected from the list comprising:
    - (a) probes comprising at least 10 contiguous nucleotides in length derived from any one of <400>1, <400>3, <400>5, <400>7, <400>8, <400>9, <400>11, <400>13, <400>15, <400>16, <400>17, <400>18, <400>19 or <400>20 or a complementary nucleotide sequence thereto; and
    - (b) hybridisation probes comprising the nucleotide sequences set forth in any one of <400>1, <400>3, <400>5, <400>7, <400>8, <400>9, <400>11, or <400>13 or a complementary nucleotide sequence thereto or a homologue, analogue or derivative thereof which is at least 40% identical to said sequence or complement; and
  - (ii) detecting the hybridisation.
23. The method of claim 22 wherein the step of detecting the hybridisation comprises detecting a reporter molecule that is covalently bound to the probe.

24. A method of identifying the isolated nucleic acid molecule according to any one of claims 1 to 21, comprising the steps of:

- (i) annealing one or more PCR primers comprising at least 10 contiguous nucleotides in length derived from any one of <400>1, <400>3, <400>5, <400>7, <400>8, <400>9, <400>11, <400>13, <400>15, <400>16, <400>17, <400>18, <400>19 or <400>20 or a complementary nucleotide sequence thereto, to genomic DNA, mRNA or cDNA; and
- (ii) amplifying a nucleotide sequence which encodes a steroid receptor polypeptide or a juvenile hormone receptor polypeptide in a polymerase chain reaction.

25. A method of identifying the isolated nucleic acid molecule according to any one of claims 1 to 21, comprising the steps of:

- (i) amplifying a nucleotide sequence which encodes a steroid receptor polypeptide or a juvenile hormone receptor polypeptide in a polymerase chain reaction using one or more PCR primers comprising at least 10 contiguous nucleotides in length derived from any one of <400>1, <400>3, <400>5, <400>7, <400>8, <400>9, <400>11, <400>13, <400>15, <400>16, <400>17, <400>18, <400>19 or <400>20 or a complementary nucleotide sequence thereto;
- (i) hybridising the amplified nucleotide sequence to genomic DNA, mRNA or cDNA with a hybridisation-effective amount of one or more probes selected from the list comprising:
  - (a) probes comprising at least 10 contiguous nucleotides in length derived from any one of <400>1, <400>3, <400>5, <400>7, <400>8, <400>9, <400>11, <400>13, <400>15, <400>16, <400>17, <400>18, <400>19 or <400>20 or a complementary nucleotide sequence thereto; and
  - (b) hybridisation probes comprising the nucleotide sequences set forth in any one of <400>1, <400>3, <400>5, <400>7, <400>8, <400>9, <400>11, or <400>13 or a complementary nucleotide sequence thereto or a homologue, analogue or derivative thereof which is at least 40% identical to said sequence or complement; and
- (iii) detecting the hybridisation.



- 71 -

26. The method of claim 25 wherein the step of detecting the hybridisation comprises detecting a reporter molecule that is covalently bound to the probe.

27. The method according to any one of claims 22 to 26, further comprising the step of isolating the identified nucleic acid molecule.

28. A genetic construct comprising the isolated nucleic acid molecule according to any one of claims 1 to 21 operably linked to a promoter sequence.

29. The genetic construct according to claim 28, wherein the promoter is the SV40, MMTV, polyhedron or p10 promoter.

30. A recombinant or isolated polypeptide comprising a steroid receptor polypeptide or juvenile hormone receptor polypeptide or a bioactive derivative or analogue thereof, wherein said polypeptide:

- (i) is selected from the list comprising EcR polypeptide of a steroid receptor, the partner protein (USP polypeptide) of a steroid receptor and the USP polypeptide of a juvenile hormone receptor; and
- (ii) comprises an amino acid sequence that is at least 40% identical to any one of the amino acid sequences set forth in <400>2, <400>4, <400>6, <400>10, <400>12 or <400>14;

wherein said polypeptide is substantially free of naturally-associated cellular components.

31. The recombinant or isolated polypeptide according to claim 30, wherein the steroid receptor is an ecdysteroid receptor.

32. The recombinant or isolated polypeptide according to claim 31, wherein the ecdysteroid receptor is an insect ecdysone receptor.

33. The recombinant or isolated polypeptide according to claim 32, wherein the insect ecdysone receptor comprises the EcR polypeptide of an insect ecdysone receptor or the

partner protein (USP polypeptide) of an insect ecdysone receptor.

34. The recombinant or isolated polypeptide according to claim 33, wherein the insect is selected from the list comprising dipteran, hemipteran, coleopteran, lepidopteran, and neuropteran insects and ants.

35. The recombinant or isolated polypeptide according to claim 34, wherein the hemipteran insect is *Myzus persicae* or a close relative thereof.

36. The recombinant or isolated polypeptide according to claim 35, wherein the insect steroid receptor polypeptide comprises an EcR polypeptide of the *M. persicae* ecdysone receptor having the amino acid sequence set forth in <400>6 or <400>10 or a bioactive analogue or derivative thereof.

37. The recombinant or isolated polypeptide according to claim 35, wherein the insect steroid receptor polypeptide comprises an EcR partner protein (USP polypeptide) of the *M. persicae* ecdysone receptor or a USP polypeptide of the *M. persicae* juvenile hormone receptor having or including the amino acid sequence set forth in <400>12 or a bioactive analogue or derivative thereof.

38. The recombinant or isolated polypeptide according to claim 34, wherein the dipteran insect is *L. cuprina* or a close relative thereof.

39. The recombinant or isolated polypeptide according to claim 38, wherein the insect steroid receptor polypeptide comprises an EcR polypeptide of the *L. cuprina* ecdysone receptor having the amino acid sequence set forth in <400>2 or a bioactive analogue or derivative thereof.

40. The recombinant or isolated polypeptide according to claim 38, wherein the insect steroid receptor polypeptide comprises an EcR partner protein (USP polypeptide) of the *L. cuprina* ecdysone receptor or a USP polypeptide of the *L. cuprina* juvenile hormone receptor

having the amino acid sequence set forth in <400>4 or <400>14 or a bioactive analogue or derivative thereof.

41. The recombinant or isolated polypeptide according to any one of claims 30 to 40, wherein the bioactive derivative or analogue comprises a fragment of an EcR polypeptide of an insect ecdysone receptor or a fragment of an EcR partner protein (USP polypeptide) of an insect ecdysone receptor, wherein said fragment includes at least one ligand-binding region of said EcR polypeptide or said EcR partner protein (USP polypeptide).

42. The recombinant or isolated polypeptide according to claim 41, wherein the ligand-binding region comprises a linker domain of the EcR polypeptide or a linker domain of the EcR partner protein (USP polypeptide).

43. The recombinant or isolated polypeptide according to claim 41, wherein the ligand-binding region comprises a hormone-binding domain of the EcR polypeptide or a hormone-binding domain of the EcR partner protein (USP polypeptide).

44. The recombinant or isolated polypeptide according to claim 41, wherein the ligand-binding region comprises a linker domain and hormone-binding domain of the EcR polypeptide or a linker domain and hormone-binding domain of the EcR partner protein (USP polypeptide).

45. The isolated or recombinant polypeptide according to any one of claims 30 to 44, which polypeptide binds to an insect steroid or juvenile hormone or analogue thereof or to an insecticidally-active agent to form a complex.

46. The isolated or recombinant polypeptide according to claim 45, wherein the complex modulates the expression of a gene which is operably connected to a promoter sequence or steroid response element sequence to which said polypeptide binds.

47. A cell comprising the nucleic acid molecule according to any one of claims 1 to 21 or the genetic construct according to claims 28 or 29.

48. The cell according to claim 47 being a prokaryotic or eukaryotic cell.
49. The cell according to claim 48, wherein the eukaryotic cell is an insect cell or a mammalian cell.
50. The cell according to claim 49 wherein the insect is *Spodoptera frugiperda* or the mammalian cell is a CHO cell.
51. A cell which expresses the isolated or recombinant polypeptide according to any one of claims 30 to 46.
52. The cell according to claim 51, being an insect cell or a mammalian cell.
53. The cell according to claim 52 wherein the insect cell is derived from *Spodoptera frugiperda* or the mammalian cell is a CHO cell.
54. A method of identifying a modulator of steroid receptor-mediated gene expression or juvenile hormone receptor-mediated gene expression comprising:
- (i) assaying the expression of a reporter gene in the presence of the recombinant or isolated polypeptide according to any one of claims 30 to 46 and a potential modulator; and
  - (ii) assaying the expression of the reporter gene in the presence of the recombinant or isolated polypeptide according to any one of claims 30 to 46 and without said potential modulator; and
  - (ii) comparing expression of the reporter gene in the presence of the potential modulator to the expression of a reporter gene in the absence of the potential modulator,
- wherein said reporter gene is placed operably under the control of a steroid response element (SRE) to which said steroid receptor binds or a promoter sequence comprising said SRE.
55. The method according to claim 54, wherein the SRE is the hsp27 ecdysone response

- 75 -

element or the 13 bp core palindromic sequence thereof.

56. The method according to claim 54, wherein the promoter is the SV40 promoter, MMTV promoter, p10 promoter or polyhedron promoter.

57. The method according to any one of claims 54 to 56, wherein the reporter gene is the CAT gene or the  $\beta$ -galactosidase gene.

58. The method of claim 54 wherein the modulator of steroid receptor-mediated gene expression or juvenile hormone receptor-mediated gene expression is a steroid receptor antagonist or juvenile hormone receptor antagonist.

59. The method of claim 54 wherein the modulator of steroid receptor-mediated gene expression or juvenile hormone receptor-mediated gene expression is a steroid receptor agonist or juvenile hormone receptor agonist.

60. The method of claims 58 or 59, wherein the modulator of steroid receptor-mediated gene expression or juvenile hormone receptor-mediated gene expression is a synthetic chemical that mimics the structure of a ligand of said receptor, thereby modulating binding of said ligand to said receptor.

61. The method of claim 60, wherein the synthetic chemical is a bisacylhydrazine insecticide, iridoid glycoside or other non-steroidal modulator of an ecdysteroid receptor or juvenile hormone receptor.

62. A method of identifying a potential insecticidal compound comprising:

- (i) assaying the binding directly or indirectly of the recombinant or isolated polypeptide according to any one of claims 30 to 46 to a steroid response element (SRE) to which said polypeptide binds, in the presence of a candidate compound; and
- (ii) assaying the binding directly or indirectly of the recombinant or isolated polypeptide according to any one of claims 30 to 46 to a steroid response element

- 76 -

(SRE) to which said polypeptide binds, in the absence of said candidate compound;  
and

(ii) comparing the binding assayed at (i) and (ii), wherein a difference in the level of binding indicates that the candidate compound possesses potential insecticidal activity.

63. The method according to claim 62, wherein the binding is assayed indirectly by determining the level of expression of a reporter gene which is placed operably under the control of the steroid response element (SRE) to which the isolated or recombinant polypeptide binds or a promoter sequence comprising said SRE.

64. The method according to claim 63, wherein the SRE is the hsp27 ecdysone response element or the 13 bp core palindromic sequence thereof.

65. The method according to claim 63, wherein the promoter is the SV40 promoter, MMTV promoter, p10 promoter or polyhedron promoter.

66. The method according to any one of claims 63 to 65, wherein the reporter gene is the CAT gene or the  $\beta$ -galactosidase gene.

67. The method according to any one of claims 62 to 66, wherein the potential insecticidal compound is an insect steroid receptor antagonist or insect juvenile hormone receptor antagonist.

68. The method according to any one of claims 62 to 66, wherein the potential insecticidal compound is an insect steroid receptor agonist or insect juvenile hormone receptor agonist.

69. The method of claims 67 or 68, wherein the agonist or antagonist is a synthetic chemical that mimics the structure of a ligand of an insect steroid receptor or a juvenile hormone receptor, thereby modulating binding of said ligand to said receptor.

70. The method of claim 69, wherein the synthetic chemical is a bisacylhydrazine insecticide, iridoid glycoside or other non-steroidal modulator of an insect ecdysteroid receptor or insect juvenile hormone receptor.
71. A method of identifying a candidate insecticidally-active agent comprising the steps of:
- expressing an EcR polypeptide of an insect steroid receptor or a fragment thereof which includes the ligand-binding region, optionally in association with an EcR partner protein (USP polypeptide) of an insect steroid receptor or ligand binding domain thereof, optionally in association with an insect steroid or analogue thereof so as to form a complex;
  - purifying or precipitating the complex;
  - determining the three-dimensional structure of the ligand binding domain of the complex; and
  - identifying compounds which bind to or associate with the three-dimensional structure of the ligand binding domain, wherein said compounds represent candidate insecticidally-active agents.
72. The method of claim 71, wherein the candidate insecticidally-active agent is a synthetic chemical that mimics the structure of a ligand of an insect steroid receptor or a juvenile hormone receptor, thereby modulating binding of said ligand to said receptor.
73. The method of claim 72, wherein the synthetic chemical is a bisacylhydrazine insecticide, iridoid glycoside or other non-steroidal modulator of an insect ecdysteroid receptor or insect juvenile hormone receptor.
74. A method of identifying a candidate insecticidally-active agent comprising the steps of:
- expressing a USP polypeptide of a juvenile hormone receptor or a fragment thereof which includes the ligand-binding region, optionally in association with an EcR polypeptide of an insect steroid receptor or ligand binding domain thereof, and optionally in association with an insect steroid or analogue thereof, so as to form a complex;

- 78 -

- b) purifying or precipitating the complex;
- c) determining the three-dimensional structure of the ligand binding domain of the complex; and
- d) identifying compounds which bind to or associate with the three-dimensional structure of the ligand binding domain, wherein said compounds represent candidate insecticidally-active agents.

75. The method of claim 74, wherein the candidate insecticidally-active agent is a synthetic chemical that mimics the structure of a ligand of an insect steroid receptor or an insect juvenile hormone receptor, thereby modulating binding of said ligand to said receptor.

76. The method of claim 75, wherein the synthetic chemical is a bisacylhydrazine insecticide, iridoid glycoside or other non-steroidal modulator of an insect ecdysteroid receptor or insect juvenile hormone receptor.

77. A synthetic compound which interacts with the three dimensional structure of a polypeptide or protein selected from the list comprising:

- (i) an EcR polypeptide of a steroid receptor or a fragment or bioactive derivative thereof;
- (ii) an EcR partner protein (USP polypeptide) of a steroid receptor or a fragment or bioactive derivative thereof;
- (iii) a USP polypeptide of a juvenile hormone receptor or a fragment or bioactive derivative thereof; and
- (iv) a functional receptor or protein complex formed by association of (i) and (ii),

wherein said compound is capable of binding to said polypeptide or protein to agonise or antagonise the binding activity or bioactivity thereof.

78. The synthetic compound of claim 77, wherein said compound mimics the structure of a ligand of a steroid receptor or a juvenile hormone receptor.



79. The synthetic compound of claim 78, wherein the synthetic chemical is a bisacylhydrazine insecticide, iridoid glycoside or other non-steroidal modulator of an insect ecdysteroid receptor or insect juvenile hormone receptor.

80. The recombinant or isolated polypeptide according to any one of claims 30 to 46, wherein the bioactive derivative or analogue comprises a synthetic or chimeric polypeptide comprising an amino acid sequence which:

- (i) differs from a naturally-occurring EcR polypeptide subunit of a steroid receptor, and/or a naturally-occurring EcR partner protein (USP polypeptide) subunit of a steroid receptor, and/or a naturally-occurring USP polypeptide of a juvenile hormone receptor; and
- (ii) comprises a first sequence of amino acids which are at least about 40% identical to a part of any one of <400>2, <400>4, <400>6, <400>10, <400>12 or <400>14 linked covalently to a second sequence of amino acids derived from an EcR polypeptide subunit of a steroid receptor, EcR partner protein (USP polypeptide) subunit of a steroid receptor, or USP polypeptide of a juvenile hormone receptor, wherein said first and second sequences are derived from different genomic sources.

81. The recombinant or isolated polypeptide according to claim 80, wherein the first sequence of amino acids and /or second sequence of amino acids comprises the ligand-binding regions of any one of <400>2, <400>4, <400>6, <400>10, <400>12 or <400>14.

82. The recombinant or isolated polypeptide according to claims 80 or 81, wherein the first sequence of amino acids comprises the N-terminal portion of the EcR polypeptide of a first ecdysteroid receptor to the end of the DNA-binding domain of said polypeptide and wherein the second sequence of amino acids comprises the C-terminal portion of the EcR polypeptide of a second ecdysteroid receptor, from the D domain and hormone-binding domain to the carboxyl terminus.

83. The recombinant or isolated polypeptide according to any one of claims 80 to 82, wherein the first sequence of amino acids and second sequence of amino acids are derived

from the EcR polypeptide subunit of a steroid receptor.

84. The recombinant or isolated polypeptide according to claim 83, wherein the first sequence of amino acids is derived from *L. cuprina* or *M. persicae*.

85. The recombinant or isolated polypeptide according to any one of claim 84, wherein the second sequence of amino acids is derived from *D. melanogaster*.

86. A method of identifying a synthetic compound for insecticidal activity comprising contacting the recombinant or isolated polypeptide according to any one of claims 30 to 46 with said compound for a time and under conditions sufficient for binding to occur and detecting said binding using a detection means, wherein the occurrence of binding is indicative of potential insecticidal activity of the compound.

87. The method of claim 86, further comprising assaying for binding of the compound to the polypeptide in the presence of a native insect steroid and comparing the binding obtained therefrom with the binding obtained in the absence of said steroid.

88. The method according to claims 86 or 87, wherein the polypeptide is immobilised on a solid support.

89. The method according to claim 88, wherein the solid support comprises one or more polymeric pins.

90. The method according to any one of claims 86 to 89, wherein the detection means comprises a reporter molecule that binds to the compound being screened.

91. The method of claim 90, wherein the reporter molecule is a radioactive label or antibody molecule.




FIGURE 1




FIGURE 2




FIGURE 3

- 1 -

## SEQUENCE LISTING

<110> COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION  
 <120> NOVEL GENETIC SEQUENCES ENCODING STEROID AND JUVENILE HORMONE  
 5 RECEPTOR POLYPEPTIDES AND INSECTICIDAL MODALITIES THEREFOR  
 <130> 2136323/MRO  
  
 <140> PCT INTERNATIONAL  
 <141> 1999-01-15  
 10  
 <150> AU PP1536  
 <151> 1998-01-15  
  
 <160> 20  
 15 <170> PatentIn Ver. 2.0  
  
 <210> 1  
 <211> 2274  
 <212> DNA  
 20 <213> *Lucilia cuprina*  
  
 <220>  
 <221> CDS  
 <222> (1)..(2271)  
 25  
 <400> 1  
 atg atg aaa cga cgt tgg tct aat aat ggc ggt ttt gcc gct tta aaa 48  
 Met Met Lys Arg Arg Trp Ser Asn Asn Gly Gly Phe Ala Ala Leu Lys  
 1 5 10 15  
 30  
 atg tta gaa gaa tcc tcc tca gaa gta acc tcc tcc tca aat ggt ctg 96

- 2 -

```

Met Leu Glu Glu Ser Ser Ser Glu Val Thr Ser Ser Ser Asn Gly Leu
                20                25                30

gtc ttg tca tcg gat ata aat atg tca cct tcc tgg gat tca ccc 144
5 Val Leu Ser Ser Asp Ile Asn Met Ser Pro Ser Ser Leu Asp Ser Pro
                35                40                45

gtt tat ggc gat cag gaa atg tgg ctg tgt aac gat tca gct tca tat 192
Val Tyr Gly Asp Gln Glu Met Trp Leu Cys Asn Asp Ser Ala Ser Tyr
10                50                55                60

aat aac agt cat cag cat agt gtt ata act tcg ctg cag ggc tgc acc 240
Asn Asn Ser His Gln His Ser Val Ile Thr Ser Leu Gln Gly Cys Thr
        65                70                75                80

15 tca tca ttg cgg gcc caa aca acc att ata cct ctg tca gct tta ccc 288
Ser Ser Leu Pro Ala Gln Thr Thr Ile Ile Pro Leu Ser Ala Leu Pro
                85                90                95

20 aat tcc aat aat gcc tcc ctg aat aat caa aat caa aat tat caa aat 336
Asn Ser Asn Asn Ala Ser Leu Asn Asn Gln Asn Gln Asn Tyr Gln Asn
                100                105                110

ggt aat tcc atg aat aca aat tta tcg gtt aac aca aat aac agt gtt 384
25 Gly Asn Ser Met Asn Thr Asn Leu Ser Val Asn Thr Asn Asn Ser Val
                115                120                125

gga gga ggt gga ggt ggt ggt gta ccc ggt atg act tca ctc aat 432
Gly Gly Gly Gly Gly Gly Gly Gly Val Pro Gly Met Thr Ser Leu Asn
30                130                135                140

```

- 3 -

ggt ctg ggt ggt ggt ggt ggc agt caa gtg aat aat cac aat cac agc 480  
  
 Gly Leu Gly Gly Gly Gly Gly Ser Gln Val Asn Asn His Asn His Ser  
 145 150 155 160  
 5  
 cac aat cat tta cac cac aac agc aac agt aat cac agt aat agc agt 528  
 His Asn His Leu His His Asn Ser Asn Ser Asn His Ser Asn Ser Ser  
 165 170 175  
 10  
 tcc cac cac aca aat ggc cac atg ggt att ggc ggc ggt ggt ggt ggc 576  
 Ser His His Thr Asn Gly His Met Gly Ile Gly Gly Gly Gly Gly Gly  
 180 185 190  
 tta tcg gtc aat att aat ggt ccc aat atc gtt agc aat gcc caa cag 624  
 15  
 Leu Ser Val Asn Ile Asn Gly Pro Asn Ile Val Ser Asn Ala Gln Gln  
 195 200 205  
 tta aac tcg tta cag gcc tca caa aat ggc caa gtt att cat gcc aat 672  
 Leu Asn Ser Leu Gln Ala Ser Gln Asn Gly Gln Val Ile His Ala Asn  
 20  
 210 215 220  
 att ggc att cac agt atc atc agt aat gga tta aat cat cat cac cat 720  
 Ile Gly Ile His Ser Ile Ile Ser Asn Gly Leu Asn His His His His  
 225 230 235 240  
 25  
 cat cat atg aat aac agt agt atg atg cat cat aca ccc aga tct gaa 768  
 His His Met Asn Asn Ser Ser Met Met His His Thr Pro Arg Ser Glu  
 245 250 255  
 30  
 tca gct aat tcc ata tca tca ggt cgt gat gat ctt tca ccc tcg agc 816  
 Ser Ala Asn Ser Ile Ser Ser Gly Arg Asp Asp Leu Ser Pro Ser Ser



- 4 -

	260	265	270	
	agt ctt aat ggc ttc tca aca agc gat gct agt gat gtt aag aaa atc			864
	Ser Leu Asn Gly Phe Ser Thr Ser Asp Ala Ser Asp Val Lys Lys Ile			
5	275	280	285	
	aaa aaa ggt cct gcg ccc cgt tta caa gag gaa ctg tgt ctg gtg tgt			912
	Lys Lys Gly Pro Ala Pro Arg Leu Gln Glu Glu Leu Cys Leu Val Cys			
	290	295	300	
10				
	ggt gat cgg gcg tcc ggt tat cat tat aac gca ctc acc tgt gaa ggc			960
	Gly Asp Arg Ala Ser Gly Tyr His Tyr Asn Ala Leu Thr Cys Glu Gly			
	305	310	315	320
15				
	tgt aag ggg ttc ttt cga cgg agt gtt acc aaa aat gcg gtg tat tgt			1008
	Cys Lys Gly Phe Phe Arg Arg Ser Val Thr Lys Asn Ala Val Tyr Cys			
	325	330	335	
	tgt aaa ttt ggt cat gcc tgc gaa atg gac atg tat atg cga cgt aaa			1056
20	Cys Lys Phe Gly His Ala Cys Glu Met Asp Met Tyr Met Arg Arg Lys			
	340	345	350	
	tgt cag gaa tgt agg ctg aaa aaa tgt ttg gct gtg ggc atg cgg ccg			1104
	Cys Gln Glu Cys Arg Leu Lys Lys Cys Leu Ala Val Gly Met Arg Pro			
25	355	360	365	
	gaa tgt gtg gtg ccc gaa aac cag tgt gca atg aaa cga cgc gaa aag			1152
	Glu Cys Val Val Pro Glu Asn Gln Cys Ala Met Lys Arg Arg Glu Lys			
	370	375	380	

30

- 5 -

aaa gca caa aaa gag aag gat aaa ata cag acc agt gtg tgt gca acg 1200  
 Lys Ala Gln Lys Lys Glu Lys Asp Lys Ile Gln Thr Ser Val Cys Ala Thr  
 385 390 395 400

5 gaa att aaa aag gaa ata ctc gat tta atg aca tgt gaa cag cca tca 1248  
 Glu Ile Lys Lys Glu Ile Leu Asp Leu Met Thr Cys Glu Pro Pro Ser  
 405 410 415

cat cca acg tgt cag ctg tta cct gaa gac att ttg gct aaa tgt caa 1296  
 10 His Pro Thr Cys Pro Leu Leu Pro Glu Asp Ile Leu Ala Lys Cys Gln  
 420 425 430

gct cgt aat ata cct cct tta tcg tac aat caa ttg gca gtt ata tat 1344  
 Ala Arg Asn Ile Pro Pro Leu Ser Tyr Asn Gln Leu Ala Val Ile Tyr  
 15 435 440 445

aaa tta ata tgg tat caa gat ggc tac gaa cag cca tcc gag gaa gat 1392  
 Lys Leu Ile Trp Tyr Gln Asp Gly Tyr Glu Gln Pro Ser Glu Glu Asp  
 450 455 460

20 ctc aaa cgt ata atg agt tca ccc gat gaa aat gaa agt caa cac gat 1440  
 Leu Lys Arg Ile Met Ser Ser Pro Asp Glu Asn Glu Ser Gln His Asp  
 465 470 475 480

gca tca ttt cgt cat ata aca gaa atc act ata cta aca gta caa tta 1488  
 Ala Ser Phe Arg His Ile Thr Glu Ile Thr Ile Leu Thr Val Gln Leu  
 485 490 495

att gtg gaa ttt gcc aag ggt ttg cca gcg ttt acc aaa ata cca caa 1536  
 30 Ile Val Glu Phe Ala Lys Gly Leu Pro Ala Phe Thr Lys Ile Pro Gln  
 500 505 510

- 6 -

gag gat caa ata aca cta tta aag gcc tgc tca tca gaa gtt atg atg 1584  
 Glu Asp Gln Ile Thr Leu Leu Lys Ala Cys Ser Ser Glu Val Met Met  
 515 520 525

5 ttg cga atg gca cga cgt tac gat cac aat tca gat tcg ata ttc ttt 1632  
 Leu Arg Met Ala Arg Arg Tyr Asp His Asn Ser Asp Ser Ile Phe Phe  
 530 535 540

cc aat aat cga tcg tat acg cgt gac tct tat aaa atg gct ggc atg 1680  
 10 Ala Asn Asn Arg Ser Tyr Thr Arg Asp Ser Tyr Lys Met Ala Gly Met  
 545 550 555 560

gct gat aat att gag gat ctg ctg cat ttc tgt cga caa atg tac tcg 1728  
 Ala Asp Asn Ile Glu Asp Leu Leu His Phe Cys Arg Gln Met Tyr Ser  
 15 565 570 575

atg aaa gtg gac aat gtc gaa tat gct cta ctc act gcc att gtg atc 1776  
 Met Lys Val Asp Asn Val Glu Tyr Ala Leu Leu Thr Ala Ile Val Ile  
 580 585 590

20 ttt tcc gat cgg cgg ggt ctc gaa gaa gcc gaa cta gtc gaa gcg ata 1824  
 Phe Ser Asp Arg Pro Gly Leu Glu Glu Ala Glu Leu Val Glu Ala Ile  
 595 600 605

25 caa agt tac tac atc gat aca ctc cgc att tac ata ctt aat cgc cat 1872  
 Gln Ser Tyr Tyr Ile Asp Thr Leu Arg Ile Tyr Ile Leu Asn Arg His  
 610 615 620

tgc ggc gat ccc atg agt ctc gta ttc ttt gcc aag ctt ctg tca att 1920  
 30 Cys Gly Asp Pro Met Ser Leu Val Phe Phe Ala Lys Leu Leu Ser Ile  
 625 630 635 640

- 7 -

cta acc gaa ctg cgt acg ttg ggc aat caa aat gcc gaa atg tgt ttc 1968  
 Leu Thr Glu Leu Arg Thr Leu Gly Asn Gln Asn Ala Glu Met Cys Phe  
 645 650 655

5 tcg ttg aaa ttg aaa aat cgc aaa ctg cca aaa ttc ctc gaa gag atc 2016  
 Ser Leu Lys Leu Lys Asn Arg Lys Leu Pro Lys Phe Leu Glu Glu Ile  
 660 665 670

tgg gat gta cat gcc att cca ccc tca gtg cag tca cac ata cag gct 2064  
 10 Trp Asp Val His Ala Ile Pro Pro Ser Val Gln Ser His Ile Gln Ala  
 675 680 685

acc cag gcg gaa aag gcc gcc cag gaa gct cag gca aca aca tcg gcc 2112  
 Thr Gln Ala Glu Lys Ala Ala Gln Glu Ala Gln Ala Thr Thr Ser Ala  
 15 690 695 700

att tca gca gcc gcc acc tca tct tcc tcc ata aat acc tcg atg gca 2160  
 Ile Ser Ala Ala Ala Thr Ser Ser Ser Ser Ile Asn Thr Ser Met Ala  
 705 710 715 720

20 aca tca tcc tca tca tcg tta tcg cca tcg gcg gcc tca aca ccc aat 2208  
 Thr Ser Ser Ser Ser Ser Leu Ser Pro Ser Ala Ala Ser Thr Pro Asn  
 725 730 735

25 ggt ggt gcc gtc gat tat gtt ggc acc gat atg agt atg agt tta gta 2256  
 Gly Gly Ala Val Asp Tyr Val Gly Thr Asp Met Ser Met Ser Leu Val  
 740 745 750

caa tcg gat aat gca tag 2274  
 30 Gln Ser Asp Asn Ala  
 755

- 8 -

<210> 2  
<211> 757  
5 <212> PRT  
<213> *Lucilia cuprina*

<400> 2  
Met Met Lys Arg Arg Trp Ser Asn Asn Gly Gly Phe Ala Ala Leu Lys  
10 1 5 10 15  
Met Leu Glu Glu Ser Ser Ser Glu Val Thr Ser Ser Ser Asn Gly Leu  
20 25 30  
15 Val Leu Ser Ser Asp Ile Asn Met Ser Pro Ser Ser Leu Asp Ser Pro  
35 40 45  
Val Tyr Gly Asp Gln Glu Met Trp Leu Cys Asn Asp Ser Ala Ser Tyr  
50 55 60  
20 Asn Asn Ser His Gln His Ser Val Ile Thr Ser Leu Gln Gly Cys Thr  
65 70 75 80  
Ser Ser Leu Pro Ala Gln Thr Thr Ile Ile Pro Leu Ser Ala Leu Pro  
25 85 90 95  
Asn Ser Asn Asn Ala Ser Leu Asn Asn Gln Asn Gln Asn Tyr Gln Asn  
100 105 110  
30 Gly Asn Ser Met Asn Thr Asn Leu Ser Val Asn Thr Asn Asn Ser Val  
115 120 125

- 9 -

Gly Gly Gly Gly Gly Gly Gly Val Pro Gly Met Thr Ser Leu Asn  
 130 135 140

Gly Leu Gly Gly Gly Gly Gly Ser Gln Val Asn Asn His Asn His Ser  
 5 145 150 155 160

His Asn His Leu His His Asn Ser Asn Ser Asn His Ser Asn Ser Ser  
 165 170 175

10 Ser His His Thr Asn Gly His Met Gly Ile Gly Gly Gly Gly Gly Gly  
 180 185 190

Leu Ser Val Asn Ile Asn Gly Pro Asn Ile Val Ser Asn Ala Gln Gln  
 195 200 205

15 Leu Asn Ser Leu Gln Ala Ser Gln Asn Gly Gln Val Ile His Ala Asn  
 210 215 220

Ile Gly Ile His Ser Ile Ile Ser Asn Gly Leu Asn His His His His  
 20 225 230 235 240

His His Met Asn Asn Ser Ser Met Met His His Thr Pro Arg Ser Glu  
 245 250 255

25 Ser Ala Asn Ser Ile Ser Ser Gly Arg Asp Asp Leu Ser Pro Ser Ser  
 260 265 270

Ser Leu Asn Gly Phe Ser Thr Ser Asp Ala Ser Asp Val Lys Lys Ile  
 275 280 285

30 Lys Lys Gly Pro Ala Pro Arg Leu Gln Glu Glu Leu Cys Leu Val Cys

- 10 -

	290	295	300	
	Gly Asp Arg Ala Ser Gly Tyr His Tyr Asn Ala Leu Thr Cys Glu Gly			
	305	310	315	320
5				
	Cys Lys Gly Phe Phe Arg Arg Ser Val Thr Lys Asn Ala Val Tyr Cys			
		325	330	335
	Cys Lys Phe Gly His Ala Cys Glu Met Asp Met Tyr Met Arg Arg Lys			
10	340	345	350	
	Cys Gln Glu Cys Arg Leu Lys Lys Cys Leu Ala Val Gly Met Arg Pro			
	355	360	365	
15	Glu Cys Val Val Pro Glu Asn Gln Cys Ala Met Lys Arg Arg Glu Lys			
	370	375	380	
	Lys Ala Gln Lys Glu Lys Asp Lys Ile Gln Thr Ser Val Cys Ala Thr			
	385	390	395	400
20				
	Glu Ile Lys Lys Glu Ile Leu Asp Leu Met Thr Cys Glu Pro Pro Ser			
		405	410	415
	His Pro Thr Cys Pro Leu Leu Pro Glu Asp Ile Leu Ala Lys Cys Gln			
25	420	425	430	
	Ala Arg Asn Ile Pro Pro Leu Ser Tyr Asn Gln Leu Ala Val Ile Tyr			
	435	440	445	
30	Lys Leu Ile Trp Tyr Gln Asp Gly Tyr Glu Gln Pro Ser Glu Glu Asp			
	450	455	460	

- 11 -

Leu Lys Arg Ile Met Ser Ser Pro Asp Glu Asn Glu Ser Gln His Asp  
 465                      470                      475                      480

Ala Ser Phe Arg His Ile Thr Glu Ile Thr Ile Leu Thr Val Gln Leu  
 5                      485                      490                      495

Ile Val Glu Phe Ala Lys Gly Leu Pro Ala Phe Thr Lys Ile Pro Gln  
 500                      505                      510

10 Glu Asp Gln Ile Thr Leu Leu Lys Ala Cys Ser Ser Glu Val Met Met  
 515                      520                      525

Leu Arg Met Ala Arg Arg Tyr Asp His Asn Ser Asp Ser Ile Phe Phe  
 15                      530                      535                      540

Ala Asn Asn Arg Ser Tyr Thr Arg Asp Ser Tyr Lys Met Ala Gly Met  
 545                      550                      555                      560

20 Ala Asp Asn Ile Glu Asp Leu Leu His Phe Cys Arg Gln Met Tyr Ser  
 565                      570                      575

Met Lys Val Asp Asn Val Glu Tyr Ala Leu Leu Thr Ala Ile Val Ile  
 580                      585                      590

25 Phe Ser Asp Arg Pro Gly Leu Glu Glu Ala Glu Leu Val Glu Ala Ile  
 595                      600                      605

Gln Ser Tyr Tyr Ile Asp Thr Leu Arg Ile Tyr Ile Leu Asn Arg His  
 30                      610                      615                      620



- 12 -

Cys Gly Asp Pro Met Ser Leu Val Phe Phe Ala Lys Leu Leu Ser Ile  
625                      630                      635                      640

Leu Thr Glu Leu Arg Thr Leu Gly Asn Gln Asn Ala Glu Met Cys Phe  
5                      645                      650                      655

Ser Leu Lys Leu Lys Asn Arg Lys Leu Pro Lys Phe Leu Glu Glu Ile  
                    660                      665                      670

10 Trp Asp Val His Ala Ile Pro Pro Ser Val Gln Ser His Ile Gln Ala  
                    675                      680                      685

Thr Gln Ala Glu Lys Ala Ala Gln Glu Ala Gln Ala Thr Thr Ser Ala  
                    690                      695                      700

15 Ile Ser Ala Ala Ala Thr Ser Ser Ser Ser Ile Asn Thr Ser Met Ala  
705                      710                      715                      720

Thr Ser Ser Ser Ser Ser Leu Ser Pro Ser Ala Ala Ser Thr Pro Asn  
20                      725                      730                      735

Gly Gly Ala Val Asp Tyr Val Gly Thr Asp Met Ser Met Ser Leu Val  
                    740                      745                      750

25 Gln Ser Asp Asn Ala  
                    755

<210> 3  
<211> 1377  
30 <212> DNA  
                    <213> *Lucilia cuprina*

- 13 -

&lt;220&gt;

&lt;221&gt; CDS

&lt;222&gt; (1)..(1374)

5 <400> 3  
atg gat aac ggc gag caa gat gct ggg ttc cga ttg gca ccg atg tct 48  
Met Asp Asn Gly Glu Gln Asp Ala Gly Phe Arg Leu Ala Pro Met Ser  
1 5 10 15

10 ccg cag gag ata aag cca gac att tca cta ctc aat gaa aat aat acg 96  
Pro Gln Glu Ile Lys Pro Asp Ile Ser Leu Leu Asn Glu Asn Asn Thr  
20 25 30

15 agt agt tat tcg ccc aaa cct gga agt cct aat cca ttt gcc atc gga 144  
Ser Ser Tyr Ser Pro Lys Pro Gly Ser Pro Asn Pro Phe Ala Ile Gly  
35 40 45

ttg cag gca ata aat gca gtc gct gcc gcg aat gcc aat aac caa aat 192  
Leu Gln Ala Ile Asn Ala Val Ala Ala Ala Asn Ala Asn Asn Gln Asn  
20 50 55 60

caa atg ttg caa act acg cca cca caa cag cag cag tat cca cca aat 240  
Gln Met Leu Gln Thr Thr Pro Pro Gln Gln Gln Gln Tyr Pro Pro Asn  
65 70 75 80

25 cac ccc ctt agt ggt tcg aaa cac ttg tgt tcc att tgt gga gac cgc 288  
His Pro Leu Ser Gly Ser Lys His Leu Cys Ser Ile Cys Gly Asp Arg  
85 90 95

30 gcc agt gga aaa cat tat ggg gtc tac agt tgt gag ggt tgt aaa ggg 336  
Ala Ser Gly Lys His Tyr Gly Val Tyr Ser Cys Glu Gly Cys Lys Gly

- 14 -

	100	105	110	
	ttc ttc aaa cgt acc gta cgc aag gac ttg aca tat gct tgt cgt gag			384
	Phe Phe Lys Arg Thr Val Arg Lys Asp Leu Thr Tyr Ala Cys Arg Glu			
5	115	120	125	
	gac aga aat tgc att ata gat aaa cga caa aga aat cgt tgc cag tat			432
	Asp Arg Asn Cys Ile Ile Asp Lys Arg Gln Arg Asn Arg Cys Gln Tyr			
	130	135	140	
10				
	tgt cgt tat caa aag tgt tta gct tgt ggc atg aaa cgc gaa gcg gtc			480
	Cys Arg Tyr Gln Lys Cys Leu Ala Cys Gly Met Lys Arg Glu Ala Val			
	145	150	155	160
15				
	caa gag gaa cga caa cgt ggt act cgt gct gct aac gct aga gct gct			528
	Gln Glu Glu Arg Gln Arg Gly Thr Arg Ala Ala Asn Ala Arg Ala Ala			
	165	170	175	
	ggt gct ggc ggt ggt gga gga ggt ggt ggt ggg gta agc aat gtg gtt			576
20	Gly Ala Gly Gly Gly Gly Gly Gly Gly Val Ser Asn Val Val			
	180	185	190	
	ggt gct ggc gga gaa gac ttt aaa ccc agc agt tca tta cgt gat ctc			624
	Gly Ala Gly Gly Glu Asp Phe Lys Pro Ser Ser Ser Leu Arg Asp Leu			
25	195	200	205	
	act ata gaa cgc atc att gaa gcc gag caa aag gct gaa tct ttg agc			672
	Thr Ile Glu Arg Ile Ile Glu Ala Glu Gln Lys Ala Glu Ser Leu Ser			
	210	215	220	
30				
	ggt gat aac gtg ttg ccc ttt ttg cgc gtt ggc aac aat tcc atg gta			720

- 15 -

Gly Asp Asn Val Leu Pro Phe Leu Arg Val Gly Asn Asn Ser Met Val  
 225 230 235 240

caa cac gac tac aaa ggc gcg gta tct cat ctc tgc cag atg gtt aac 768  
 5 Gln His Asp Tyr Lys Gly Ala Val Ser His Leu Cys Gln Met Val Asn  
 245 250 255

aaa caa ctc tac caa atg gtt gaa tat gca cgt cga aca cca cat ttt 816  
 Lys Gln Leu Tyr Gln Met Val Glu Tyr Ala Arg Arg Thr Pro His Phe  
 10 260 265 270

aca cat ttg cag cgt gag gat cag ata cta ttg tta aag gct ggc tgg 864  
 Thr His Leu Gln Arg Glu Asp Gln Ile Leu Leu Leu Lys Ala Gly Trp  
 275 280 285

15 aat gaa ctg cta att gca aat gtt gcc tgg tgc agt att gag tct ctg 912  
 Asn Glu Leu Leu Ile Ala Asn Val Ala Trp Cys Ser Ile Glu Ser Leu  
 290 295 300

20 gat gcc gaa tat gcc tct cct ggt acg gta cat gac ggt tct ttt ggt 960  
 Asp Ala Glu Tyr Ala Ser Pro Gly Thr Val His Asp Gly Ser Phe Gly  
 305 310 315 320

cgg cgt tca cca gtg cgt cag ccc caa caa ctc ttc ctt aat cag aat 1008  
 25 Arg Arg Ser Pro Val Arg Gln Pro Gln Gln Leu Phe Leu Asn Gln Asn  
 325 330 335

ttc tcg tat cat cgc aat agt gct att aag gcc aat gtt gtt tca att 1056  
 Phe Ser Tyr His Arg Asn Ser Ala Ile Lys Ala Asn Val Val Ser Ile  
 30 340 345 350

- 16 -

ttc gat cgt atc ctc tcg gag ttg agc atc aaa atg aaa cgt ctt aac 1104  
 Phe Asp Arg Ile Leu Ser Glu Leu Ser Ile Lys Met Lys Arg Leu Asn  
 355 360 365

5 atc gat cgc tcg gag ttg tcg tgt ctg aag gca atc ata ctc ttc aat 1152  
 Ile Asp Arg Ser Glu Leu Ser Cys Leu Lys Ala Ile Ile Leu Phe Asn  
 370 375 380

cca gac ata cgc ggt ctg aaa tgt cga gcc gac gtc gag gta tgt cgt 1200  
 10 Pro Asp Ile Arg Gly Leu Lys Cys Arg Ala Asp Val Glu Val Cys Arg  
 385 390 395 400

gaa aaa atc tat gcc tgt ctg gac gaa cac tgc cgc aca gaa cat cca 1248  
 Glu Lys Ile Tyr Ala Cys Leu Asp Glu His Cys Arg Thr Glu His Pro  
 15 405 410 415

ggt gat gat gcc cgc ttt gct cag cta cta cta agg ttg ccc gca ttg 1296  
 Gly Asp Asp Gly Arg Phe Ala Gln Leu Leu Leu Arg Leu Pro Ala Leu  
 420 425 430

20 ctt cca tca atc tca aat gtc tcg atc att tgt ttt cct ccg ttt aat 1344  
 Leu Pro Ser Ile Ser Asn Val Ser Ile Ile Cys Phe Pro Pro Phe Asn  
 435 440 445

25 agg cga aag agc att gga gga att aat tgc tga 1377  
 Arg Arg Lys Ser Ile Gly Gly Ile Asn Cys  
 450 455

30 <210> 4  
 <211> 458

- 17 -

&lt;212&gt; PRT

<213> *Lucilia cuprina*

&lt;400&gt; 4

5 Met Asp Asn Gly Glu Gln Asp Ala Gly Phe Arg Leu Ala Pro Met Ser

1 5 10 15

Pro Gln Glu Ile Lys Pro Asp Ile Ser Leu Leu Asn Glu Asn Asn Thr

20 25 30

10

Ser Ser Tyr Ser Pro Lys Pro Gly Ser Pro Asn Pro Phe Ala Ile Gly

35 40 45

Leu Gln Ala Ile Asn Ala Val Ala Ala Ala Asn Ala Asn Asn Gln Asn

15 50 55 60

Gln Met Leu Gln Thr Thr Pro Pro Gln Gln Gln Gln Tyr Pro Pro Asn

65 70 75 80

20 His Pro Leu Ser Gly Ser Lys His Leu Cys Ser Ile Cys Gly Asp Arg

85 90 95

Ala Ser Gly Lys His Tyr Gly Val Tyr Ser Cys Glu Gly Cys Lys Gly

100 105 110

25

Phe Phe Lys Arg Thr Val Arg Lys Asp Leu Thr Tyr Ala Cys Arg Glu

115 120 125

Asp Arg Asn Cys Ile Ile Asp Lys Arg Gln Arg Asn Arg Cys Gln Tyr

30 130 135 140

- 18 -

Cys Arg Tyr Gln Lys Cys Leu Ala Cys Gly Met Lys Arg Glu Ala Val  
145 150 155 160

Gln Glu Glu Arg Gln Arg Gly Thr Arg Ala Ala Asn Ala Arg Ala Ala  
5 165 170 175

Gly Ala Gly Gly Gly Gly Gly Gly Gly Gly Gly Val Ser Asn Val Val  
180 185 190

10 Gly Ala Gly Gly Glu Asp Phe Lys Pro Ser Ser Ser Leu Arg Asp Leu  
195 200 205

Thr Ile Glu Arg Ile Ile Glu Ala Glu Gln Lys Ala Glu Ser Leu Ser  
210 215 220

15 Gly Asp Asn Val Leu Pro Phe Leu Arg Val Gly Asn Asn Ser Met Val  
225 230 235 240

Gln His Asp Tyr Lys Gly Ala Val Ser His Leu Cys Gln Met Val Asn  
20 245 250 255

Lys Gln Leu Tyr Gln Met Val Glu Tyr Ala Arg Arg Thr Pro His Phe  
260 265 270

25 Thr His Leu Gln Arg Glu Asp Gln Ile Leu Leu Leu Lys Ala Gly Trp  
275 280 285

Asn Glu Leu Leu Ile Ala Asn Val Ala Trp Cys Ser Ile Glu Ser Leu  
290 295 300

30 Asp Ala Glu Tyr Ala Ser Pro Gly Thr Val His Asp Gly Ser Phe Gly

- 19 -

305                      310                      315                      320  
  
 Arg Arg Ser Pro Val Arg Gln Pro Gln Gln Leu Phe Leu Asn Gln Asn  
                                  325                      330                      335  
  
 5  
 Phe Ser Tyr His Arg Asn Ser Ala Ile Lys Ala Asn Val Val Ser Ile  
                                  340                      345                      350  
  
 Phe Asp Arg Ile Leu Ser Glu Leu Ser Ile Lys Met Lys Arg Leu Asn  
 10                      355                      360                      365  
  
 Ile Asp Arg Ser Glu Leu Ser Cys Leu Lys Ala Ile Ile Leu Phe Asn  
                                  370                      375                      380  
  
 15    Pro Asp Ile Arg Gly Leu Lys Cys Arg Ala Asp Val Glu Val Cys Arg  
                                  385                      390                      395                      400  
  
 Glu Lys Ile Tyr Ala Cys Leu Asp Glu His Cys Arg Thr Glu His Pro  
                                  405                      410                      415  
  
 20  
 Gly Asp Asp Gly Arg Phe Ala Gln Leu Leu Leu Arg Leu Pro Ala Leu  
                                  420                      425                      430  
  
 Leu Pro Ser Ile Ser Asn Val Ser Ile Ile Cys Phe Pro Pro Phe Asn  
 25                      435                      440                      445  
  
 Arg Arg Lys Ser Ile Gly Gly Ile Asn Cys  
                                  450                      455

30



- 20 -

<210> 5  
 <211> 585  
 <212> DNA  
 <213> *Myzus persicae*

5

<220>  
 <221> CDS  
 <222> (1)..(585)

10

<400> 5  
 gaa ttc ggc acg agc gcc att gtt aat gga ttt atc cgc acc att agt 48  
 Glu Phe Gly Thr Ser Ala Ile Val Asn Gly Phe Ile Arg Thr Ile Ser  
 1 5 10 15

15

ttg atc ctt att ttt ctt ctt ctt ttt ctt tgg agg ttg ttg gcc ttc 96  
 Leu Ile Leu Ile Phe Leu Leu Leu Phe Leu Trp Arg Leu Leu Ala Phe  
 20 25 30

cgg ttc ttg ttt ata tct gaa caa cca cct ccc gaa gag ctg tgc ctg 144  
 Arg Phe Leu Phe Ile Ser Glu Gln Pro Pro Pro Glu Glu Leu Cys Leu  
 35 40 45

gtg tgt ggc gac cgg tgg tcc ggt tac cat tac aac gct ctc aca tgc 192  
 Val Cys Gly Asp Arg Ser Ser Gly Tyr His Tyr Asn Ala Leu Thr Cys

25

50 55 60

gaa gga tgc aag ggg ttc ttc cgg agg agc atc acc aag aac gcc gtg 240  
 Glu Gly Cys Lys Gly Phe Phe Arg Arg Ser Ile Thr Lys Asn Ala Val  
 65 70 75 80

30

tac cag tgc aag tac ggc aac aat tgc gaa atc gac atg tac atg agg 288

- 21 -

Tyr Gln Cys Lys Tyr Gly Asn Asn Cys Glu Ile Asp Met Tyr Met Arg  
 85 90 95

cgg aag tgc cag gag tgc cgg ctg aaa aaa tgc ctg acc gtc ggc atg 336  
 5 Arg Lys Cys Gln Glu Cys Arg Leu Lys Lys Cys Leu Thr Val Gly Met  
 100 105 110

agg cct gaa tgt gtt gta cct gaa gtt caa tgc gca gta aaa aga aag 384  
 Arg Pro Glu Cys Val Val Pro Glu Val Gln Cys Ala Val Lys Arg Lys  
 10 115 120 125

gag aaa aaa gct caa cga gaa aaa gat aaa cca aat tct act aca gac 432  
 Glu Lys Lys Ala Gln Arg Glu Lys Asp Lys Pro Asn Ser Thr Thr Asp  
 130 135 140

15 att tct cct gaa ata ata aaa ata gaa cct aca gag atg aag att gaa 480  
 Ile Ser Pro Glu Ile Ile Lys Ile Glu Pro Thr Glu Met Lys Ile Glu  
 145 150 155 160

20 tgt ggt gaa cca atg ata atg ggc aca cct atg ccg act gta cct tac 528  
 Cys Gly Glu Pro Met Ile Met Gly Thr Pro Met Pro Thr Val Pro Tyr  
 165 170 175

gtg aaa cct ttg agt tct ctc gtg ccg aat tcg gca cga gtc acg ggt 576  
 25 Val Lys Pro Leu Ser Ser Leu Val Pro Asn Ser Ala Arg Val Thr Gly  
 180 185 190

tac aaa ttt 585  
 Tyr Lys Phe  
 30 195

- 22 -

<210> 6  
<211> 195  
<212> PRT  
5 <213> Myzus persicae

<400> 6  
Glu Phe Gly Thr Ser Ala Ile Val Asn Gly Phe Ile Arg Thr Ile Ser  
1 5 10 15  
10  
Leu Ile Leu Ile Phe Leu Leu Leu Phe Leu Trp Arg Leu Leu Ala Phe  
20 25 30  
Arg Phe Leu Phe Ile Ser Glu Gln Pro Pro Pro Glu Glu Leu Cys Leu  
15 35 40 45  
Val Cys Gly Asp Arg Ser Ser Gly Tyr His Tyr Asn Ala Leu Thr Cys  
50 55 60  
20 Glu Gly Cys Lys Gly Phe Phe Arg Arg Ser Ile Thr Lys Asn Ala Val  
65 70 75 80  
Tyr Gln Cys Lys Tyr Gly Asn Asn Cys Glu Ile Asp Met Tyr Met Arg  
85 90 95  
25  
Arg Lys Cys Gln Glu Cys Arg Leu Lys Lys Cys Leu Thr Val Gly Met  
100 105 110  
Arg Pro Glu Cys Val Val Pro Glu Val Gln Cys Ala Val Lys Arg Lys  
30 115 120 125

- 23 -

Glu Lys Lys Ala Gln Arg Glu Lys Asp Lys Pro Asn Ser Thr Thr Asp  
 130 135 140

Ile Ser Pro Glu Ile Ile Lys Ile Glu Pro Thr Glu Met Lys Ile Glu  
 5 145 150 155 160

Cys Gly Glu Pro Met Ile Met Gly Thr Pro Met Pro Thr Val Pro Tyr  
 165 170 175

10 Val Lys Pro Leu Ser Ser Leu Val Pro Asn Ser Ala Arg Val Thr Gly  
 180 185 190

Tyr Lys Phe  
 195

15

<210> 7  
 <211> 208  
 <212> DNA  
 <213> Myzus persicae

20

<400> 7  
 catgcctgca ggtcgactct agaggatccc ctgcgccggt taccattaca acgcactcac 60  
 ctgtgaaggc tgtaaggggt tctttcgacg gagtggtacc aaaaatgcgg tgattgttg 120

25

taaatttggt catgcctgcg aaatggacat gtatatgcga cgtaaagtgc aggaatgtag 180  
 gctgaaaaaa tgtttggctg tgggcatg 208

30

- 24 -

<210> 8  
<211> 436  
<212> DNA  
<213> Myzus persicae

5  
<400> 8  
catgcggccg gaatgtgtgg tgcccgaaaa ccagtgtgca atgaaacgac gcgaaaagaa 60  
  
agcacaaaaa gagaaggata aaatacagac cagtgtgtgt gcaacggaaa ttaaaaagga 120  
10  
aatactgat ttaatgacat gtgaaccgcc atcacatcca acgtgtccgc tgttaacctga 180  
  
agacattttg gctaaatgtc aagctcgtaa tatacctcct ttatcgtaca atcaattggc 240  
  
15  
agttatatat aaattaatat ggtatcaaga tggctaogaa cagccatccg aggaagatct 300  
  
caaacgtata atgagttcac ccgatgaaaa tgaagtgcaa cacgatgcat catttcgtca 360  
  
tataacagaa atcactatac taacagtaca attaattgtt gaatgtgcca aaggtctagg 420  
20  
gtaccgagct cgaatt 436

<210> 9  
25  
<211> 1353  
<212> DNA  
<213> Myzus persicae

<220>  
30  
<221> CDS  
<222> (1)..(1350)

- 25 -

<400> 9

atg tcg acc aac agc tac gac ccg tac agt ccg atg agt gga aaa atc 48  
 Met Ser Thr Asn Ser Tyr Asp Pro Tyr Ser Pro Met Ser Gly Lys Ile  
 1 5 10 15

5 gtc aaa gaa gag ttg tct ccg cca aac agc ctg tcg gga gtc agc agc 96  
 Val Lys Glu Glu Leu Ser Pro Pro Asn Ser Leu Ser Gly Val Ser Ser  
 20 25 30

10 cat tcg gat ggg ttg aag aag aag aaa ctc aac cac acg ccc tcg acc 144  
 His Ser Asp Gly Leu Lys Lys Lys Lys Leu Asn His Thr Pro Ser Thr  
 35 40 45

ggg gtc gtc aac acc tcg gca tcg ggc ccc ggg ggt ggc gtt ggt ggc 192  
 15 Gly Val Val Asn Thr Ser Ala Ser Gly Pro Gly Gly Gly Val Gly Gly  
 50 55 60

aat gtg ctg aac aac cga cct ccc gaa gag ctg tgc ctg gtg tgt ggc 240  
 Asn Val Leu Asn Asn Arg Pro Pro Glu Glu Leu Cys Leu Val Cys Gly  
 20 65 70 75 80

gac cgg tcg tcc ggt tac cat tac aac gct ctc aca tgc gaa gga tgc 288  
 Asp Arg Ser Ser Gly Tyr His Tyr Asn Ala Leu Thr Cys Glu Gly Cys  
 85 90 95

25 aag ggg ttc ttc cgg agg agc atc acc aag aac gcc gtg tac cag tgc 336  
 Lys Gly Phe Phe Arg Arg Ser Ile Thr Lys Asn Ala Val Tyr Gln Cys  
 100 105 110

30 aag tac ggc aac aat tgc gaa atc gac atg tac atg agg cgg aag tgc 384  
 Lys Tyr Gly Asn Asn Cys Glu Ile Asp Met Tyr Met Arg Arg Lys Cys

- 26 -

	115	120	125	
	cag gag tgc cgg ctg aaa aaa tgc ctg acc gtc ggc atg agg cct gaa			432
	Gln Glu Cys Arg Leu Lys Lys Cys Leu Thr Val Gly Met Arg Pro Glu			
5	130	135	140	
	tgt gtt gta cct gaa gtt caa tgc gca gta aaa aga aag gag aaa aaa			480
	Cys Val Val Pro Glu Val Gln Cys Ala Val Lys Arg Lys Glu Lys Lys			
	145	150	155	160
10				
	gct caa cga gaa aaa gat aaa cca aat tct act aca gac att tct cct			528
	Ala Gln Arg Glu Lys Asp Lys Pro Asn Ser Thr Thr Asp Ile Ser Pro			
	165	170	175	
15				
	gaa ata ata aaa ata gaa cct aca gag atg aag att gaa tgt ggt gaa			576
	Glu Ile Ile Lys Ile Glu Pro Thr Glu Met Lys Ile Glu Cys Gly Glu			
	180	185	190	
	cca atg ata atg ggc aca cct atg cgg act gta cct tac gtg aaa cct			624
20	Pro Met Ile Met Gly Thr Pro Met Pro Thr Val Pro Tyr Val Lys Pro			
	195	200	205	
	ttg agt tct gaa caa aaa gaa ctg atc cac cga ctt gtc tat ttc cag			672
	Leu Ser Ser Glu Gln Lys Glu Leu Ile His Arg Leu Val Tyr Phe Gln			
25	210	215	220	
	gat caa tat gaa gct cct agt gaa aaa gac atg aaa cgt tta aca ata			720
	Asp Gln Tyr Glu Ala Pro Ser Glu Lys Asp Met Lys Arg Leu Thr Ile			
	225	230	235	240
30				
	aat aat caa aat atg gat gaa tat gat gaa gaa aaa caa agt gac acc			768

- 27 -

	Asn Asn Gln Asn Met Asp Glu Tyr Asp Glu Glu Lys Gln Ser Asp Thr	
	245	250 255
	aca tat cga atc atc act gag atg aca ata ctc aca gtt caa ctg att	816
5	Thr Tyr Arg Ile Ile Thr Glu Met Thr Ile Leu Thr Val Gln Leu Ile	
	260	265 270
	gtt gag ttt gcc aaa cga tta cca ggt ttc gat aaa ctt gta aga gaa	864
	Val Glu Phe Ala Lys Arg Leu Pro Gly Phe Asp Lys Leu Val Arg Glu	
10	275	280 285
	gat caa atc act tta ctc aag gct tgc tca agt gaa gct atg atg ttc	912
	Asp Gln Ile Thr Leu Leu Lys Ala Cys Ser Ser Glu Ala Met Met Phe	
	290	295 300
15		
	agg gta gca agg aag tat gac atc acc act gac tca ata gtg ttt gct	960
	Arg Val Ala Arg Lys Tyr Asp Ile Thr Thr Asp Ser Ile Val Phe Ala	
	305	310 315 320
20	aac aac cag cca ttt tca gct gat tca tat aac aaa gct gga ttg gga	1008
	Asn Asn Gln Pro Phe Ser Ala Asp Ser Tyr Asn Lys Ala Gly Leu Gly	
	325	330 335
	gat gcc att gaa aac caa ctg tca ttc agt cgg ttt atg tac aat atg	1056
25	Asp Ala Ile Glu Asn Gln Leu Ser Phe Ser Arg Phe Met Tyr Asn Met	
	340	345 350
	aag gtg gat aac gca gaa tat gcc tta ttg acc gcc atc gtc ata ttt	1104
	Lys Val Asp Asn Ala Glu Tyr Ala Leu Leu Thr Ala Ile Val Ile Phe	
30	355	360 365



- 28 -

tcg agt agg cca aat tta cta gat ggt tgg aaa gtg gag aaa atc caa 1152  
 Ser Ser Arg Pro Asn Leu Leu Asp Gly Trp Lys Val Glu Lys Ile Gln  
 370 375 380

5 gaa atc tac cta gag tcc tta aaa gct tat gta gat aat cga gac cgt 1200  
 Glu Ile Tyr Leu Glu Ser Leu Lys Ala Tyr Val Asp Asn Arg Asp Arg  
 385 390 395 400

gac aca gca act gta cga tat gcg cga ctt ctc tca gta ctt aca gaa 1248  
 10 Asp Thr Ala Thr Val Arg Tyr Ala Arg Leu Leu Ser Val Leu Thr Glu  
 405 410 415

ttg cgc aca tta ggc aat gaa aac tct gag cta tgt atg aca ctg aaa 1296  
 Leu Arg Thr Leu Gly Asn Glu Asn Ser Glu Leu Cys Met Thr Leu Lys  
 15 420 425 430

ctg aaa aac aga gta gta ccc cca ttc ttg gcc gaa ata tgg gat gtc 1344  
 Leu Lys Asn Arg Val Val Pro Pro Phe Leu Ala Glu Ile Trp Asp Val  
 435 440 445

20 atg cca tag 1353  
 Met Pro  
 450

25 <210> 10  
 <211> 450  
 <212> PRT  
 <213> *Myzus persicae*

30 <400> 10

- 29 -

Met Ser Thr Asn Ser Tyr Asp Pro Tyr Ser Pro Met Ser Gly Lys Ile  
 1 5 10 15

Val Lys Glu Glu Leu Ser Pro Pro Asn Ser Leu Ser Gly Val Ser Ser  
 5 20 25 30

His Ser Asp Gly Leu Lys Lys Lys Lys Leu Asn His Thr Pro Ser Thr  
 35 40 45

10 Gly Val Val Asn Thr Ser Ala Ser Gly Pro Gly Gly Gly Val Gly Gly  
 50 55 60

Asn Val Leu Asn Asn Arg Pro Pro Glu Glu Leu Cys Leu Val Cys Gly  
 65 70 75 80

15 Asp Arg Ser Ser Gly Tyr His Tyr Asn Ala Leu Thr Cys Glu Gly Cys  
 85 90 95

Lys Gly Phe Phe Arg Arg Ser Ile Thr Lys Asn Ala Val Tyr Gln Cys  
 20 100 105 110

Lys Tyr Gly Asn Asn Cys Glu Ile Asp Met Tyr Met Arg Arg Lys Cys  
 115 120 125

25 Gln Glu Cys Arg Leu Lys Lys Cys Leu Thr Val Gly Met Arg Pro Glu  
 130 135 140

Cys Val Val Pro Glu Val Gln Cys Ala Val Lys Arg Lys Glu Lys Lys  
 145 150 155 160

30 Ala Gln Arg Glu Lys Asp Lys Pro Asn Ser Thr Thr Asp Ile Ser Pro

- 30 -

	165	170	175
	Glu Ile Ile Lys Ile Glu Pro Thr Glu Met Lys Ile Glu Cys Gly Glu		
	180	185	190
5	Pro Met Ile Met Gly Thr Pro Met Pro Thr Val Pro Tyr Val Lys Pro		
	195	200	205
	Leu Ser Ser Glu Gln Lys Glu Leu Ile His Arg Leu Val Tyr Phe Gln		
10	210	215	220
	Asp Gln Tyr Glu Ala Pro Ser Glu Lys Asp Met Lys Arg Leu Thr Ile		
	225	230	240
15	Asn Asn Gln Asn Met Asp Glu Tyr Asp Glu Glu Lys Gln Ser Asp Thr		
	245	250	255
	Thr Tyr Arg Ile Ile Thr Glu Met Thr Ile Leu Thr Val Gln Leu Ile		
20	260	265	270
	Val Glu Phe Ala Lys Arg Leu Pro Gly Phe Asp Lys Leu Val Arg Glu		
	275	280	285
	Asp Gln Ile Thr Leu Leu Lys Ala Cys Ser Ser Glu Ala Met Met Phe		
25	290	295	300
	Arg Val Ala Arg Lys Tyr Asp Ile Thr Thr Asp Ser Ile Val Phe Ala		
	305	310	320
30	Asn Asn Gln Pro Phe Ser Ala Asp Ser Tyr Asn Lys Ala Gly Leu Gly		
	325	330	335

- 31 -

Asp Ala Ile Glu Asn Gln Leu Ser Phe Ser Arg Phe Met Tyr Asn Met

340

345

350

Lys Val Asp Asn Ala Glu Tyr Ala Leu Leu Thr Ala Ile Val Ile Phe

5

355

360

365

Ser Ser Arg Pro Asn Leu Leu Asp Gly Trp Lys Val Glu Lys Ile Gln

370

375

380

10

Glu Ile Tyr Leu Glu Ser Leu Lys Ala Tyr Val Asp Asn Arg Asp Arg

385

390

395

400

Asp Thr Ala Thr Val Arg Tyr Ala Arg Leu Leu Ser Val Leu Thr Glu

405

410

415

15

Leu Arg Thr Leu Gly Asn Glu Asn Ser Glu Leu Cys Met Thr Leu Lys

420

425

430

Leu Lys Asn Arg Val Val Pro Pro Phe Leu Ala Glu Ile Trp Asp Val

20

435

440

445

Met Pro

450

25

<210> 11

<211> 140

<212> DNA

<213> Myzus persicae

30

- 32 -

&lt;220&gt;

&lt;221&gt; CDS

&lt;222&gt; (9) .. (134)

5 &lt;400&gt; 11

aattctgc gag gga tgc aag gga ttc ttc aaa cgc aca gtg agg aaa aat 50

Glu Gly Cys Lys Gly Phe Phe Lys Arg Thr Val Arg Lys Asn

1

5

10

10 ttg tca tac gcg tgt cgc gaa gaa aac aaa tgc atc atc gac aag cgc 98

Leu Ser Tyr Ala Cys Arg Glu Glu Asn Lys Cys Ile Ile Asp Lys Arg

15

20

25

30

caa cga aat cgg tgc caa tac tgc agc tac caa aaa tgatcg 140

15 Gln Arg Asn Arg Cys Gln Tyr Cys Ser Tyr Gln Lys

35

40

20 &lt;210&gt; 12

&lt;211&gt; 42

&lt;212&gt; PRT

&lt;213&gt; Myzus persicae

25 &lt;400&gt; 12

Glu Gly Cys Lys Gly Phe Phe Lys Arg Thr Val Arg Lys Asn Leu Ser

1

5

10

15

Tyr Ala Cys Arg Glu Glu Asn Lys Cys Ile Ile Asp Lys Arg Gln Arg

30

20

25

30

- 33 -

Asn Arg Cys Gln Tyr Cys Ser Tyr Gln Lys  
35 40

5 <210> 13  
<211> 150  
<212> DNA  
<213> *Lucilia cuprina*

10 <220>  
<221> CDS  
<222> (9)..(134)  
  
<400> 13

15 aattctgc gaa gga tgc aag gga ttc ttc aaa cgt acc gta cgc aag gac 50  
Glu Gly Cys Lys Gly Phe Phe Lys Arg Thr Val Arg Lys Asp  
1 5 10

ttg aca tat gct tgt cgt gag gac aga aat tgc att ata gat aaa cga 98

20 Leu Thr Tyr Ala Cys Arg Glu Asp Arg Asn Cys Ile Ile Asp Lys Arg  
15 20 25 30

caa aga aat cgt tgc cag tat tgt cgc tac caa aag tgatcgatgc cgtcga 150  
Gln Arg Asn Arg Cys Gln Tyr Cys Arg Tyr Gln Lys

25 35 40

<210> 14  
<211> 42

30 <212> PRT  
<213> *Lucilia cuprina*

- 34 -

&lt;400&gt; 14

Glu Gly Cys Lys Gly Phe Phe Lys Arg Thr Val Arg Lys Asp Leu Thr

1

5

10

15

5 Tyr Ala Cys Arg Glu Asp Arg Asn Cys Ile Ile Asp Lys Arg Gln Arg

20

25

30

Asn Arg Cys Gln Tyr Cys Arg Tyr Gln Lys

35

40

10

&lt;210&gt; 15

&lt;211&gt; 32

&lt;212&gt; DNA

15 &lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; Description of Artificial Sequence:primer

20 &lt;400&gt; 15

cggaattccg cctctggtta ycaytayaay gc

32

&lt;210&gt; 16

25 &lt;211&gt; 32

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

30 &lt;223&gt; Description of Artificial Sequence:primer

- 35 -

<400> 16  
cgcggaaccr cactcctgac actttcgycr ca 32

5 <210> 17  
<211> 23  
<212> DNA  
<213> Artificial Sequence

10 <220>  
<223> Description of Artificial Sequence:primer

<400> 17  
gcctcggggt atcactataa cgc 23

15

<210> 18  
<211> 23  
<212> DNA

20 <213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence:primer

25 <400> 18  
gcactcctga cactttcgtc tca 23

<210> 19

30 <211> 23  
<212> DNA



- 36 -

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; Description of Artificial Sequence:primer

5

&lt;400&gt; 19

tcgtccggtt accattacaa cgc

23

10 &lt;210&gt; 20

&lt;211&gt; 24

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

15 &lt;223&gt; Description of Artificial Sequence:primer

&lt;400&gt; 20

tagacctttg gcraytcna caat

24

## INTERNATIONAL SEARCH REPORT

 International application No.  
**PCT/AU 99/00033**

<b>A. CLASSIFICATION OF SUBJECT MATTER</b>		
Int Cl <sup>6</sup> : C12N15/12, 5/10; C12Q1/68; C07K14/705; G01N33/68; A01N37/28, 65/00		
According to International Patent Classification (IPC) or to both national classification and IPC		
<b>B. FIELDS SEARCHED</b>		
Minimum documentation searched (classification system followed by classification symbols) See electronic database box below.		
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched Medline, Toxline (Toxicology literature Online US National Library of Medicine) See keywords(KW) below.		
Electronic data base consulted during the international search (name of data base and, where practicable, search terms used) Medline: KW ecdysone or ecdysteroid receptor Toxline: KW ecdysteroid agonist; iridoid glycoside. Dgene (Derwent Patent database) sequence id 2,4,6,10 and 14. EMBL, GeneBank. PIR, Swiss-protein sequence id 2, 4, 6, and 10-20.		
<b>C. DOCUMENTS CONSIDERED TO BE RELEVANT</b>		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
PX	WO 98/35550 (NEW ZEALAND PASTORAL AGRICULTURE RESEARCH INSTITUTE LIMITED) 20 August 1998 See the whole document.	1-91.
X	WO 97/38117 (THE SALK INSTITUTE FOR BIOLOGICAL STUDIES) 16 October 1997. See the whole document.	1-61, 80-85.
Y		62-79, 86-91.
X,Y	WO 96/37609 (ZENECA LIMITED) 28 November 1996 See the whole document.	1-91.
<input checked="" type="checkbox"/> Further documents are listed in the continuation of Box C <input checked="" type="checkbox"/> See patent family annex		
* Special categories of cited documents: "A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier application or patent but published on or after the international filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone "Y" document of particular relevance, the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art "&" document member of the same patent family		
Date of the actual completion of the international search 5 March 1999		Date of mailing of the international search report - 9 MAR 1999
Name and mailing address of the ISA/AU AUSTRALIAN PATENT OFFICE PO BOX 200 WODEN ACT 2606 AUSTRALIA Facsimile No.: (02) 6285 3929		Authorized officer  J.H. CHAN Telephone No.: (02) 6283 2340

## INTERNATIONAL SEARCH REPORT

International application No.

PCT/AU 99/00033

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 93/03162 (GENENTECH INC) 18 February 1993. See the whole document, especially figure 1.	1-7, 17-20, 22-36, 38-39, and 41-61
X	WO 91/13167 (THE BOARD OF TRUSTEES OF LELAND STANFORD JR. UNIVERSITY) 5 September 1991. See the examples and pp 92-105.	1-7, 17-20, 22-36, 38-39, and 41-61
X	HANNAN G.N. and HILL R. "Cloning and characterization of LcEcR: A functional ecdysone receptor from the sheep blowfly <i>Lucilia cuprina</i> " Insect Biochem Mol Biol. vol 27 no6 pp 479-488 1997. See whole document especially figures 1 and pp 483-485.	1-61, 80-85.
Y		62-79, 86-91
X	Fujiwara H. <i>et al</i> "Cloning of an Ecdysone receptor homolog from <i>Manduca sexta</i> and the developmental profile of its mRNA in wings" Insect Biochem Mol Biol vol 25 no. 7 pp 845-856 1995. See especially pp 845-851.	1-5, 17-18, 22-33, 41, 47, and 48
X	Toxline accession no. 1995:261581 & ISHAAYA I. <i>et al</i> "Comparative toxicity of two ecdysteroid agonists, RH-2485, and RH-5992, on susceptible and pyrethroid-resistant strains of the Egyptian cotton leafworm, <i>Spodoptera littoralis</i> ." <i>Phytoparasitica</i> (1995) vol 23, no.2 pp. 139-145. See the whole abstract.	77-79
X	Medline Abstract no. 9712450 & ELBRECHT A. <i>et al</i> "8-O-acetylharpagide is a nonsteroidal ecdysteroid agonist." Insect Biochem Mol Biol 1996 June; 26(6); 519-523. See the whole abstract.	77-79
X	Toxline accession no. 1995:257526 & OBERLAND H. <i>et al</i> "Non-steroidal ecdysteroid agonists: Tools for the study of hormonal action" Archives of Insect Biochemistry and Physiology (1995) vol. 28 no. 3 pp. 209-233. See the whole abstract.	77-79

## INTERNATIONAL SEARCH REPORT

International application No.

PCT/AU 99/00033

**Box I** Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:  
because they relate to subject matter not required to be searched by this Authority, namely:
  
2. ☒ Claims Nos.: 77 -79.  
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:  

The synthetic compounds defined in claim 77 are not in any way, be linked to the inventive features of the invention namely, the specific sequences id nos.1 to 20. Thus the scope of these compounds can include many compounds, each of which has no structural relationship with the others; indeed they include many known classes of insecticides (see claim 79). Therefore these claims as drafted cannot be effectively and economically searched.
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a)

**Box II** Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.  
☐
  
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

**Remark on Protest**

- ☐ The additional search fees were accompanied by the applicant's protest.  
☐ No protest accompanied the payment of additional search fees.

## INTERNATIONAL SEARCH REPORT

### Information on patent family members

International application No.

PCT/AU 99/00033

This Annex lists the known "A" publication level patent family members relating to the patent documents cited in the above-mentioned international search report. The Australian Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

Patent Document Cited in Search Report				Patent Family Member			
WO	98/35550	AU	60077/98				
WO	97/38117	AU	25572/97				
WO	96/37609	AU	57716/96	CA	2219121	CN	1191568
		CZ	9703722	EP	828829	NO	975419
		PL	323587				
WO	93/03162	EP	598011				
WO	91/13167	AU	74922/91	AU	17792/95	AU	49218/97
		CA	2076386	EP	517805	US	5514578
END OF ANNEX							